

























































Abstract: Measurement and mechanisms of 
complement-induced neutrophil dysfunction 
Dr Alexander JT Wood 
Critical illness is an aetiologically and clinically heterogeneous syndrome that is 
characterised by organ failure and immune dysfunction. Mortality in critically ill patients is 
driven by inflammation-associated organ damage and a profound vulnerability to nosocomial 
infection. Both factors are influenced by the complement protein C5a, released by unbridled 
activation of the complement system during critical illness. C5a suppresses antimicrobial 
functions of key immune cells, in particular the neutrophil, and this suppression has been 
shown to be associated with poorer outcomes amongst critically ill adults. The intracellular 
signalling pathways which mediate C5a-induced neutrophil dysfunction are incompletely 
understood, and scalable tools with which to assess immune cell dysfunction in patients are 
lacking. This thesis aimed to develop tools with which to assess neutrophil function and 
delineate intracellular signalling pathways driving C5a-induced impairment. 
Neutrophils were isolated from healthy volunteer blood and functions (priming, phagocytosis 
and reactive oxygen species production) were assessed using light microscopy, confocal 
microscopy and flow cytometry. A new assay was developed using an Attune Nxt™ acoustic 
focusing cytometer (Life Technologies) which allowed the rapid assessment of multiple 
neutrophil functions in small samples of unlysed, minimally-manipulated human whole blood. 
Complete proteomes and phosphoproteomes of phagocytosing neutrophils were obtained 
from four healthy donors pre-treated with C5a or vehicle control. 
Several key insights were gained from this work and are summarised here. Firstly, C5a was 
found to induce a prolonged (greater than seven hours) impairment of neutrophil 
phagocytosis. This defect was found to be preventable by previous or concurrent 
phagocytosis, indicating common signalling mechanisms. Secondly, a novel assay was 
developed which allows the rapid assessment of multiple neutrophil functions in less than2 
mL of whole blood, and this assay can feasibly be applied in clinical settings. Thirdly, cell-
surface expression of the C5a receptor was found to be markedly decreased during 
phagocytosis, and this decrease was not mediated by protease activity. Finally, unbiased 
proteomics quantified 4859 proteins and 2712 phosphoproteins respectively. This 
quantification is the deepest profile of the human neutrophil proteome published to date, and 
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Structure of thesis  
This thesis is structured into seven chapters, and is navigable using hyperlinks for figures, 
tables and subheadings if reading in Word or Adobe Acrobat Reader. Bookmarks for ease of 
navigation are accessible by enabling the ‘Navigation pane’ in both Word and Adobe Acrobat 
Reader. The first chapter (literature review) outlines the relevant literature pertaining to this 
work and identifies key areas in need of further investigation. The second chapter (Methods) 
details the experimental and statistical techniques used to generate and analyse data 
presented throughout the rest of the thesis. The methods discussed in Chapter II: are 
supplemented by full-length protocols for key experiments provided in the Appendices.  
Chapters III-VI are the experimental chapters. Each is structured identically, beginning with a 
brief recapitulation of relevant literature, before hypotheses and aims for the chapter are 
discussed. Notes on the methods used throughout the chapter are provided, before results 
are presented. Each chapter concludes with a detailed discussion of the results in the 
context of the thesis and the wider literature. The final chapter summarises key findings and 




Chapter I: Literature review 
This chapter is divided into three parts. It begins with a discussion of the many and varied 
functions of polymorphonuclear neutrophils (PMN), with a focus on microbicidal capabilities 
of relevance to this thesis. This is followed by an overview of critical illness, with a focus on 
the immune dysfunction known to occur in this context. The discussion then turns to the 
activated complement fragment C5a, the inflammatory molecule of central importance to this 
thesis. The generation, functions, receptors and role of this anaphylatoxin in immune and 
other organ dysfunction is discussed, before the chapter is summarised and further avenues 
for investigation are highlighted.  
1. Neutrophils 
The polymorphonuclear neutrophil is commonly described as the foot soldier or first 
responder of the immune system. These cells make up 70% of circulating human leucocytes 
(ref), can be rapidly mobilised from the bone marrow1 and infiltrate inflamed tissues2 where 
they carry out a diverse range of functions, from bacterial killing to modulation of adaptive 
immune responses.3 Their importance for homeostasis is demonstrated by the high 
prevalence of severe bacterial and fungal infections seen in individuals with inherited or 
acquired neutrophil dysfunction.1,4  
1.1. Mobilisation 
Neutrophil development can be traced backwards to as early as week three of 
embryogenesis, after which an exquisitely complex and regulated process occurs, 
transitioning haematopoietic stem cells through common myeloid progenitors and eventually 
into mature neutrophils, capable of leaving the bone marrow.5 In the adult, between 5x1010-
10x1010 neutrophils are produced in the bone marrow each day from common myelocyte 
progenitors under the control of multiple proliferation signals including 
granulocyte/macrophage colony stimulating factors (G-CSF, GM-CSF) and interleukins 3 and 
6 (IL-3, IL-6).1 In the context of systemic inflammation or infection, upregulation of these 
cytokines stimulates increased myeloid progenitor proliferation, known as emergency 
granulopoiesis6 which can lead to the observation of band-type subsets of neutrophils in the 
circulation.6,7  
Stromal cell-derived factor 1α/C-X-C receptor 4 (SDF-1α/CXCR4) interaction tends to retain 
neutrophils within the bone marrow.1 It is the gradual loss of CXCR4 from the neutrophil  cell 
surface with maturity, in combination with increased expression of CXCR2, that shifts the 
balance of signals from retention to release, allowing trans-endothelial migration into the 
circulation.1,5,8 This balance is further shifted during infection and inflammation by interleukin 
8, C5a, formylated peptides, tumour necrosis factor alpha and leukotriene B4 (IL-8, TNF-α, 
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LTB4) leading to the neutrophilia characteristic of systemic inflammation and sepsis.9–11 More 
recently, the significance of the IL-8/CXCR2 interaction in this context has become clearer as 
phase 1 and 2 clinical trials demonstrated a reversible reduction in circulating neutrophil 
count after treatment with CXCR2 antagonists.12,13 
1.2. Neutrophils in the circulation 
Physiological concentrations of neutrophils in the blood range between 1.8 – 7.7 x 109 
cells/L.14 The half-life of neutrophils in the circulation has been the subject of some debate, 
with early estimates generated by re-injection of radiolabelled neutrophils into healthy 
humans ranging from six to seven hours.15–17 More recent data from Pillay et al18 estimated a 
half-life of nearly four days, though methodological concerns have been raised related to that 
study’s high approximation of the blood:precursor neutrophil ratio erroneously increasing 
their estimate of half-life.19 It would seem that the weight of published evidence would 
suggest a half-life closer to the original estimate.1,8,15,19–21 Importantly, the vast majority of 
total blood neutrophils in health are in an unprimed state, where they are minimally 
responsive to activating stimuli,22,23 and can be found distributed equally between the freely 
circulating and marginated pools (consisting of liver, spleen and bone marrow).1 In disease 
states, this homeostatic unprimed state is disrupted, leading to neutrophil retention in a 
variety of vascular beds and associated tissue destruction,1,23,24 which is discussed further in 
Section 1.5.      
1.3. Transmigration and chemotaxis 
A key determinant of appropriately targeted neutrophil function is migration toward and 
around sites of infection and inflammation. Many recent advances in this field have been 
facilitated by the use of genetically tractable and transparent zebrafish models and high-
speed, high-resolution microscopy techniques alongside in-vitro and in-vivo models using 
primary human cells (reference in-vitro model, cell coculture transmigration and skin blister 
window work).12,25 The first step is transmigration of neutrophils from the bloodstream across 
post-capillary venules and into tissues. In response to pathogen and damage associated 
molecular patterns (PAMPs and DAMPs respectively) as well as cytokines such as IL-1β and 
TNF-α secreted by macrophages and dendritic cells,2 neutrophils participate in a leukocyte 
adhesion cascade.26,27 This series of events begins with weak neutrophil-endothelium 
interactions, followed by rolling, firmer adhesion and extension of neutrophil processes 
through and between endothelial cells. The leukocyte adhesion cascade is mediated 
primarily by two families of molecules; integrins and selectins, key members of which include 
P- and E- selectin, vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion 
molecules 1 and 2 (ICAM-1,2).26,27 Neutrophil migration is not a one-way phenomenon; 
reverse transendothelial migration (rTEM)28 mediated by ICAM-1 junctional adhesion 
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molecule C (JAM-C)29 and redox-regulated Src family kinases30 has now been confirmed in 
vitro and in vivo and shown to be of importance in mediating systemic inflammation.31 
For many years the importance of nuclear deformation during leukocyte transmigration has 
been appreciated,32–34 though the mechanisms regulating this process remain only partially 
understood. Human neutrophils (diameter 7-10 µM) regularly pass through spaces which are 
much smaller during their transit through capillary beds (5.5 µM)34 cellular membranes and 
the interstitium.35 This necessitates the application of deforming forces to the nucleus, both 
during migration through endothelial cell membranes36 and during rapid, integrin-independent 
migration through three-dimensional spaces.37 In an elegant study of mammalian dendritic 
cell migration, Rabb and colleagues38 provided evidence for nuclear envelope disintegration 
and importantly, repair, carried out by endosomal sorting complexes (ESCRT) required for 
cell survival during migration through tight spaces. The relevance of these observations to 
other leucocyte functions involving deformation of the actin cytoskeleton (such as 
phagocytosis) have yet to be explored.   
During and following transmigration, neutrophils both move randomly (Brownian random 
walk)39 and respond to established gradients of inflammatory molecules which lead them to 
the site of injury or infection; a process known as chemotaxis. Neutrophil chemotaxis is 
regulated primarily by the ligation of G protein-coupled receptors (GPCRs) by chemokines 
such as CXCL1, N-formylmethionyl-leucyl-phenylalanine (fMLP), LTB4 and CXCL8/IL-8.2,12 In 
response to GPCR ligation, signalling molecules (phosphoinositide-3-kinases (PI3Ks), 
phospholipase C (PLC), Rho-family GTPases and their regulators such as P-Rex1) 
accumulate at the leading edge of the cell, leading to actin polymerisation and cell movement 
toward the increasing chemokine concentrations.12,40,41  
Work by Sarris and colleagues39 demonstrated an important role for extracellular heparan 
sulfate proteoglycans for the maintenance of chemokine gradients in tissues, and the ability 
of CXCL8/IL-8 to increase neutrophil speed and straightness only when moving toward 
maximal chemokine concentration. Another key phenomenon recently identified is neutrophil 
swarming, a process whereby neutrophils self-amplify their recruitment by secretion of LTB4, 
facilitating isolation of damaged tissue from healthy.42,43 These complex interactions between 
neutrophils and chemokines allow these cells to survey the tissue environment, and 
eventually get to where they need to be.  
It should be noted at this point that the transmigrated or tissue neutrophil is distinct from its 
circulating counterpart.44 Sorensen and colleagues observed that tissue neutrophils were 
more phagocytically active.45 Data from the Nourshargh lab and others28 has demonstrated 
that neutrophil expression of ICAM-1 is increased in cells that have undergone rTEM,29 and 
that expression of this molecule has consequent effects on phagocytosis and ROS 
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production in mice.46 Further, transmigrated neutrophils produce cytokines differently and 
display discrete transcriptional signatures, which may be related to wound healing.44 Whether 
these phenotypic changes are due simply to priming or activation, which commonly 
accompany transmigration,47 or are due to changes induced by the act of transmigration itself 
is presently unclear. Once neutrophils have reached the site of inflammation, their 
destructive potential is brought to bear, where host-pathogen interactions result in 
phagocytosis, phagosome maturation and the respiratory burst.  
1.4. Phagosome formation 
Phagocytosis (internalisation of particles > 0.5 µm)48,49 is a complex and dynamic process 
involving multiple signalling pathways which differ according to phagocytic target.48 
Phagocytosis begins with engagement of phagocytic receptors on the surface of phagocytes 
often by endogenous opsonic ligands such as immunoglobulins or iC3b, a product of the 
complement system, but also by microbial PAMPs binding to a variety of receptors.49,50 Once 
immunoglobulin or complement receptors (Fc receptors and CD11b/CD18 respectively) are 
engaged, particle binding is further enhanced by diffusion of more receptors through the 
phagocyte membrane and extensions of cellular processes around the pathogen.49,51,52  
Following receptor clustering around prey, multiple signalling cascades are activated through 
SRC-family kinases (SFKs) and phospholipases.53 The consequent tyrosine residue 
phosphorylation and phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P3) accumulation 
(following phosphoinositide-3-kinase action) drives Rho family GTPase activation and 
rearrangement of the actin cytoskeleton into a nascent phagosome, after which phagosomal 
maturation and pathogen killing occur.49,53,54 It should be noted that complement-mediated 
and Fc-receptor mediated phagocytosis tend to engage different Rho family GTPases (RhoA 
and cell division control protein homolog 42/Rac respectively)55 which explain important 
mechanistic differences between these pathways.48,49 Further discussion of intracellular 
signalling pathways leading to phagocytic dysfunction in the context of C5a is provided in 
Section 3.5. 
1.5. Phagosomal maturation and bacterial killing 
Once a pathogen-containing phagosome is formed, a choreographed process of granule 
fusion, pH change, and degradative enzyme activation occurs, collectively known as 
phagosome maturation. Neutrophil phagocytosis begins seconds after prey encounter and is 
generally complete by 15-20 minutes for large particles such as complement-opsonised 
zymosan.56,57 Important signalling proteins involved in these processes are the small 
GTPases of the Rab family, many of which are recruited to the phagosomal membrane by 
phosphatidylinositol-3-phosphate (PtdIns3P, note difference from PtdIns(3,4,5)P3 above) 
produced predominantly by the class III PI3-kinase Vps34.48,58 Many aspects of phagosome 
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maturation have been studied in macrophages and applied to neutrophils, though there are 
substantive differences between the two cell types. For instance, neutrophils are thought to 
have a less acidic phagosomal pH compared to macrophages, at least at early time-
points.59,60 Further, neutrophil phagosome maturation is characterised by PtdIns3P-
dependent fusion with pre-formed, oxidase-containing granules present within the 
cytosol,61,62 as opposed to the gradual endosomal maturation which occurs in 
macrophages.48,49,63 
Four categories of neutrophil granule are recognised; azurophilic, specific, gelatinase and 
secretory vesicles.64 Granules contain a multitude of microbicidal components; 
myeloperoxidase (MPO), cathepsin G, elastase and proteinase 3 as well as components of 
the nicotinamide adenine dinucleotide phosphate oxidase complex (NADPH-oxidase, NOX-
2).54,64,65 Release of granule contents into the phagosome is accompanied by the neutrophil 
respiratory burst; a NOX-2-mediated process responsible for electron transfer to oxygen, 
forming the superoxide anion (O2-) which dismutates to hydrogen peroxide (H2O2) both of 
which are toxic to microbes.49,54,64 The production of these reactive oxygen species (ROS) 
can be greatly augmented or ‘primed’ by pre-exposure to PAMPs (fMLP, LPS) and 
endogenous proteins including platelet activating factor (PAF), GM-CSF or TNF-α.23 Priming 
is thought to ensure the appropriate activation of neutrophil destructive mechanisms to 
control collateral tissue damage and augment microbicidal activity.23,66 Recent data from our 
group provides evidence for neutrophil de-priming, which can occur secondary to repetitive 
mechanical distortion (such as induced by transit through the pulmonary vasculature) and is 
disturbed in ARDS.24,67 
Phagosomal biochemical events following the respiratory burst are only partially understood, 
owing to the difficulty in interrogating molecular events in such conditions. The large charge 
shift and membrane depolarisation generated by NOX-2 is compensated by ion channels 
and active proton pumps, including cystic fibrosis transmembrane conductance regulator 
(CFTR) and vacuolar ATPases (V-ATPases). This charge compensation allows further 
oxidative species to be generated.63,68 Using halogens such as chloride in combination with 
H2O2, MPO generates cytotoxic hypochlorous acid (HOCl) and other hypohalous acids.54 
Proteases are also released from granules, and are likely to function inside phagolysosomes, 
at least for certain phases of phagosomal maturation.54 Whilst the biochemistry may not yet 
be fully understood, it is clear that these interdependent processes generate an environment 
which is highly toxic to microbes, resulting in their destruction.54,63,64 The careful control of 
these destructive processes is necessary to prevent destruction of the neutrophils 
themselves and damage to healthy bystander tissue.69 It should be noted, however, that 
pathogens also have an extensive armamentarium of evasive measures at their disposal, 
which have been reviewed elsewhere.70,71      
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Neutrophils serve a variety of other functions; cytokine production, modulation of the 
adaptive immune system,15,20 neutrophil extracellular trap (NET) production72–74 and 
resolution of inflammation through apoptosis and removal by macrophages.3,20 These 
functions, whilst important, are not the focus of this thesis and as such will not be discussed 
in detail.  
In summary, neutrophils are far from the simple foot soldiers of the immune system they 
were once thought to be. These motile first-responders are mobilised in large numbers 
during infection and inflammation. Neutrophils adhere to and exit the microvasculature and 
migrate along chemotactic gradients to sites of infection. There, they engulf microbes in an 
intricate and complex process involving a multitude of receptors and signalling pathways, 
eventually culminating in actin polymerisation and internalisation of pathogens. Once 
microbes are phagocytosed, toxic granules and the NADPH-oxidase complex fuse with the 
phagosome, thus creating a highly destructive milieu leading to pathogen neutralisation. 
Defects in the above functions predispose humans to infection and can be driven by 
endogenous molecules such as complement activation product C5a, a key mediator present 
at high concentrations during critical illness. Before we enter into a detailed discussion of the 
generation and effects of C5a, an understanding of critical illness biology is necessary. It is to 
this topic that we now turn.      
2. Critical illness, immune perturbation and organ failure 
2.1. Definitions, epidemiology 
Critical illness is difficult to define but can be conceptualised pragmatically as any severe 
illness necessitating invasive monitoring and organ support, usually within an intensive care 
or therapy unit (ICU/ITU).75 Common causes of critical illness are severe infections, trauma-
haemorrhage, burns, pancreatitis and post cardiac-arrest reperfusion. Differences in 
definitions, treatment thresholds and surveillance make the burden of critical illness 
challenging to accurately quantify. Based on a systematic meta-analysis, Adhikari and 
colleagues estimated the absolute number of adult deaths due to critical illness syndromes 
worldwide to be over 58 million in 2004.76 More recently, a worldwide prospective audit 
revealed crude mortality rates for critically ill patients of 13 % in high income countries, 
though mortality estimates vary depending on aetiology, from less than 3 % for routine post-
operative care77 to 26 % for severe sepsis78 to over 40 % with acute respiratory distress 
syndrome79 and septic shock.76,80,81 
A key predictor of these widely variable mortality rates is the number of dysfunctional organs 
and the degree to which they are impaired.82 Several mortality prediction tools such as 
Simplified Acute Physiology Score (SAPS)83, Sepsis-related Organ Failure Assessment 
(SOFA)84 and Acute Physiology and Chronic Health Evaluation II (APACHE II)85 are 
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predicated on this fact, and their respective predictive validities have been validated in a wide 
variety of cohorts by multiple groups.80,86–88 Indeed Sepsis-3,89 the most recent consensus 
definition of this prototypical critical illness syndrome, relies on the presence of organ 
dysfunction for the diagnosis of sepsis. Impaired functioning of more than one organ system 
is known as multi-organ dysfunction syndrome (MODS), which is often a final common 
pathway for critically ill patients who die, regardless of the initial insult leading to their ICU 
admission.90 Of importance to this thesis, and arguably to patients, is the ability to assess, 
predict and ameliorate organ dysfunction, regardless of initial insult or arbitrary critical illness 
syndrome. The following section provides an overview of the known pathophysiological 
mechanisms which lead to organ dysfunction in critically ill patients, before we consider the 
specific biology and role of the complement component C5a in these processes.  
2.2. PAMPS, DAMPS and immune activation 
Injury to host tissues may be caused by a number of insults such as microbial invasion, 
trauma, ischaemia, burns or chemical (including pancreatic enzyme) exposure. Following 
tissue destruction or microbial invasion, DAMPs and PAMPs are released.91,92 These 
compounds, such as high mobility group box 1 (HMGB1)93 and mitochondrial DNA94 from 
damaged cells, LPS,95 formylated peptides and flagellin from bacteria96–98 signal via pattern 
recognition receptors (PRRs) including toll-like receptors (TLRs) on innate immune and 
endothelial cells, leading to neutrophil priming, pro-inflammatory gene transcription and 
cytokine release.69,96,97,99 PAMPs are also potent activators of the complement and 
coagulation cascades, which further generate inflammatory and pro-coagulant 
compounds92,97 and are discussed in Section 3.1.  
Key to critical illness pathology is the concept of systemic overspill of PAMPs and DAMPs, 
with resultant systemic or non-specific immune activation. In the context of localised infection 
or injury, PAMPs and DAMPs act locally to drive a controlled immune response, leading to 
inflammation, control of damage or pathogens and eventual resolution. However, in critical 
illness this tight control is lost,92,100 due to the magnitude of the insult or virulence of the 
pathogen along with a multitude of inherited and acquired host factors.101 The result is a 
global, overactive immune response, often driven by multiple positive feedback loops and 
cross-amplification. An important component of this phenomenon is known as the cytokine 
storm, which is discussed in the next section.          
2.3. Cytokine storm 
Systemic stimulation of neutrophils, monocytes, macrophages and T-cells by DAMPs and 
PAMPs leads to direct functional responses, such as chemotaxis and reactive oxygen 
species (ROS) generation, as well as secretion of multiple cytokines.102 Whilst the term 
‘cytokine storm’ is not precisely defined, it can be thought of as a deleterious positive 
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feedback loop where activated cells secrete cytokines, which then further activate immune 
cells, generating a profoundly dysregulated inflammatory state.97,102,103 The functions of 
cytokines in critical illness are protean and have been reviewed extensively elsewhere.97,102–
105 Two prototypical cytokines produced in critical illness (TNF-α and IL-1beta) are released 
within 30 minutes of LPS challenge or trauma and upregulate adhesion molecules, drive 
inflammasome formation,106  nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) signalling107 and stimulate neutrophils to produce ROS and neutrophil extracellular 
traps (NETs).97,103,105 Other cytokines share similar functions but differ in their plasma profile, 
cellular targets and signalling mechanisms. Whilst elevated levels of certain cytokines such 
as (IL-6) have been associated with mortality, trials of cytokine antagonists have failed to 
show an improvement in meaningful clinical outcomes.108,109 The reasons for this apparently 
disparate finding have been the subject of much research and debate within the intensive 
care community in recent years, and likely relate to inadequate immunophenotyping of 
patients prior to randomisation.108,110,111 This constellation of tissue destruction, pathogen 
invasion, systemic DAMP or PAMP release and the cytokine storm leads to the hallmark of 
critical illness, organ dysfunction, which is the focus of the next section.   
2.4. Mechanisms of organ dysfunction 
The exact mechanisms underlying organ dysfunction in critical illness remain poorly 
understood, though the factors identified below play a significant role. In this Section, general 
mechanisms that lead to organ dysfunction are discussed, to give the reader an overview of 
the existing literature. After C5a is introduced, the specific defects induced by this 
anaphylatoxin are reviewed in Section 3.4, and as such are not discussed in detail here.  
2.4.1. Hyperinflammation and collateral damage 
Perhaps the most obvious category is collateral damage to tissues secondary to immune cell 
activation and the cytokine storm. Such immune-mediated damage is most obvious in the 
acute respiratory distress syndrome (ARDS) where neutrophil protease release and ROS 
production directly damage alveolar epithelium and pulmonary vascular endothelium.97,112,113 
Neutrophil extracellular traps have also been shown to play an important role in causing 
collateral damage and driving inflammation during critical illness73,114,115and other disease 
such as cystic fibrosis.73 Such cell-mediated toxicity is not limited to the lung or to one cell 
type; infiltration by macrophages and neutrophils, as well as neutrophil degranulation, have 
been demonstrated in the liver, kidney and gastrointestinal tract of multiple species in the 
context of sepsis and trauma.97,116,117 These findings are consistent with the premise that 
immune cells can damage bystander organs, though organs are differentially affected and 
tissue destruction is not always obvious (Section 2.4.4). 
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2.4.2. The gastrointestinal tract 
A further driver of organ dysfunction in critical illness is the gastrointestinal tract (GIT). 
Initially, microbial translocation through the epithelial barrier secondary to increased barrier 
permeability and GIT stasis was thought to occur.118–121 However, data in support of this 
hypothesis in critically ill humans is lacking.82,122 Current models list several other factors, 
including epithelial apoptosis, mucous disruption, alterations to the microbiome and the 
secretion of cytokines, PAMPs and DAMPs through the mesenteric lymphatic systems as 
key drivers of distant organ failure.122–125      
2.4.3. Hypoperfusion and hypoxia 
Another mechanism of organ dysfunction is compromised tissue perfusion. There are many 
ways in which this can occur, including distributive shock secondary to vasodilation90 and 
myocardial depression caused by cytokines and complement activation products (particularly 
C5a and TNF-α).103,105,126 Indiscriminate activation of the complement and coagulation 
cascades can precipitate disseminated intravascular coagulation (DIC) and leucocyte-platelet 
aggregates which lead to microvascular occlusion, endothelial damage and tissue 
hypoxia.97,127–129 These perturbations often manifest clinically as hypotension, altered mental 
status, lactate accumulation, reduced urine output and microcirculatory abnormalities.82 
Whilst these phenomena have been well documented in critical illness and sepsis 
particularly, the dogma that hypoperfusion and lack of oxygen leads to widespread tissue 
necrosis has little supporting evidence.130–133 The effects of these physiological phenomena 
on cellular metabolism and machinery are becoming clearer, and may provide  a more 
accurate picture of what causes organs to fail.  
2.4.4. Cellular energy processing 
Mitochondrial synthesis of adenosine triphosphate (ATP) through oxidative phosphorylation 
is a process critical for normal cellular function. Critical illness induces defects in cellular 
respiration firstly through impairing oxygen delivery to cells as outlined above, as well as 
inducing defects in vital cellular machinery. For example, activated macrophages can induce 
an open configuration of the mitochondrial permeability transition pore (MPTP). When MPTP 
is constitutively open, the proton gradient necessary for electron transfer is lost, and the cell 
is deprived of an essential method of ATP production, leading to necrosis.134 Similar 
mechanisms of impaired cellular respiration have been demonstrated in hepatocytes 
exposed to TNF-α135 and in a rat myocardial ischaemia model.136  
Another example of damage to vital cellular machinery in critical illness is widespread 
activation of poly ADP-ribose polymerase (PARP) by ROS, which are abundant in critical 
illness.137 Under these conditions, PARP depletes the cell of ATP-forming substrates.137,138 
Inhibition of PARP in animal models of sepsis and multiple organ dysfunction is associated 
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with a survival benefit and (with appropriate targeting) offers an attractive option for 
pharmacotherapy in critical illness.137,139 In addition to impairment of cellular energy supply, 
mitochondrial components are DAMPs which may further exacerbate critical illness-induced 
inflammation.94 In a recent review, Singer140 synthesised available evidence and suggested 
that together, mitochondrial dysfunction induced by initial hypoperfusion, nitric oxide species, 
ROS, failure to maintain mitochondrial numbers and uncoupling of mitochondrial action from 
ATP production are central components of organ dysfunction. 
The roles of collateral tissue damage, hypoperfusion, the GIT and impaired cellular 
metabolism in organ dysfunction are becoming clearer, though several questions remain. 
Severe organ dysfunction (outside of ARDS) is generally not accompanied by histological 
evidence of widespread tissue destruction, as one might expect.97,133,137 Why this is the case 
remains the subject of intense investigation; cellular ‘hibernation’ and apoptosis have been 
offered as potential explanations to date.133,140–142 Intelligent therapeutic trial design also 
remains a challenge, given the failure of multiple biologically promising strategies to show 
benefit133,143–145 Up to now, this thesis has focussed on the initial inflammatory response 
which occurs in critically ill patients. This response, however, is only part of the story. The 
coexistence of a profound immunological impairment with hyperinflammation in critical illness 
is well-documented, only partially understood and is the subject of the next section. 
2.5. Immune dysfunction: vulnerability to nosocomial infection 
and worsening sepsis  
It has been clear for decades that the function of the immune system, including neutrophil 
function, is impaired in critical illness, with coexisting profound systemic inflammation and 
immunoparesis.146–148 Furthermore, immune cell impairment predicts nosocomial (hospital 
acquired) infection.133,147,149,150 Nosocomial infections can affect as many as 37 % of ICU 
patients, are a major determinant of morbidity and mortality and claim $ 3.5 billion from the 
US healthcare budget per year.133,151–154 Critical illness-related immune dysfunction can be 
divided broadly into phenomena driving cell loss or cellular functional impairment, which are 
discussed below. There is significant crossover between mechanisms involved in both 
aspects, and it is important to bear in mind that the immune impairment discussed below can 
occur concomitantly with, or after hyperinflammation. Finally, the following paragraphs give 
an overview of generalised immune cellular changes in the context of critical illness; specific 
effects of C5a on neutrophils are discussed in greater detail in Section 3.5.  
2.5.1. Changes in immune cell populations 
Impairment of immunity in critical illness is driven partly by a reduction in numbers of multiple 
cell types. Cell loss was first characterised through autopsy studies of bowel and spleens 
harvested peri-mortem in patients with sepsis142,155,156 or acute trauma-haemorrhage.157 
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These seminal studies displayed depletion of epithelial cells, CD4 and CD8 T, B and 
dendritic cell populations, in the blood and the organ in question. Similar observations have 
now been made in thymus, lymph nodes and gut-associated lymphoid tissue.133,158 A key 
mechanism responsible for this reduction in cell numbers is caspase-9-driven apoptotic cell 
death.155 Apoptosis in critical illness affects different cell populations to different degrees; for 
example, regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) have an 
immunosuppressive phenotype and tend to be resistant to apoptosis.133,147,159–162  
Neutrophil numbers may be dramatically increased in critical illness states, particularly 
sepsis. This increase in neutrophil number is thought to be driven by release of neutrophils 
from marginated pools by the presence of pro-inflammatory mediators such as TNF-α, C5a, 
and IL-6.1  Similar mediators including LPS and GM-CSF drive a decrease in apoptotic cell 
death, often culminating in a significant circulating neutrophilia,1,23,149 though the supply is not 
inexhaustible and can be overwhelmed by high bacterial loads or concomitant stimuli.163 
Despite this neutrophilia, patients remain profoundly vulnerable to bacterial infections 
traditionally controlled by neutrophils such as Staphylococcus aureus and Pseudomonas 
aeruginosa.69,147  An attractive explanation for this paradox is that neutrophils observed in 
critical illness or systemic inflammatory states are characterised by altered or reduced 
function, and is discussed below.   
2.5.2. Decreased functional responses of immune cells 
One of the best-characterised functional immune defects is known as endotoxin tolerance, 
which Cavaillon and Adib-Conquy164 define as a “reduced responsiveness to LPS challenge 
following a first encounter with endotoxin.” Endotoxin tolerance has been shown to occur in a 
variety of immune cell types with diverse responses,165 though is perhaps best known to refer 
to reduced TNF-α secretion by monocyte-macrophages in response to prolonged or repeated 
LPS exposure.164,166,167 Associated with this defect is the T-cell receptor ligand, D-related 
human leukocyte antigen (HLA-DR). Initially, persistently low monocyte HLA-DR levels147,168 
were shown to be associated with nosocomial infection in sepsis.150,169 More recently, HLA-
DR levels have been shown to predict mortality and nosocomial infection in critical illness 
generally.133,147,170 
A more recently characterised cell-surface marker is programmed death ligand 1 (PD-L1). 
Expressed on the surface of neutrophils, PD-L1 expression is upregulated in sepsis and in 
response to LPS challenge, and suppresses T-cell proliferation through an interferon-γ-
dependent mechanism.69,133,171 Anti-PD-1 antibody treatment reverses immune dysfunction 
and improves survival in mouse models,172 and has been shown to increase phagocytic 
capacity in neutrophils from septic humans.173 
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Neutrophil subsets also appear and behave differently during systemic inflammation and 
critical illness. Circulating neutrophils in this context have been demonstrated to have low 
expression of maturation markers CD10 and CD16, kill activated T-cells and were associated 
with progression of sepsis.174 Pillay and colleagues have also provided evidence for a subset 
of neutrophils found after LPS challenge or trauma which suppress T-cell proliferation via the 
integrin dimer macrophage-1 antigen (Mac-1, complement receptor 3 or αMβ2 integrin).7  
In addition to these defects, the direct antimicrobial functions of neutrophils have been shown 
to be significantly impaired in critical illness by multiple groups. In a comprehensive 
assessment of septic shock patients at days three-six and six-eight after onset of shock, 
Demaret and colleagues149 demonstrated impaired chemotaxis toward multiple 
chemoattractants, defective phagocytosis and oxidative response to E. coli, and correlated 
these findings with mortality. Many other groups have found similar results with respect to 
chemotaxis,175 phagocytosis176–179 and ROS generation179–181 in different critical illness states 
including burns, sepsis and trauma. Data on ROS generation by neutrophils can at times be 
difficult to interpret, with some groups showing an increase in ROS production in sepsis182,183 
and ARDS184 whereas many others show decreased ROS production as outlined previously 
and summarised in authoritative reviews.167,185 These contrasting findings illustrate the 
importance of context in interpreting neutrophil functional responses, and in most cases can 
be explained by differences in experimental time-points, stimuli and purification procedures.  
It is clear that both the number, subsets and diverse functions of multiple immune cell types 
are profoundly altered in the context of critical illness, and that these alterations predict 
clinically significant outcomes. Further, a focus of current work is understanding how these 
changes persist over time, and the role of epigenetic and post-translational modifications in 
the persistence of these effects after critical illness.167,186 Equipped with an understanding of 
the effects of critical illness on immune cells in general, it is now time to explore the central 
role of C5a in mediating these defects.   
3. C5a as a central mediator of organ and immune 
dysfunction 
3.1. Complement cascade 
The term ‘complement’ was coined in 1899 by Paul Ehrlich after the heat-sensitive ability of 
serum to kill bacteria was noted in 1888 and 1891.92,187 The name is derived from Ehrlich’s 
thought that the system ‘complemented’ the antimicrobial functions of antibodies. It is a 
cascade of over 30 plasma glycoproteins (designated C-xq, where x indicates a protein 
number and q the protein subunit) which are activated through proteolytic cleavage at sites of 
inflammation, in a similar way to the coagulation cascade.187,188 The precursor proteins 
(zymogens) are predominantly synthesised by hepatocytes but tissue macrophages, 
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monocytes and epithelial cells are also capable of synthesis.92,187 There are four key 
functions of the complement system, namely; opsonisation, propagation of the inflammatory 
response, pathogen destruction by the membrane attack complex (MAC) and enhancement 
of adaptive immunity.187,189 There are multiple activation pathways; three are well-
characterised and converge on the activation of the C3 convertase.189 Others have more 
recently been identified such as the macrophage serine protease- and thrombin-triggered 
arms.92,190,191 Figure I-1 summarises known complement activation pathways and 
demonstrates how C5a is produced.   
3.2. C5a anaphylatoxin 
Human C5a is a 74 amino acid protein, composed of four α-helices in anti-parallel with 
bridging disulphide bonds.192–194 It is formed from cleavage of the amino terminal of C5 by the 
C5a convertase in the plasma.192,195,196 Along with the less-potent C3a, C5a is a key 
inflammatory anaphylatoxin generated by multiple upstream pathways of the complement 
cascade (classical, lectin and alternative) as well as being generated directly or indirectly by 
activated neutrophils,197 macrophages,191 platelets198 and coagulant cascade proteins.199 
Figure I-1 provides a summary of the pathways of relevance to C5a production.50,200,201  
Several mechanisms determine the regulation of C5a function in the plasma. Firstly, C5a is 
cleared by receptor-mediated internalisation by immune cells in vascular organs such as the 
lung, spleen, liver and kidney.202,203 Furthermore, removal of the C-terminal arginine residue 
(desargination) from the C5a molecule204 by serum carboxypeptidases N, B or R yields 
C5ades-arg, which exerts less potent inflammatory effects, as discussed below.204–207 Under 
normal conditions, the plasma concentration of C5a is very low (in the range of 1-5 nM)208 as 
the anaphylatoxin is cleared within 3-5 minutes through the mechanisms outlined 
above.203,209 In critical illness, tight control of C5a production is lost, and plasma 
concentrations can exceed 100 nM.92,208,210 However, given the rapidity of C5a clearance, it is 
hypothesised that the presence of detectable plasma C5a concentrations most likely indicate 
receptor saturation and hence the plasma concentration  of C5a may give a relatively 
unreliable indication of the cellular exposure to this agent. Ligation of the C5a receptor by 
C5a leads to internalisation, and hence several authors have used neutrophil C5a receptor 
surface expression as a more accurate marker of C5a exposure. Whilst down-regulation of 
neutrophil surface C5a receptor expression may not be caused solely by C5a, at least in 
vitro,211,212 it is a reliable marker of neutrophil phagocytic dysfunction213 and has been 




3.3. C5a receptors 
There are two known receptors for C5a; C5aR1 or cluster of differentiation molecule 88 
(CD88) and C5L2, also known as G-protein coupled receptor 77 (GPR77).193,215 For the 
purposes of this thesis, abbreviations C5aR1 and C5aR2 refer to CD88 and C5L2 
respectively. C5aR1 is a G-protein coupled receptor with seven transmembrane domains 
and three extracellular loops.92,193,216 In a series of seminal papers, Chenoweth and Hugli first 
identified the receptor on human neutrophils in 1978, and demonstrated distinct roles for the 
carboxyl terminal of the C5a molecule in terms of receptor binding and activation.196,206,217 
Since then, debate has ensued regarding the nature of C5a-C5aR1 interactions. Data 
generated using three distinct peptides able to impair C5a binding and functional responses 
suggested three interaction sites between recombinant C5a and C5aR1 on human 
Figure I-1: Simplified overview of C5a generation 
The classical complement pathway is activated by IgG and IgM-induced activation of C1 
subunits. The lectin pathway is activated after exposure of mannose binding lectin (MBL) in 
serum to bacterial mannose monomers. This interaction generates active MBL-associated 
serine proteases 1 (MASPs) in the serum. The alternative pathway relies on the gram-
negative bacterial pathogen associated molecular pattern (PAMP) lipopolysaccharide 
(LPS). Through intermediary complement proteins, the canonical pathways converge on 
the C3 convertase. Non-canonical pathways generally converge on the C5 convertase, and 
are initiated by proteases released by activated neutrophils and tissue macrophages191, as 
well as thrombin190 and properdin.197 
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neutrophils.193 More recently, Baranski’s group have used 3D modelling and saturation 
mutagenesis in yeast to provide further evidence for a ‘two-site’ C5a:C5aR1 binding model 
advanced by Siciliano in 1994.218–220 These authors propose multiple interactions between 
the N-terminals of C5a and C5aR1 as the first binding site, whereas the second site is 
formed by salt bridges and hydrogen bonds between the extracellular loops of the 
transmembrane domains of C5aR1 with the carboxyl terminus of C5a.218,220,221 These findings 
differentiate C5aR1 from the C3a receptor at which the biological activity of the ligand is 
largely determined by the carboxyl terminus.222,223  These nuances are of paramount 
importance for effective drug design, which is discussed in more detail below.  
In 2000 Ohno and colleagues identified a second receptor (C5aR2) in immature dendritic 
cells and granulocytes which was subsequently found to bind C5a, and its desarginated 
form, with high affinity.215,224 Since that time, the effects, ligand selectivity and physiological 
relevance of C5aR2 have been the subject of debate.210,225,226 Like C5aR1, C5aR2 is a seven 
transmembrane domain receptor, encoded on chromosome 19.227 C5aR2 shares 37% of its 
amino acid sequence identity with C5aR1228 and binds C5a with high affinity.215,227 Relative to 
C5aR1, C5aR2 binds the desarginated form of C5a with 10-50 times higher affinity as 
evidenced by competitive ligand-binding assays in transfected cell lines.227,229  
A key difference between the receptors is the uncoupling of C5aR2 from G-protein signal 
transduction pathways; in cell lines transfected with C5aR2, minimal C5a-induced calcium 
flux,230 degranulation,215 C5aR2 phosphorylation or extracellular signal related kinase (ERK) 
phosphorylation229 occurred. Bamberg and colleagues demonstrated that C5aR2 co-localised 
with β-arrestins after C5a stimulation of primary human neutrophils and downregulated 
ERK1/2 signalling,231 a known mechanism of GPCR signal modulation.232 Van Lith233 and 
Cui234 also demonstrated similar colocalization of C5aR2 with β-arrestins in transfected 
human osteosarcoma and embryonic kidney cells respectively. This work was extended by 
Croker et al, who showed that C5aR2-related inhibition of ERK activation may be related to 
C5aR1/2 heteromer formation in human monocyte-derived macrophages.235 Collectively, 
these findings lent weight to the hypothesis that C5aR2 may act as a ‘decoy’ receptor or 
even dampen C5a responses.227,229,236 From the conflicting data presented, it is difficult to 
make generalisations about the relative role of C5aR2, and indeed any effects are almost 
certainly context-dependent. Bearing this in mind, we now turn to the effects of C5a on key 
organ systems and neutrophils in the context of critical illness.  
3.4. C5a in critical illness: effects on key organ systems  
In critical illness states there is systemic overspill of cytokines, DAMPs and PAMPs (see 
Section 2).102,185 A similar phenomenon occurs with C5a; rather than localised, controlled 
generation of the anaphylatoxin, C5a is generated in massive quantities throughout the 
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circulation, saturating its receptors on organ systems and driving the effects discussed 
below.92,208 
3.4.1. Cardiovascular system and endothelium  
C5a induces cardiac dysfunction in multiple rodent models, with defects being detectable by 
echocardiography in as little as 8 hours.126,237,238 The roles of mitogen activated protein 
kinases, action potential disturbances and the inflammasome have only more recently been 
elucidated in subsequent studies by the same group.238–240 With respect to the endothelium, 
C5a stimulates tissue factor and adhesion molecule expression with resulting disruption of 
the endothelial glycocalyx, leading to further DAMP release into the circulation.127,185,241 
Collectively, these data indicate C5a worsens cardiovascular dysfunction both through 
vascular leakage and pump failure, exacerbating refractory shock and tissue hypoperfusion.  
3.4.2. Platelets and coagulation 
There are multiple sites of interaction between the complement and coagulation cascades, 
two evolutionarily ancient but distinct systems, which aim to maintain homeostasis in the face 
of infection and haemorrhage respectively.199,242 The importance of this interplay cannot be 
overstated in the setting of critical illness, where haemorrhage and pathogen invasion 
frequently co-exist and disseminated intravascular coagulopathy (DIC) is common.185 C5a 
has been shown to play an important role in the interaction between these two systems; it 
may be generated by multiple enzymes present at the site of clot, including thrombin,190 
tissue plasminogen activator,243 damaged endothelium, plasmin,185 elastase and free DNA.242 
Furthermore, C5a and other complement products, once generated, go on to induce platelet 
activation, endothelial glycocalyx disruption,185 leukocyte-platelet aggregation and further 
tissue factor activation.244–248 Once this vicious cycle begins, microvascular occlusion, 
endothelial damage and tissue hypoxia follow, worsening organ damage and mortality.97,127–
129,249  
3.5. C5a in critical illness: effects on neutrophils 
Data from the Ensembl database250 indicate both C5a receptors are widely transcribed 
(reviewed by Lee et al227) and enriched amongst cells of the immune system, particularly in 
neutrophils and monocytes, suggesting a key role in the modulation of innate immunity. 
Transcriptional data almost certainly does not fully reflect the tissue-specific expression of 
C5a receptors, and it is likely that new data arising from systematic proteomic studies will 
shed new light on this important area in the near future. Below is a brief outline of the known 
effects of C5aR1 and C5aR2 ligation in human neutrophils, with substitution of animal data 
where human studies have not yet been conducted. 
C5a has long been known to induce chemotaxis in neutrophils.251,252 More recently, the 
signalling pathways driving chemotaxis and ROS production have been elucidated. After C5a 
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ligation of C5aR1, conformational changes activate the α- and βγ-subunits of the G-protein 
complex. The α-subunit activates the small guanosine triphosphatase (GTPase) Ras, 
whereas the βγ-subunits activate adenylyl cyclase, phospholipase C (PLC) and other 
downstream targets including PI3K.92,227,253,254 Ras can also independently activate PLC. 
Specifically of relevance to chemotaxis is the spatial localisation of PtdIns(3,4,5)P3 and its 
key phosphatase, phosphatase and tensin homolog (PTEN), to the leading edge and 
peripheries of the cell respectively,255,256 allowing actin polymerisation and directional 
migration in the presence of multiple chemoattractants.257,258  
Phosphorylated PLC strongly activates protein kinase C (PKC) which leads to downstream 
activation of the mitogen activated protein kinase (MAPK)/extracellular signal-related kinase 
(ERK) pathway and mobilisation of intracellular calcium stores.92,227,253 Activation of the 
MAPK pathway results in translocation of the cytosolic subunits of the NADPH oxidase to 
cellular and phagosomal membranes and the generation of ROS.179,259,260 Recent reports by 
Denk and colleagues demonstrated that C5a-C5aR1 interactions lead to sodium/hydrogen 
exchanger (NHE1) dependent changes in intracellular pH and fluid content, driving neutrophil 
degranulation, shape change and chemotaxis.261,262 C5aR1 ligation also prolongs neutrophil 
survival through potentiation of the Akt/Bad pathway and decreasing activity of the pro-
apoptotic caspase 9.227,263,264 In neutrophils, the effects of C5a on ROS production and 
apoptosis have been demonstrated to be dependent on phosphoinositide signalling.259,263–265  
Phagocytosis is also affected by C5a. Ingestion of E. coli by neutrophils and monocytes in a 
human whole-blood model was shown to be dependent on preserved C5a-C5aR1 
interactions.266 The authors postulated that the effect was mediated by upregulation of the 
complement receptor 3 complex (CR3) on leukocyte membranes, which increases 
phagocytosis by binding to its ligand iC3b deposited on pathogen surfaces during 
opsonisation.200,266,267 A similar C5a-mediated CR3 upregulation and increased phagocytosis 
was demonstrated by Demaster and colleagues using streptococci.268  
In the context of critical illness, the effects of C5a on neutrophils appear divergent from the 
effects identified above. As discussed above, C5a signals through pathways known to drive 
chemotaxis, form ROS and enhance phagocytosis. One would think these enhanced immune 
responses would be of benefit in critical illness states, where control of pathogens is 
necessary. However, a seminal study published in 1999 by Czermak and colleagues269 
demonstrated a survival benefit of C5a blockade in a CLP-induced sepsis model in rats. The 
authors showed that antibody blockade of C5a resulted in increased neutrophil ROS 
production and better control of bacterial outgrowth, evidenced by bacterial colony forming 
unit counts in liver and spleen, relative to control-treated animals.269   
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Since the late 1990s, advances have been made in understanding the mechanism of these 
effects. Huber-Lang and colleagues demonstrated in 2002 that pre-exposure of adherent, 
purified, rat neutrophils to C5a reduced phagocytosis of opsonised zymosan particles, as 
well as subsequent ROS production and chemotaxis in similar studies.179,270,271 Further 
studies also showed a deleterious effect of C5a in sepsis induced by caecal ligation and 
puncture (CLP) in mice.179,269,270 Work from our group has demonstrated pivotal roles for the 
small GTPase RhoA and PI3K-δ in mediating the C5a-induced reduction in phagocytosis.213 
This work showed that PI3K-δ inhibition prevented the C5a-dependent impairment of 
phagocytosis of serum-opsonised zymosan by adherent human neutrophils, and that this 
was accompanied by restored RhoA activity.213 This inhibitory role for PI3K-δ is supported by 
work from Papakonstanti and colleagues272 who suggested active PI3K-δ inhibits RhoA 
activation via p190 Rho-GTPase activating protein (GAP). Papakonstanti went on to 
demonstrate that in a mouse macrophage cell line with constitutively inactivated PI3K-δ, 
RhoA activity was increased, and that it returned to wild-type levels when RhoA’s 
downstream effector Rho-associated, coiled-coil-containing protein kinase 1 (ROCK) was 
inhibited.272 Beta-adrenoreceptor agonist induced defects in phagocytosis are also mediated 
by PI3K-delta and inhibition of RhoA,273 although in contrast to the C5a-induced defect, 
adenylyl cyclase is a key upstream mediator in this setting.177,213 These signalling effects of 







Figure I-2: C5a-induced signalling through C5aR1 affecting key neutrophil functions 
Signalling in neutrophils after C5a-C5aR1 ligation leads to activation of cAMP (not shown), 
PLC and Ras. Phosphorylated PLC activates PKC which leads to MAPK/ERK signalling, 
release of calcium, phosphorylation of the NADPH oxidase and activation of NHE1.179,261 
These events lead to translocation of the oxidase to the phagosome, increased intracellular 
pH and glycolysis. The dual effect of  C5a on ROS production appears to be dependent on 
whether C5a exposure is a primary stimulus (generates ROS) or occurs prior to another 
stimulus (dampens subsequent ROS production).179,259 C5aR1 activation also leads to the 
inhibition of caspase 9 activity mediated by p-Akt, resulting in prolonged neutrophil 
survival.263,264 The effect of C5a on phagocytosis appears to be mediated through PI3K 
signalling and inhibition of RhoA/ROCK activity, which is required for effective actin 
polymerisation and phagocytosis.213,272 cAMP: cyclic adenosine monophosphate; MAPK: 
mitogen-activated protein kinase, also known as ERK: extracellular signal-regulated kinase; 
NADPH: nicotinamide adenine dinucleotide phosphate-oxidase; NHE1: sodium/hydrogen 
exchanger 1; p190RhoGAP: Rho GTPase activating protein 190; PI3K: phosphatidylinositol-
3-kinase; PIP2: phosphatidylinositol 4,5-bisphosphate; PIP3: phosphatidylinositol 3,4,5-
trisphosphate; PKC: protein kinase C; PLC: phospholipase C; RBD: Ras-binding domain; 
ROCK: Rho-associated, coiled-coil-containing protein kinase; ROS: reactive oxygen species; 
SH2: Src homology domain.  
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These in vitro findings have more recently been extended to human critical illness, where 
neutrophil phagocytosis and bactericidal capacity is defective, and decreased C5aR1 
expression (indicating C5a exposure) is correlated with the development of nosocomial 
infection.147,177,213 In addition to C5aR1 downregulation, C5aR2 is also involved; data from 
septic humans showed associations between C5aR2 downregulation, multi-organ failure and 
death.226  
In addition to disruption of vital neutrophil functions, C5a exerts a number of effects on 
macrophages and their circulating precursors. C5aR1 and C5aR2 are highly transcribed in 
monocytes (similar to neutrophils) but less abundantly so in tissue macrophages.92,210,250 C5a 
is able to potentiate LPS-induced production of TNF-α by alveolar macrophages in rats, and 
is required for efficient E. coli-induced ROS production in human circulating monocytes.266,274 
In addition to TNF-α production, C5a induces HMGB-1 production through C5aR2 in mouse 
peritoneal macrophages.127,210 Paradoxically, macrophages seem to have enhanced 
functional responses following exposure to C5a, whereas neutrophil function is depressed. 
This may be due to reduced receptor expression in macrophages, or may reflect changes in 
monocyte/macrophage signalling mechanisms induced by endothelial transmigration and the 
differentiation from monocyte to macrophage.275 A summary of C5a-induced effects on key 
organ systems in critical illness is provided in Figure I-3.   
It has been hypothesised that the divergence of C5a-induced effects is due to the 
concentration of C5a present.92,270,276 However, published dose-response curves do not 
support this biphasic response. To my knowledge, published data only demonstrate 
decreasing phagocytosis177,270 and increasing ROS production277,278 with increasing 
concentrations of exogenous C5a in the absence of other stimulants. However, regardless of 
potential concentration effects, preliminary data from our lab (discussed in Chapter V:) 
indicate that timing of C5a exposure with respect to pathogen encounter may be a critical 
factor that drives different responses. While C5a can facilitate neutrophil phagocytosis, ROS 
production, and bacterial killing when pathogens are encountered, exposure to C5a prior to 
such encounters may result in subsequent inhibition of these processes during pathogen 
encounter, potentially driving susceptibility to nosocomial infection and increased 
mortality.147,177,213,269–271 Whilst some key signalling ‘nodes’ have been identified in previous 
studies, a comprehensive picture of C5a-induced signalling in neutrophils has yet to be 




3.6. Therapies targeting C5a 
C5a signalling is an attractive therapeutic target in critical illness, given its multiple 
deleterious functions, the need for novel immunomodulatory therapies and increasing 
antimicrobial resistance in the intensive care unit.111,185 Anti-C5a antibodies have been 
employed for many years and have shown significant mortality benefits in animal sepsis 
models.179,269,279 Despite such promising findings, the only licenced therapy which 
manipulates the C5a axis directly is eculizumab. This monoclonal antibody targets C5, 
preventing the generation of both C5a and the terminal complement complex. Blockade of 
C5 in this way reduces complement-mediated intravascular haemolysis, which is the 
hallmark of paroxysmal nocturnal haemoglobinuria, the disease for which eculizumab is 
licenced.280 However, the increased susceptibility of patients treated with eculizumab to 
Neissieria spp infection (likely due to impaired complement haemolytic activity) sounds a 
note of caution with respect to use of this agent in a critical illness context.281  
Newer monoclonal antibodies which selectively target C5aR1 and/or 2 without inhibiting 
membrane attack complex formation are currently in various stages of development for 
Figure I-3: C5a-induced organ dysfunction during critical illness 
During critical illness, unbridled activation of the complement pathway occurs, leading to 
systemic overspill of complement proteins, particularly C5a. In this context, C5a leads to 
widespread platelet activation and thrombus formation, reduced cardiomyocte function and 
impaired antimicrobial activity of the innate immune system.177,179,238 
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indications as diverse as macular degeneration and vasculitis.282–285 Of key relevance to 
critical illness is IFX-1, a monoclonal antibody which has enjoyed success in phase II dose-
escalation trials for early sepsis-induced organ dysfunction, though full trial results have not 
yet been reported.286   
4. Chapter summary and areas for further research 
Neutrophils are now known to be much more than the simple infantry of the immune system, 
with a diverse array of effects on multiple cell types and the ability to rapidly adapt to diverse 
environments. Amongst these functions, neutrophil phagocytosis, and the subsequent 
maturation of the phagosome are critical events for pathogen killing. In the context of critical 
illness, which often culminates in nosocomial infections, organ failure and death, neutrophil 
dysfunction is pronounced, and has been correlated with numerous patient-centred 
outcomes. The causes of neutrophil and the broader immune dysfunction observed in these 
patients are the subject of ongoing investigation, though it is clear a key mediator is the 
anaphylatoxin C5a.  
Whilst our understanding of C5a and critical illness biology has increased substantially in the 
last two decades, fundamental questions remain. The in vitro effects of C5a exposure on 
neutrophil phagocytosis have not been assessed in the context of clinically relevant 
pathogens, or over periods of time greater than one hour. Further, whilst changes in C5aR1 
expression have been documented in response to C5a, the fate of the receptor has yet to be 
interrogated in settings in which C5a clearly has an impact, such as phagocytosis. There 
remains a relative paucity of data on interactions between cells of the immune system after 
exposure to C5a in clinically relevant models such as human whole blood. Often, studies of 
critical illness-related immune dysfunction have measured cell surface marker expression or 
cytokine levels, rather than cellular function in response to a known stimulus. Quantifying 
important cellular functions is currently cumbersome and not scalable, hampering our 
understanding of important biology in clinical settings.  
Finally, our understanding of C5a-induced intracellular signalling networks in immune cells 
was generated using inhibitors and pull-down assays in isolated cell populations.179,213 The 
field will benefit from unbiased transcriptomic or proteomic approaches which more 
completely capture the complex networks involved, and may uncover previously 
unappreciated signalling processes. This thesis aims to address these issues and 




Chapter II: Methods 
1. Consumables and reagents 
Table 1: Consumables and reagents 
Consumable/reagent Supplier Location 
IPI-549 PI3K inhibitor Active Biochem Kowloon, Hong 
Kong 




CAL-101 PI3K inhibitor ApexBio Boston, USA 
Pasteur pipettes, strippettes (10 ml, 25 ml) Appleton Woods  Birmingham, UK  
Sterile saline (0.9%)  Baxter Healthcare  Berkshire, UK  
CellFIX stock solution, polypropylene Falcon 
tubes (15 ml, 50 ml), polystyrene round bottom 
tube (5 ml), syringes (50 ml) 
BD Biosciences  
  
Oxford, UK  
  
Bio-Rad Quick start protein assay kit, 
lipoteichoic acid (LTA) 
Bio-Rad Watford, UK 
Purified human C5a Complement 
Technology Inc 
Tyler, USA 
5ml round bottom polystyrene FACS tube Corning New York, USA 
PCR-clean 2 mL safe-lock microcentrifuge tubes Eppendorf Hamburg, 
Germany 
Dextran 500, ECL prime western blotting 
detection reagent, high performance 
chemiluminescence film 
GE Healthcare  Little Chalfont, 
UK 
19-gauge Butterfly needle  Hospira  Lake Forest, UK  
AF488 S. aureus (Wood strain) Bioparticles, 
phenol red-free Iscove's Modified Dulbecco's 
Medium (IMDM), pHrodo Bioparticles (E. coli, S. 
aureus), trypan blue, Abc total antibody 
compensation beads 
Life Technologies  Paisley, UK 
Sterile calcium chloride, sterile sodium citrate Martindale/Ethyfarm  Wooburn 
Green, UK 
24-well cover glass imaging plates Miltenyi Biotech  Bergisch-
Gladbach, 
Germany 
Dried semi-skinned milk powder Premier Foods St Alban's, UK 
Argatroban, secretory leukocyte protease 
inhibitor (SLPI), TNF-α 
R&D Systems Abingdon, UK  
S-Monovette citrate, EDTA, heparin vacutainers, 
24- and 96- well tissue culture plates 
Sarstedt Numbrecht, 
Germany 
Cytocentrifuge white filter cards, Diff-Quick stain 
kit 
Shandon Lipshaw  Pittsburgh, USA  
Ammonium persulfate, calcium chloride, 
chloroform, diphenyleneiodonium chloride (DPI), 
Dulbecco’s phosphate buffered saline, fMLP, 
glycine, hydrochloric acid, lipopolysaccharide 
derived from E. coli, Luria broth base, 
lyophilised bovine serum albumin (BSA), 
lyophilised zymosan particles, marimastat 
Sigma-Aldrich  Dorset, UK 
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metalloprotease inhibitor, methyl 
methanethiosulfonate, Percoll Plus, 
polyvinylidene difluoride membrane, sodium 
dodecyl sufate (SDS), tris(2-
carboxyethyl)phosphine (TCEP), 
Triethylammonium bicarbonate (TEAB), Triton 
X-100, Trizma base, Tween-20 
Pipette tips (graduated, filter tip)  Starlab  Milton Keynes, 
UK  
12 % NuPage Bis-Tris gels, GM-CSF, HALT 
protease inhibitor cocktail, High-Select™ Fe-
NTA Phosphopeptide enrichment Kit, PageRuler 
Plus prestained protein ladder, pHrodo dye 
conjugation kit, Pierce trypsin protease, RPMI 





PAF Tocris Bioscience Abingdon, UK  
DPX mountant, glycerol, methanol  VWR International  Lutterworth, UK 
 
Table 2: Antibodies and stains for flow cytometry, fluorescence microscopy or 
western blotting 
Antibody Supplier Location 
BV421 mouse anti-human CD54 clone LB.2 BD 
Biosciences  
Oxford, UK  
BV711 mouse anti-human CD64 clone 10.1 
PerCP/Cy5.5 mouse anti-human C5aR1 clone S5/1  Biolegend London, UK 
PerCP/Cy5.5 mouse isotype control clone MOPC  
BV605 rat anti-mouse/human CD11b clone M1/70 
Pacific Blue mouse anti-human CD16 clone 3G8 
Purified mouse IgG2a, κ Isotype Ctrl clone MG2A-53 
Purified mouse anti-C5aR1 clone S5/1 
PerCP-Cy7 mouse anti-human CD32 clone FUN-2 
FITC mouse anti-human C5aR1 IgG2a antibody, 
clone S5/1 
BioRad  Hertfordshire, UK  
FITC mouse IgG2a isotype control  
DRAQ7 far-red fluorescent live/dead stain  Biostatus Leicestershire, 
UK 
Dihydrorhodamine (DHR) ROS probe CalBiochem Watford, UK 
Rabbit anti-human Akt primary  Cell Signalling 
Technologies 
Hitchin, UK 
Rabbit anti-human p-Akt primary  






USA  Hoechst 33342 
AF488 mouse anti-human TNFR1 clone H398 
AF488 mouse IgG1 isotype control 




2. Preparation of human neutrophils  
Ethical permission for taking peripheral blood from healthy volunteers was obtained from the 
Cambridge Local Research Ethics Committee (REC reference 06/Q0108/281). Neutrophils 
were isolated from citrated peripheral blood by using a modification of the technique initially 
described by Böyum in 1968,287 routinely employed in the Chilvers’/Summers’ laboratory. 
Briefly, red cells were removed by dextran sedimentation of whole blood, before the 
leukocyte-rich layer was aspirated and centrifuged over 42 and 51 % plasma-Percoll 
gradients. Granulocytes (including neutrophils) separate from peripheral blood mononuclear 
cells (PBMCs) according to density, with granulocytes located at the interface between the 
51 and 42 % gradients. The granulocyte layer is then aspirated, washed, counted and 
checked for purity > 95 % by cytospin before resuspension in the required media for use in 
experiments. The complete neutrophil preparation protocol is provided in the Appendices.  
3. Prepared neutrophil viability 
Neutrophil purity and cell viability were assessed by visual examination of cytospins under 
light microscopy at a magnification of 400X. Numbers of neutrophils, red blood cells (RBCs), 
PBMCs and eosinophils were counted in three fields containing at least 100 cells for each 
preparation. Preparations yielding a neutrophil purity ≥ 95 % were used in subsequent 
experiments.   
4. Phagocytosis of zymosan by adherent, purified 
neutrophils 
Purified human neutrophils (suspended in phenol red-free IMDM with 1 % autologous serum 
(AS) at a concentration of 106/mL) were allowed to adhere to 24-well tissue culture plates for 
20 minutes, before being exposed to 100 nM C5a or vehicle control for 30 minutes as 
previously reported.177 Opsonised zymosan (five µg/mL) was then added for 30 minutes, 
before non-internalised zymosan particles were washed off with warm IMDM. Plates were 
incubated at all stages at 37 °C in 5 % CO2. Plates were allowed to air dry before being fixed 
with methanol and stained with QuickDIFF staining kit. Phagocytosis was measured by 
manual counting of cells under light microscopy at 400 X. Neutrophils with ≥ 2 internalised 
zymosan particles were counted as a proportion of total neutrophils in two separate fields per 
well as previously described.177 Each condition was run in triplicate. 
5. Phagocytosis of pHrodo S. aureus and E. coli 
Bioparticles by purified neutrophils 
pHrodo Bioparticles™ (referred to as Bioparticles throughout the remainder of this thesis) are 
microbe particle-dye conjugates used to assess phagocytosis. The complex consists of a 
proprietary pH-sensitive fluorophore (pHrodo ‘green’ or ‘red’) conjugated to either heat-killed 
26 
 
S. aureus, E. coli or zymosan derived from S. cerevisiae. The pH-sensitive nature of the dye 
means it increases fluorescence in acidic conditions,288 such as inside the phagolysosome 
and therefore allows for the detection of phagocytosis without the need to quench 
extracellular fluorescence from non-phagocytosed, cell adherent particles. A detailed 
protocol for the use of Bioparticles to assess phagocytosis is included in the Appendices. In 
brief, purified human neutrophils (200 µL suspended in phenol red-free IMDM with 1 % AS at 
a concentration of 5 x 106/mL) were incubated in 2 mL round-bottom microcentrifuge tubes 
with C5a or controls for one hour. Meanwhile pHrodo-conjugated S. aureus or E. coli 
Bioparticles were serum opsonised, by incubation in 50 % AS.  Opsonised Bioparticles were 
then added to the neutrophil suspension for 120 minutes, before the mixture was fixed (1:40 
BD CellFIX) and analysed by flow cytometry (FACSCalibur and Accuri C6; BD Biosciences, 
Attune Nxt™; Life Technologies). Phagocytosis was quantified by the phagocytic index53 (PI: 
percentage of Bioparticle-positive cells x the median fluorescence intensity (MFI) in the 
relevant channel). 
6. Confirmation of flow cytometry phagocytosis signals 
The purpose of these experiments was to provide visual evidence of pHrodo Bioparticle 
fluorescence inside human neutrophils, to support the work done by flow cytometry. These 
experiments are not intended for quantification purposes in their current form. Purified human 
neutrophils (200 µL suspended in phenol red-free IMDM with 1 % AS at a concentration of 5 
x 106/mL) were incubated in 2 mL round-bottom micro-tubes with semi-log increasing ratios 
of Bioparticles:PMNs for 120 minutes. Cells were then fixed, stained with DAPI for 10 
minutes and analysed on an ImageStream X Mark II cytometer (Millipore; Hertfordshire; UK) 
which allows cell-by-cell concurrent fluorescence microscopy and flow cytometry. 
7. Confocal microscopy of purified human neutrophils 
Confocal microscopy was used to confirm pHrodo particle ingestion and fluorescence as well 
as to localise C5aR1. Purified human neutrophils at a concentration of 106/mL in RPMI 1640, 
10 mM HEPES and 1 % AS were adhered to AS-coated 24-well glass imaging plates for 30 
minutes in the presence of Hoescht 22342. Neutrophils were fixed using 1:40 diluted BD 
CellFix, washed and permeabilised with 0.1 % Triton X-100 and blocked in 5 % BSA for 60 
minutes. Primary antibodies were added, and cells stained for 60 minutes. Cells were 
washed, secondary antibodies or stains were added, and cells stained for 60 minutes 
protected from light. Neutrophils were washed, left in PBS and visualised by confocal 
microscopy at 630 X magnification using a Leica Sp5 confocal microscope (Leica 
Microsystems, Milton Keynes, UK). Antibodies used are specified in relevant figure legends 
and Table 1. 
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8. PtdIns(3,4,5)P3 production assay 
In order to independently confirm that C5a generates PtdIns(3,4,5)P3 intracellularly in human 
neutrophils, a highly sensitive mass spectrometric method was employed as previously 
described.289 Neutrophils were isolated according to our standard protocol and resuspended 
at a concentration of 3 x 107/mL  in PBS containing Ca2+ and Mg2+. Aliquots of cells (170 uL) 
in triplicate were primed with 100 ng/mL LPS or PBS control for 30 minutes. Cells were then 
stimulated with fMLP (100 nM), C5a (100 nM) or PBS control for 15 seconds, before 
reactions were quenched by addition of 750 uL ice-cold quench mix (65 % methanol, 32 % 
chloroform and 3 % 1M HCl) before storage at -80°C for transport to the Babraham Institute, 
Cambridge, UK. I observed the remainder of this process being carried out by Dr Karen 
Anderson working within Professor Len Stephen’s laboratory at the Babraham Institute.  
Lipids were extracted by centrifugation into lipid and protein phases and a non-organic 
PtdIns(3,4,5)P3 internal standard was spiked into the mixture to allow quantification of 
neutrophil-derived PtdIns(3,4,5)P3. Lipids were derivatised using trimethylsilyl diazomethane, 
which chemically protects the acidic phosphate groups on PtdIns(3,4,5)P3 allowing for 
accurate identification by mass spectrometry. Complete details of this experimental protocol 
and mass spectrometer settings is available in the group’s 2011 paper.289 PtdIns(3,4,5)P3 
abundance was quantified as a ratio of the C38:4 species to the spike-in internal standard, 
thus accounting for differences in lipid extraction and derivatisation during this process.  
9. Bacterial killing assay 
Methicillin-sensitive Staphylococcus aureus (MSSA) bacteria were grown on a Columbia 
blood agar plate overnight at 37 oC in 5 % CO2. A single colony-forming unit (CFU) from the 
plate was removed and cultured in 10 mLs of Luria broth (LB) overnight at 200 rpm, 37 oC. 
50 L of this liquid culture was placed into a fresh 10 mLs of LB and grown to early log-phase 
growth indicated by an optical density (OD) of 0.5 – 0.7, which took approximately 3 hours.  
In the interim, neutrophils were prepared at a concentration of 5 million/mL in IMDM. 180 L 
of the cell solution was transferred into 2 mL round-bottom Eppendorf tubes and treated with 
100 nM C5a or PBS vehicle control for 60 minutes. 10 L of the final MSSA culture was 
subsequently fed to the pre-treated neutrophils with an average multiplicity of infection (MOI) 
of 10:1, for one hour at 200 rpm, 37 oC. 50 L of the cell solution was transferred to 450 L of 
pH 11, distilled water for 3 minutes to lyse the neutrophils without adversely affecting MSSA 
viability. The solution was then vigorously vortexed for 15 seconds and 1 L transferred to 
999 L of LB. 100 L of this final dilution was plated and grown overnight at 37 oC at 5 % 
CO2. CFUs were visually counted the following morning. These experiments were planned by 




10. No-wash, no-lyse whole blood assay of neutrophil 
phagocytosis and ROS production 
The method discussed here is an adaptation of work initially described by Life 
Technologies290 and a detailed protocol for this procedure is included in the Appendices. 
Blood was drawn from a peripheral vein into the anticoagulant of choice 
(Ethylenediaminetetraacetic acid (EDTA), trisodium citrate, heparin or argatroban where 
specified). The initial choice of anticoagulant was informed by work from Mollnes, Brekke and 
colleagues266,267 which showed that direct thrombin inhibitors (lepirudin was used in their 
studies but is no longer available so argatroban was substituted) allowed complement 
activation and minimally affected leukocyte function. This was subsequently confirmed in my 
own experiments shown in Figure IV-2. Argatroban concentration was 150 µg/mL, which was 
the lowest concentration allowing for successful macroscopic anticoagulation at 37 °C for 7 
hours. Concentrations of EDTA, citrate and heparin when used were 1.6 mg/mL, 27.34 
µg/mL and 16 IU/mL as determined by their respective Sarstedt vacutainers listed in Table 1.  
Blood was treated with inhibitors or priming agents as indicated in respective figure legends. 
After treatment, 50 µL of blood was aliquoted into 96 well plates in triplicate and a combined 
S. aureus pHrodo red/dihydrorhodamine-123 (DHR) probe was added at final concentrations 
of 15 µg/mL and 3 µM respectively. The function of pHrodo is to indicate phagocytosis as 
discussed in Section 5 of this chapter. Dihydrorhodamine-123 is a non-fluorescent compound 
that is readily oxidised by ROS to polarised rhodamine-123, which remains intracellular 
owing to its electrostatic charge, and can be detected by devices such as flow cytometers or 
confocal microcopes.291 Volume was made up to 100 uL with RPMI 1640 and plates were 
incubated at 37 °C and 5 % CO2 for 30 minutes to allow phagocytosis to occur. 5 uL from 
each well was transferred into ice-cold RPMI 1640 media in flow cytometry tubes and stained 
with anti-CD16 antibody on ice in the dark for 30 minutes. Volume was made up to 4 mL with 
ice-cold PBS before the cells were analysed on an Attune Nxt™ Acoustic Focusing 
Cytometer (LifeTechnologies, Paisely, UK). This cytometer uses a combination of 
hydrodynamic and ultrasound focusing to allow much higher flow rates (up to 1 mL/minute) 
and consequent processing of highly dilute samples. Dilution of RBCs in this way allows 
discrimination from leukocytes based on cell-surface markers or violet laser scatter 
properties, as shown in Figure IV-1. Neutrophils were gated on CD16 expression and light 
scatter properties, phagocytosis was quantified by phagocytic index (excitation 561 nM, 
emission 585/16 nM) as previously described and ROS production by MFI of the DHR signal 
(excitation 488 nM, emission 530/30 nM).    
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10.1. S. aureus pHrodo vs AlexaFluor 488 assessment 
In a slight variation to this assay, a non pH-sensitive fluorophore (AlexaFluor 488: AF488) 
was used to confirm that the results with the pHrodo dyes were not simply due to an effect of 
C5a on intracellular pH. In these experiments, blood was drawn as usual and aliquoted into 
96-well plates. The S. aureus-AF488 probe (without DHR) was added at a concentration of 
15 µg/mL and plates were incubated at 37 °C and 5 % CO2 for 30 minutes to allow 
phagocytosis. 5 uL from each well was transferred into ice-cold RPMI 1640 media in flow 
cytometry tubes and fluorescence of extracellular particles was quenched with 15 µL of 
trypan blue. Volume was made up to 4 mL with ice-cold PBS before the cells were analysed 
on an Attune Nxt™ as previous. Violet laser scatter properties were used to identify the 
neutrophil population as trypan blue prevents the use of extracellular antibody stains.  
10.2. Dual phagocytic challenge  
Another variation to the basic phagocytosis assay made use of two pHrodo S. aureus 
Bioparticles with different fluorescence excitation and emission properties; pHrodo green and 
pHrodo red. These two Bioparticles can be measured in separate channels by flow 
cytometry, allowing for assessment of phagocytosis of two different particles or ‘meals’ in the 
same sample. Blood was drawn and treated with inhibitors or priming agents as indicated in 
respective figure legends. After treatment, 50 µL of blood was aliquoted into 96 well plates in 
triplicate and the first Bioparticle S. aureus pHrodo red was added at a final concentration of 
15 µg/mL and incubated for 30 minutes at 37 °C and 5 % CO2 to allow phagocytosis to occur. 
The second Bioparticle S. aureus pHrodo green was then added and cells were allowed to 
phagocytose as before. 5 uL from each well was transferred into ice-cold RPMI 1640 media 
in flow cytometry tubes and stained with anti-CD16 antibody on ice in the dark for 30 
minutes. Volume was made up to 4 mL with ice-cold PBS before the cells were analysed on 
an Attune Nxt™. 
10.3. Phagosomal maturation assessments 
Combinations of fluorophores were used to provide an assessment of phagosomal 
maturation. AlexaFluor 488-labelled S. aureus Bioparticles as above were conjugated to 
pHrodo dye according to the manufacturer’s instructions, providing a particle that could 
measure internalisation in a non-pH dependent manner (AF488) as well as an estimate of 
phagosomal acidification (pHrodo).292 In duplicate conditions, DHR was used in combination 
with pHrodo S. aureus red as previously described to provide a side-by-side assessment of 




10.4. Patient recruitment  
Patients were recruited under existing local ethical approvals (12/WA/0148) from routine 
immunology outpatient clinic appointments at a tertiary referral centre. Written informed 
consent was obtained directly from patients. Inclusion criteria were: age 16 – 75 years and a 
diagnosed congenital immunodeficiency syndrome. Exclusion criteria were: cancer 
diagnosis, HIV infection, pregnancy or lack of informed consent.   
11. Whole blood assay of neutrophil ROS production  
Blood was drawn from a peripheral vein into 150 µg/mL argatroban and 50 uL of blood was 
aliquoted into 2 mL microcentrifuge tubes in triplicate. Cells were primed with 20 ng/mL TNF-
α and the volume made up to 100 uL with RPMI 1640 media. Cells were incubated at 37° C 
and 300 rpm in a thermomixer for 30 minutes. Dihydrorhodamine-123 and fMLP were then 
added at concentrations of 30 µM and 1 µM respectively and cells were incubated for 20 
minutes. Tubes were placed on ice and stained with anti-CD16 antibody for 30 minutes in the 
dark, before ice-cold PBS was added to make the volume up to 2 mL. Cells were analysed 
on an Attune Nxt™ Acoustic Focusing Cytometer, neutrophils were gated based on CD16 
and light scatter properties and ROS was quantified by MFI of the DHR signal.   
12.  Whole blood phagocytic receptor profiling 
Blood was drawn from a peripheral vein into 150 µg/mL argatroban and 50 uL of blood was 
aliquoted into 2 mL microcentrifuge tubes in triplicate. Blood was pre-treated as indicated in 
figure legends before 5 uL of blood was transferred into 95 µL ice-cold RPMI 1640 media in 
flow cytometry tubes containing antibody master-mix. The master-mix consisted of pre-
titrated dilutions of the following antibodies: ICAM-1, 1:40; CD11b, 1:50; CD16, 1:200; CD88, 
1:100; CD32 1:50. Manufacturer and clone details can be found in Table 1. Tubes were 
placed on ice and stained for 30 minutes in the dark, before ice-cold PBS was added to 
make the volume up to 2 mL. Cells were analysed on an Attune Nxt™. 
13. Preparation of whole human neutrophil lysates 
Neutrophils were isolated from whole blood as detailed in Section 2 and resuspended in 
RPMI 1640 media containing 10 mM HEPES with 1 % AS at a concentration of 10 x 106 
cells/mL. Cells were treated as detailed in figure legends, centrifuged at 400 g for 5 minutes 
at 4 °C, supernatants were aspirated and cell pellets were snap frozen in liquid N2 at relevant 
time points. Lysis buffers (detailed in Table 3) were added and cells were subjected to freeze 
thaw cycles or sonicated to achieve cell lysis. Lysates were centrifuged at 20 000 g at 4 °C 












4 % sodium 
dodecyl sulfate 
(SDS)  
250 mM Tris-HCl 
pH 6.8 
20 % glycerol v/v 
Pepstatin A 10 µg/mL  
Aprotinin 10 µg/mL 
Leupeptin 10 µg/mL  
ABSF 1mM 
Add 200 µL to 10 x 106 cells. 2 
x freeze-thaw cycles (dry ice – 









1 X or 3 X HALT™ 
protease and 
phosphatase inhibitor 
cocktail as specified in 
figure legends. 
Add 200 µL to 10 x 106 cells. 1 
x freeze-thaw cycle and 2 x 20 
s probe sonication. 
14. SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Lysate protein concentration was determined by Bradford Protein Assay (Bio-Rad, Quick 
Start). Proteins were reduced by heating to 90 °C for 5 minutes in the presence of beta-
mercaptoethanol (βME). Protein (25 µg) or a pre-stained protein ladder (PageRuler™ Plus) 
was loaded into each well of a 12 % pre-cast SDS NuPAGE™ Bis-Tris gel and run according 
to the manufacturer’s instructions in an adaptation of the original method described by 
Laemmli.293  
15. Silver staining of SDS-PAGE gels 
SDS-PAGE gels were fixed in 30 % ethanol and 10 % acetic acid for 30 minutes at room 
temperature on a gel rocker. Gels were washed three times for 10 minutes in 30 % ethanol 
on a gel rocker ad sensitised for 1 minute in 370 µg/mL sodium thiosulfate-5-hydrate. Gels 
were then washed twice in deionised water (dH2O) for 1 minute each before being stained in 
2 mg/mL silver nitrate and 0.75 µL/mL of 38 % formaldehyde. Gels were washed in dH2O 
and developed in 600 mg/mL sodium carbonate, 0.45 µL/mL, 38 % formaldehyde and 5 
µg/mL sodium thiosulfate for 8 minutes or until bands were visible. Staining was terminated 
by addition of acetic acid, gels were washed once in dH2O and photographed.   
16. Western blotting 
Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane using a wet 
tris/glycine/methanol-based transfer method on ice. Membranes were washed, blocked in 5 
% milk or 5 % bovine serum albumin (BSA) and stained with primary antibodies (1:5 000) 
overnight at 4 °C. Membranes were washed, stained with secondary antibody (1:10 000) for 
one hour at room temperature, washed again and developed with ECL prime detection 
reagent according to the manufacturer’s instructions.  
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17. Proteomic and phosphoproteomic studies 
17.1. Neutrophil preparation 
Neutrophils were isolated from whole blood of n = 4 healthy human volunteers as detailed in 
Section 2 and resuspended in RPMI 1640 media containing 10 mM HEPES with 1 % AS at a 
concentration of 107 cells/mL. Cells were treated as outlined below. 
17.2. Treatments and conditions 
Technical triplicates of 107 neutrophils each were treated in 2 mL Eppendorf microcentrifuge 
tubes with control (PBS, 60 minutes), C5a (100 nM, 60 minutes), or PAF (1 µM, 5 minutes) at 
37 °C in a thermomixer rotating at 300 rpm before pHrodo S. aureus Bioparticles were added 
at a concentration of 15 µg/mL. Cells were allowed to phagocytose for 15 minutes. At 
baseline, immediately before Bioparticles were added and after phagocytosis aliquots of 400 
µL were withdrawn from each replicate and pooled to give 12 million cells per condition. Each 
pooled condition was centrifuged at 400 g for 5 minutes at 4 °C, supernatant was aspirated 
and the cell pellets were snap frozen in liquid N2. The experimental design including relevant 
conditions is depicted in Figure II-1. Samples were stored at -70 before transfer to Cancer 




















Figure II-1: Phosphoproteomics experimental design 
Neutrophils were purified as described and suspended in RPMI 1640 media supplemented 
with 10 mM HEPES and one % AS. Red circles indicate instances where aliquots of cells 
were removed for analysis. An untreated aliquot was removed and snap frozen and cells 
were then treated with 100 nM C5a, 1 µM PAF or control for 60 minutes (5 minutes for PAF). 
Post-treatment, pre-phagocytosis aliquots were removed and snap frozen, and pHrodo S. 
aureus Bioparticles were added; cells were allowed to phagocytose for 15 minutes before 
the final aliquots were removed and snap frozen. Phagocytosis was measured at the end of 
the procedure by flow cytometry of remaining (non-frozen) sample. Samples were batched 
until all 22 conditions were ready for analysis. Samples were transported to CRUK-CI on dry 
ice, lysed and digested as specified. The phosphoproteomic workflow included TMT 
labelling, fractionation and enrichment of phosphopeptides prior to LC-MS analysis in two 
separate batches or plexes with the 22 samples from four donors distributed across them as 
shown. Bioinformatics analysis (extraction of protein data from measured peptides and 
normalisation of peptide intensities) was completed at CRUK-CI before the data was 




17.3. Cell lysis and trypsin digestion 
Cells were lysed in freshly prepared ice-cold lysis buffer (0.5 % SDS, 0.1 M TEAB containing 
1 X HALT protease and phosphatase inhibitors). Cell suspensions were incubated at 90 °C 
for 5 minutes and sonicated twice for 20 seconds (EpiShear™ Probe Sonicator, Active Motif). 
The insoluble fraction was removed by centrifugation at 20 000 g for 10 minutes at 4 °C. 
Lysate protein concentration was determined by Bradford Protein Assay (Bio-Rad, Quick 
Start). 
100 µg of protein per sample was reduced in 5 mM Tris(2-carboxyethyl)phosphine (TCEP) 
for one hour at 60 °C, which was followed by alkylation of cysteines with 10 mM methyl 
methanethiosulfonate in the dark at room temperature. Lysates were then diluted 1:10 with 
0.1 M TEAB before trypsin was added at a 1:30 trypsin:protein ratio by mass. Digestion was 
carried out overnight at room temperature. 
17.4. Tandem mass tag labelling 
Tandem mass tag (TMT) reagents (0.8 mg) were reconstituted in 40 µl anhydrous acetonitrile 
and peptide samples were labelled according to the manufacturer’s protocol. Following 
incubation at room temperature for one hour, the reaction was quenched with hydroxylamine 
to a final concentration of 5% (v/v) for 15 min at room temperature. The TMT-labelled 
samples were pooled at 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1 across the 11 samples. The pooled 
sample was vacuum centrifuged to dryness and subjected to basic pH reversed-phase (bRP) 
fractionation. 
17.5. Off-line reverse phase fractionation at basic pH  
The TMT mixture was fractionated on a Dionex Ultimate 3000 system (Thermo Fisher 
Scientific) at high pH. The labelled peptide mixture was reconstituted in 20 mM ammonium 
hydroxide in water (pH 10) and subjected to a 45 minute linear gradient from 4.5% to 45% 
acetonitrile in 20 mM ammonium hydroxide (pH 10) at a flow rate of 0.2 ml/min over an 
XBridge C18 column Reversed-Phase (3.5 µm particles, 2.1 mm ID, 150 mm in length; 
Waters). The peptide mixture was fractionated into a total of 48 fractions. 15% (v/v) of each 
fraction was separated into a new tube and was used for full proteome analysis. The 
remaining volume in each fraction will be subjected to phosphopeptide enrichment. All 
fractions were dried on a centrifugal vacuum concentrator. 
17.6. Phosphopeptide enrichment 
The initial 48 fractions were consolidated into 14 and submitted to phosphopeptide 
enrichment by using the High-Select™ Fe-NTA Phosphopeptide Enrichment Kit according to 
the manufacturer’s protocol. Eluates containing the phosphopeptides were dried via vacuum 
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centrifugation and reconstituted in 10 µl of 0.1 % formic acid for liquid chromatography and 
tandem mass spectrometry (LC-MS/MS) processing. 
17.7. LC-MS/MS analysis of full proteome fractions 
The initial 48 fractions were pooled into a final number of 32 fractions. Each fraction was 
reconstituted in 10 µl of 0.1% formic acid and 5 µl were analysed on a Dionex Ultimate 3000 
UHPLC system coupled with an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher 
Scientific, San Jose, CA). Samples were loaded on an Acclaim PepMap 100, 100 μm × 2 cm 
C18, 5 μm, 100 Å trapping column with the ulPickUp injection method at a loading flow rate of 
5 μL/min for 10 min. For peptide separation, an EASY-Spray analytical column 
75 μm × 25 cm, C18, 2 μm, 100 Å column was used for multi-step gradient elution at a flow 
rate of 300 nL/min. Mobile phase (A) was composed of 2 % acetonitrile, 0.1 % formic acid; 
mobile phase (B) was composed of 80 % acetonitrile, 0.1 % formic acid. Peptides were 
eluted using a gradient as follows: 0 - 10 min, 5 % mobile phase B; 10 – 95 min, 5 – 45% 
mobile phase B; 95 -100 min, 45% - 95% B; 100 -  108 min, 95% B; 108 – 110min, 95% - 5% 
B; 110 – 120 min, 5% B. 
Data-dependent acquisition began with an MS survey scan in the Orbitrap (380 – 1500 m/z, 
resolution 120,000 full width half maximum (FWHM), automatic gain control (AGC) target 
3E5, maximum injection time 100 ms). The top ten precursors were then selected for 
MS2/MS3 analysis. MS2 analysis consisted of: collision-induced dissociation (CID), 
quadrupole ion trap analysis, AGC target 1E4, normalized collision energy (NCE) 35, q-value 
0.25, maximum injection time 35 ms, an isolation window at 0.7, and a dynamic exclusion 
duration of 45 seconds. Following acquisition of MS2 spectrum, MS3 precursors were 
fragmented by high energy collision-induced dissociation (HCD) using 10 frequency notches 
and analysed in the Orbitrap (resolution 50,000 FWHM, AGC target 5E4, NCE 55, maximum 
injection time 86 ms, and isolation window at 0.7. 
17.8. LC-MS/MS analysis of phosphopeptide-enriched fractions 
All the fractions (10 µl) were analysed on a Dionex Ultimate 3000 UHPLC system coupled to 
a Q-Exactive HF mass spectrometer (Thermo Fisher Scientific, San Jose, CA). Samples 
were loaded on an Acclaim PepMap 100, 100 μm × 2 cm C18, 5 μm, 100 Å trapping column 
with the ulPickUp injection method at a loading flow rate of 5 μL/min for 10 min. For peptide 
separation, an EASY-Spray analytical column 75 μm × 25 cm, C18, 2 μm, 100 Å column was 
used for multi-step gradient elution at a flow rate of 300 nL/min. Mobile phase (A) was 
composed of 2 % acetonitrile, 0.1 % formic acid, 5 % dimethyl sulfoxide (DMSO); mobile 
phase (B) was composed of 80 % acetonitrile, 0.1 % formic acid, 5 % DMSO. Peptides were 
eluted using a gradient as follows: 0 - 10 min, 5 % mobile phase B; 10 – 95 min, 5 – 45 % 
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mobile phase B; 95 -100 min, 45 % - 95% B; 100 - 108 min, 95 % B; 108 – 110min, 95 % - 5 
% B; 110 – 120 min, 5 % B. 
Data-dependent acquisition began with an MS survey scan in the Orbitrap (400 – 1600 m/z, 
resolution 60,000 FWHM, AGC target 3E6, maximum injection time 100 ms). The top 10 
precursors were then isolated and fragmented with CID. MS2 analysis consisted of: 
resolution 30,000 FWHM, AGC target 2E4, NCE  33, maximum injection time 100 ms, MS2 
isolation window 2.0 m/z. 
17.9. Phosphoproteomics data analysis 
Spectral .raw files from data dependent acquisition were processed with the SequestHT 
search engine on Thermo Scientific Proteome Discoverer™ 2.1 software. Data was searched 
against both human and Staphylococcus aereus UniProt reviewed databases at a 1 % 
spectrum level false discover rate (FDR) criteria using Percolator (University of Washington). 
MS1 mass tolerance was constrained to 20 ppm and the fragment ion mass tolerance was 
set to 0.5 Da. TMT tags on lysine residues and peptide N termini (+229.163 Da) and 
methylthio (+45.988) of cysteine residues (+57.021 Da) were set as static modifications, 
while oxidation of methionine residues (+15.995 Da) and deamidation (+0.984) of asparagine 
and glutamine residues were set as variable modifications. For TMT-based reporter ion 
quantitation, we extracted the signal-to-noise (S:N) ratio for each TMT channel. Moreover, 
parsimony principle was applied for protein grouping. 
18. Statistical analysis 
18.1. Wet-laboratory data 
Data are presented as individual data points with summary statistics (median and 
interquartile range; IQR or mean and standard deviation (SD) specified in the figure legend 
according to whether data are normally distributed. Parametric or non-parametric statistical 
tests were applied as appropriate after data was tested for normality using the D'Agostino-
Pearson or Shapiro-Wilk tests as appropriate. Differences between two groups were 
assessed by paired or unpaired t-tests or Wilcoxon’s test. Differences between three or more 
groups were assessed by one-way ANOVA or Friedman’s test with Dunn’s multiple 
comparisons correction as appropriate. Differences between grouped data were assessed 
with two-way ANOVA with Sidak’s or Dunnett’s multiple comparisons test as appropriate. 
Differences where p < 0.05 were considered statistically significant, and non-significant 
differences have not been indicated in figures for clarity. Statistical analysis was performed 
with GraphPad Prism v8.0 (GraphPad Software; San Diego; California). 
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18.2. Phosphoproteomics data 
Peptide and phosphopeptide intensities were normalised across conditions using median 
scaling and then summed to generate protein and phosphoprotein intensities. Log base 2 
fold-changes (Log2FC) were calculated between conditions of interest, compared across n = 
4 donors and tested for statistical significance by limma-based linear models with 
Bonferroni's correction for multiple testing. Hierarchical clustering using Euclidean distance 
was performed on the entire dataset and heatmaps generated and volcano plots generated 
as shown in Results. Statistical analysis was performed in RStudio294 using the 




Chapter III: C5a rapidly induces a prolonged 
impairment of neutrophil phagocytosis 
1. Chapter summary 
C5a has been shown to reduce neutrophil phagocytosis in vitro in rats179 and humans.177,213 
in addition to mediating organ failure and death in various in-vivo studies discussed in 
Section 3.5 of Chapter I:. This in vitro work177,179,213 made use of an experimental system that 
appears to be quite abstracted from the cellular environment in vivo; neutrophils were 
purified from whole blood, allowed to adhere to tissue culture plastic and exposed to 
zymosan particles (a derivative of Saccharomyces cerevisiae or Baker’s yeast).  
Furthermore, quantification of phagocytosis relied on manual counting following visual 
inspection of microscope fields. Work from our group has shown that, in this experimental 
system, the phagocytic defect induced by C5a is dependent on signalling via the ẟ isoform of 
PI3K.177  
 Phosphatidylinositol-3-kinases are intracellular enzymes which selectively phosphorylate the 
3-hydroxyl group of the inositol ring of phosphatidylinositol lipids.297 They are widely 
expressed throughout mammalian cells and mediate a plethora of cellular functions. 
Neutrophils are rich in the gamma and delta isoforms of this enzyme254 and PI3K signalling is 
crucially involved in phagocytosis.58,63,298 
Given the context-sensitivity of intracellular signalling, it seems that interrogating neutrophils 
in a context significantly different from the situation in vivo could lead to difficulties 
extrapolating mechanistic understanding to critically ill patients. This chapter establishes and 
validates an assay of phagocytosis of clinically relevant pathogens, confirms PI3K 
involvement and demonstrates C5a impairs phagocytosis rapidly, and that the impairment is 
much longer-lasting than previously appreciated. Finally, it demonstrates that impairment of 
phagocytosis translates to impaired microbicidal activity of the common nosocomial 




2. Hypotheses and aims 
C5a induces a prolonged defect in neutrophil phagocytosis of clinically relevant 
pathogens, and this leads to impaired bacterial killing. 
• To replicate previous work demonstrating a defect in phagocytosis of zymosan 
particles by purified adherent neutrophils. 
• To establish and validate an assay of neutrophil phagocytosis by cells in suspension 
using clinically relevant bacterial targets. 
• To confirm that C5a exposure is accompanied by a spike in PtdIns(3,4,5)P3 
production. 
• To demonstrate that C5a impairs phagocytosis by neutrophils in this new 
experimental system and confirm that this impairment is preventable by pre-treatment 
with PI3K inhibitors. 
• To confirm that C5a-induced phagocytic impairment translates to impaired bacterial 
killing. 
• To assess the time course of C5a-induced neutrophil phagocytic impairment. 
3. Notes on methods 
Methods used in this chapter were developed in an iterative process as described. Assays 
used to generate data shown in figures are presented in Chapter II: Methods and full 
protocols are included in Appendices. Data for E. coli red Bioparticles and S. aureus killing 
presented in Figure III-4 and Figure III-6 respectively were kindly generated by Dr Arlette 





4.1. C5a pre-treatment reduces phagocytosis of zymosan by 
purified, adherent human neutrophils  
I first attempted to replicate results demonstrated by Conway-Morris213 and show that C5a 
applied to adherent human neutrophils reduces phagocytosis of zymosan particles. Figure 
III-1A and B are representative images of control- and C5a-treated adherent neutrophils, with 
positive and negative cells indicated. Figure III-1C provides quantification of phagocytosis, 
showing a reduction in the median proportion of neutrophils with ≥ 2 zymosan particles from 
71.4 to 57.1 % (p = 0.031) with C5a treatment relative to PBS control. 
4.2. pHrodo fluorescence indicates ingestion of particles 
Prior to my project, pHrodo Bioparticles had not been used extensively in our group for flow 
cytometric assessment of phagocytosis, and thus characterisation of their performance in-
assay was required. In order to verify the manufacturer’s claims of pH-related Bioparticle 
fluorescence (i.e. Bioparticles only fluoresce when intracellular due to low phagosomal pH) 
confocal microscopy (Leica Sp5) was undertaken. Figure III-2 demonstrates increasing 
intracellular fluorescence with increasing concentrations of S. aureus Bioparticles by confocal 
microscopy (A, B) though at higher concentrations some extracellular fluorescence is also 
noted. Similarly, increasing intracellular fluorescence was noted by concurrent fluorescence 
microscopy and flow cytometry using an ImageStream X Mark II cytometer (BD Biosciences), 
which also demonstrated that positive cells by flow cytometry correspond to cells with 
intracellular, fluorescent particles, and their negative counterparts have no intracellular 
fluorescence. Taken together, these results suggest pHrodo Bioparticles reliably indicate 
successful phagocytosis, with minimal confounding by extracellular fluorescence, especially 














Figure III-1: C5a pre-treatment reduces phagocytosis of zymosan by purified, 
adherent human neutrophils 
Purified human neutrophils were allowed to adhere to 24-well tissue culture plates for 30 
minutes before being treated with PBS control (A) or C5a (B) for 30 minutes. Serum-
opsonised zymosan was then added for 30 minutes, before phagocytosis was quantified. An 
example positive cell (≥ 2 internalised zymosan particles) is indicated by the red arrow in A. 
White and black arrows in A indicate negative cells (with 1 and 0 internalised zymosan 
particles respectively) viewed at 400 X magnification. C: Quantification of 6 separate 
experiments, showing a reduction in the median percentage of cells with ≥ 2 internalised 














Figure III-2: pHrodo fluorescence indicates ingestion of particles  
Neutrophils were incubated in 24-well glass imaging plates with S. aureus green Bioparticles 
for 30 minutes at concentrations of 5 (A) and 30 µg/mL (B) as shown. Neutrophils were fixed, 
nuclei stained with Hoechst 33342 and visualised by confocal microscopy at 630 X 
magnification. White arrows indicate intracellular S. aureus Bioparticles (green). C: 
Increasing concentrations of S. aureus green Bioparticles were incubated with PMNs for 2 
hours, fixed and analysed. A single cell is photographed/excited by lasers and is shown in 
three channels: channel 1 shows bright-field images; channel 2 shows fluorescence of 
pHrodo green S. aureus Bioparticles; channel 3 shows fluorescence of DAPI nuclear 
staining. Images correspond to histograms of channel 2 Bioparticle fluorescence, showing 
that fluorescence as measured by flow cytometry indicates intracellular Bioparticles. 
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4.3. pHrodo bioparticles quantify phagocytosis  
Figure III-3 shows the gating strategy to identify neutrophils, and subsequently pHrodo-
positive phagocytosis events for 4 (no phagocytosis) and 37˚C (efficient phagocytosis) in 
orange and blue respectively. Dose-response experiments were conducted to ascertain the 
optimal Bioparticle concentration to reliably demonstrate phagocytosis. Figure III-4A and B 
show the resulting dose-response curves assessed by % phagocytosing cells (Bioparticle 
positive) and phagocytic index with accompanying EC50 values for each Bioparticle type. A 







The optimal time point for measurement of phagocytosis was then assessed through time-
course experiments using the EC50 Bioparticle concentration. Phagocytosis was again 
quantified by the proportion of Bioparticle-positive cells (C) and phagocytic index (median 
fluorescence intensity x % positive cells: D) at intervals over five hours to determine the 
kinetics of Bioparticle phagocytosis. Figure Figure III-4C demonstrates that phagocytosis is 
an extremely rapid process, beginning within minutes. Taken together, these results suggest 
pHrodo Bioparticles reliably indicate successful phagocytosis, with minimal confounding by 
extracellular fluorescence, especially when neutrophils are gated by forward and side scatter.   
 
Figure III-3: Gating strategy for assessing neutrophil phagocytosis 
PMNs were incubated at 4˚C (no phagocytosis) and 37˚C to determine the fluorescence 
which constitutes a positive cell in terms of pHrodo Bioparticle ingestion. Positive cells are 












Figure III-4: pHrodo bioparticles can quantify phagocytosis 
PMNs were incubated with increasing concentrations of pHrodo S. aureus green, E. coli 
green and E. coli red Bioparticles and the percentage of positive cells (A) or phagocytic 
index (B) were measured by flow cytometry. The Bioparticle concentration required for 50 % 
cell positivity (EC50 (95 % CI)) was calculated for each bacteria/dye combination: S. aureus 
green 3.26 µg/mL (3.014 – 3.027); E. coli green 4.692 µg/mL (3.713 – 5.928); E. coli red 
1.85 µg/mL (1.644 – 2.081). PMNs were then incubated with the EC50 of each bacteria/dye 
combination for up to 5 hours. Cells were fixed at the indicated time points and the 
percentage of positive cells (C) and phagocytic index (D) were measured by flow cytometry. 
Results are presented as median and IQR of n = 4 - 6 (A and B) and 2 (S. aureus green) 4 
(E. coli green) and 9 (E. coli red; C and D) independent experiments. Data for E. coli red 
kindly collected by Dr Arlette Vassallo as part of her own experiments. 
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4.4. C5a pre-treatment induces a phagocytic defect of S. 
aureus and E. coli Bioparticles that is PI3K-dependent 
Having observed the previously demonstrated effect of C5a on adherent neutrophils, the 
effect of C5a on neutrophil phagocytosis in suspension with physiologically relevant bacterial 
targets was evaluated. Figure III-5A and B show a relative reduction in phagocytic index of 
29.66 % for S. aureus and 29.25 % with E. coli respectively for cells treated with C5a relative 
to control. Previous data from our group has shown that C5a-mediated impairment of 
neutrophil phagocytosis was PI3K-dependent.177,213 I first confirmed that C5a induced a rapid 
spike in PtdIns(3,4,5)P3 production at 15 s similar to fMLP, with minimal effect of LPS at 30 
minutes, shown in Figure III-5C. Finally, the role of PI3K enzymes in mediating C5a-induced 
neutrophil phagocytic dysfunction was assessed in the newly characterised assay of 
phagocytosis. Figure III-5D shows that pre-treatment with PI3K inhibitors selective for either 
the delta (idelalisib 100 nM) or gamma isoform (IPI-549 100 nM) prevented C5a-induced 
















Figure III-5: C5a induces phagocytic defect of S. aureus and E. coli bioparticles that is 
PI3K-dependent 
Neutrophils were pre-treated with 100 nM C5a or vehicle control for 60 minutes before 
incubation with S. aureus green (A) or E. coli green (B) Bioparticles at their respective EC50 
concentrations before being fixed and analysed by flow cytometry. Data are presented as 
the median phagocytic index of C5a-treated cells relative to their paired PBS control for 7 (A) 
or 6 (B) independent experiments, *p-value < 0.05 by Wilcoxon’s matched-pairs signed rank 
test. C: PtdIns(3,4,5)P3 production was quantified as a ratio of the C38:4 PtdIns(3,4,5)P3 to 
internal standard after 30 minutes of priming and 15 s of stimulation with the agents 
identified. Data shown are triplicates from one independent experiment, thus no statistical 
tests were performed. D: Neutrophils were pre-treated with 100 nM idelalisib (ẟ isoform 
inhibitor) or 100 nM IPI-549 (γ isoform inhibitor) for 30 minutes prior to C5a treatment (60 
minutes) before phagocytosis was quantified as above. p = 0.03 by two-way repeated 
measures ANOVA, ***p < 0.001 by Sidak’s test for multiple comparisons. 
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4.5. C5a pre-treatment impairs neutrophil bactericidal activity 
Killing of bacteria is a key neutrophil function dependent on a variety of processes (including 
phagocytosis) as discussed in Chapter 1. To confirm the relevance of C5a-mediated 
phagocytic impairment to bacterial killing, the ability of neutrophils to kill the common 
nosocomial pathogen S. aureus was assessed in vitro. Pre-incubation of neutrophils with 100 
nM C5a for 60 minutes prior to the bacterial killing assay resulted in an increase in CFU 












Figure III-6: C5a pre-treatment reduces killing of S. aureus by human neutrophils  
Live MSSA (strain ASASM6) were fed to human neutrophils for 60 minutes at an MOI of 
10:1 bacteria per neutrophil. Neutrophils were lysed, bacteria plated and grown overnight 




4.6. Transient C5a pre-treatment induces prolonged impairment 
of neutrophil phagocytosis  
The effect of duration and timing of exposure to C5a was assessed in a time-course 
experiment using the basic phagocytosis assay established above. Purified neutrophils were 
exposed to C5a or control for the durations indicated, C5a was removed by washing, and 
cells were then exposed to Bioparticles for up to 7 hours, the results of which are shown in 
Figure III-7. C5a induces a defect in phagocytosis, and this defect is induced after short 
periods of exposure (as little as 5 minutes in some cases). Further, this experiment shows 
that the defect induced by C5a is persistent and affects phagocytosis for at least 7 hours 
even after removal of C5a. Importantly, these results are not due to experimental treatments 











Figure III-7: C5a rapidly induces long-lasting impairment of human neutrophil 
phagocytosis without inducing cell death 
Neutrophils were pre-treated with 100 nM C5a or PBS control for 60 minutes, which was 
removed by large volume washes. S. aureus Bioparticles were then added and cells were 
incubated for the indicated time points. A: data are presented as the mean and SD of the 
phagocytic index of C5a-treated cells relative to their paired PBS control for 5 independent 
experiments. p < 0.0001 for time and p = 0.0186 for treatment by two-way ANOVA. ***p = 
0.0001 ****p < 0.0001 by Dunnett’s multiple comparisons. B: data are presented as the mean 
and SD of the percentage of DRAQ7 positive, dead cells for n = 5 independent experiments. 
p = 0.378 for time and p = 0.349 for treatment by two-way ANOVA, non-significant ANOVA so 




This chapter discussed initial work which lays the foundation for the rest of this thesis and 
characterises the tools with which I will proceed to interrogate neutrophil phagocytosis. Using 
the same phagocytic target and adherent neutrophils as Conway-Morris177 and Huber-
Lang179 I have replicated the finding that neutrophils from healthy volunteers exposed to C5a 
exhibit reduced phagocytosis (Figure III-1), confirming the basis on which this thesis rests. 
Neutrophil behaviour is extremely context-dependent, with well-demonstrated changes in 
function secondary to chemoattractant exposure23 and even simple adhesion.299 Further, the 
size of the phagocytic particle has a profound effect on Rho-family GTPase signalling and 
the involvement of PI3Ks, which have been shown to be important for phagocytosis of large 
particles (e.g. fungi, zymosan, apoptotic cells) but not small particles (e.g. bacteria) during 
IgG-mediated phagocytosis by RAW 264.7 cells.300 Therefore, for any interrogation of 
intracellular signalling networks related to phagocytosis and C5a exposure to be relevant to 
critically ill patients, a more physiological assay was needed.  
pHrodo Bioparticles™ offer an attractive option for assessing phagocytosis, as the 
fluorescence intensity of the proprietary pH-sensitive dye increases in acidic conditions,301 
and can therefore indicate completed phagocytosis, distinguishing particles that are ‘inside’ 
the cell from those that are simply ‘on’ the cell.302 The Bioparticles were tested in initial 
experiments and confirmed to indicate completed phagocytosis and phagosomal acidification 
by both confocal microscopy and flow cytometry (Figure III-2 and Figure III-3). The kinetics of 
phagocytosis and maturation in this system was assessed (Figure III-4) and found to be 
consistent with previously published kinetic data on phagocytosis.56,57  
Our group has previously shown that selective inhibition of the PI3K-ẟ isoform prevented 
C5a-mediated neutrophil phagocytic impairment in the adherent neutrophil and zymosan 
system previously described.177 I therefore aimed to test this hypothesis in my newly 
characterised experimental system. Figure III-5A and B show that C5a impaired 
phagocytosis of S. aureus and E. coli Bioparticles in the new assay, which extended the 
relevance of previous findings to clinical pathogens and indicated that the effect of C5a on 
phagocytosis is likely pathogen and size-independent.  
I then sought to demonstrate that C5a induced production of PtdIns(3,4,5)P3 and therefore 
that the use of PI3K-inhibitors to modulate cellular signalling was appropriate in this context. 
The PtdIns(3,4,5)P3 production induced by C5a at 15 s is similar to that induced by fMLP 
(Figure III-5C) and consistent with that expected from stimulation of neutrophil GPCRs and 
previous work on C5a.66,289 Interestingly, priming did not seem to increase the magnitude of 
the PtdIns(3,4,5)P3 spike, as may be expected from the effect of priming on ROS production 
(see Chapter I: Section 1.5). However, previous work from our laboratory showed that 
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priming with TNF-α did not increase the magnitude of the PtdIns(3,4,5)P3 response at 15 s 
but tended to maintain the magnitude of the response over time,303 consistent with data 
shown above.  
Pre-treatment of neutrophils with selective inhibitors of the gamma and delta isoforms of 
PI3K demonstrated that signalling through both enzymes is required to mediate the effect of 
C5a on phagocytosis (Figure III-5D) in contrast to previous data showing that only PI3K-ẟ 
was required.177 There are a number of potential explanations for these divergent 
observations. Firstly, the use of isoform-selective inhibitors is always fraught with uncertainty, 
which I strove to minimise by choosing next-generation PI3K inhibitors with IC50s orders of 
magnitude lower for the preferred isoform which had been validated in similar cell types.304–
306 However, there remains a possibility that off-target effects of the PI3K-γ inhibitor are 
responsible for this observation. I believe a more plausible explanation is that differences in 
mechanism exist between the two experimental systems, and that this may well be mediated 
by the cells in my assay being non-adherent and therefore unprimed prior to C5a exposure, 
with consequent differences in outcome. 
The primary function of neutrophils in the context of infection is bacterial killing, and therefore 
it was important to demonstrate that C5a-induced impairment in phagocytosis resulted in 
impaired bacterial killing. C5a-treatment has been previously shown to impair the killing of P. 
aeruginosa in vitro177 though the effect of C5a on the killing of other bacteria was previously 
unknown. With kind assistance from my colleague Dr Vassallo who performed the killing 
assays alongside her own work, C5a has now been shown to impair the killing of S. aureus 
by neutrophils in suspension (Figure III-6) providing important functional relevance for the 
phagocytic defect induced by C5a. 
The experimental work of this chapter concluded with an assessment of the effects of C5a on 
phagocytosis over time. Previous studies of C5a on neutrophil phagocytosis have focussed 
on early time-points of up to one hour after C5a exposure.177,179,213 Given the time-courses of 
GPCR- and PI3K-mediated signal transduction (seconds to minutes)254,307 a recovery of 
phagocytic function or phagosome maturation was expected. The data in Figure III-7 show 
this is not the case, with even short exposures to C5a inducing prolonged defects in 
phagocytosis lasting for up to seven hours. It would appear that a rapid initial signalling 
phenomenon results in a fundamental change in cellular behaviour, or that ongoing signalling 
is occurring, as has recently been described for endosomal GPCRs-beta-arrestin 
complexes.308 Whilst the pHrodo signal was used here primarily as an indicator of 
internalised particles, the signal is actually a composite of internalisation and phagosomal 
pH, as fluorescence increases with decreasing pH.301 The data described here were the 
basis for the time points selected for phosphoproteomic studies discussed in Chapter VI:. A 
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further discussion of persistent signalling changes and phagosomal pH in the context of C5a 





Chapter IV: Development and application of a 
rapid, scalable whole blood assay of neutrophil 
function 
1. Chapter summary 
As discussed previously, numerous studies have demonstrated associations between 
immune cell phenotypes and outcomes such as nosocomial infection and mortality.110,147,149 
However, as a community of clinicians and researchers we have failed to translate our 
understanding of immune dysfunction to efficacious therapies.108,109 There is now a 
consensus in the field that a key driver of this failure has been an inability to target therapies 
to patients manifesting the immune dysfunction of interest, in a context that bears some 
relation to the situation in vivo.111,185,309 Therefore a key challenge for the field is to develop 
tools which allow accurate interrogation of immune cellular function that can be applied in 
clinical contexts. I argue that these tools need to directly interrogate cellular function rather 
than proxies of function such as cell surface marker expression310,311 or gene transcripts312 
and that if large clinical studies are to be possible, such methods need to be readily scalable, 
and ideally avoid cell preparation steps used in previous targeted trials.313 This chapter 
discusses the development of a protocol for rapidly assessing neutrophil function in small 




2. Hypotheses and aims 
Neutrophil function can be rapidly interrogated in small samples of whole blood, 
providing insights into mechanisms of C5a-induced neutrophil dysfunction. 
• To establish methods for measurement of neutrophil phagocytosis and ROS 
production in small samples of minimally manipulated whole blood. 
• To determine the optimal anticoagulant to preserve important neutrophil functions and 
mimic the situation in vivo. 
• To confirm C5a induces a prolonged defect in neutrophil phagocytosis in whole blood, 
whereas other common neutrophil priming agents do not. 
• To demonstrate that C5a decreases both phagocytosis and phagosomal maturation. 
• To assess the role of PI3K enzymes in mediating C5a-induced neutrophil dysfunction 
in whole blood. 
• To assess whether C5a exposure reduces the expression of common phagocytic 
receptors on neutrophils. 
• To apply this novel assay of neutrophil function in a clinical context.  
3. Notes on methods 
This chapter presents results generated using methods detailed in Chapter II: Section 10; 
namely, the assessment of neutrophil phagocytosis, ROS production and receptor 
expression in whole blood analysed without RBC lysis or wash steps. These experimental 
techniques make use of an Attune Nxt™ Acoustic Focusing Cytometer from Life 
Technologies (Paisely, UK), which allows large, dilute samples to be run very rapidly, thus 
eliminating the need for RBC lysis and wash steps. Quantitative data presented in Figure 
IV-7C were generated by experiments designed and carried out in conjunction with Carmelo 
Zinnato, a talented summer student from the University of Pavia to whom I provided direct 
supervision directed by Dr Andrew Conway Morris. The ethical approval number for the 




Figure IV-1: Schematic of interrogation of neutrophil function in whole blood without 
lysis of RBCs or wash steps 
Whole blood was collected into the anticoagulant of choice. Blood was aliquoted into 96-well 
plates and a combined pHrodo/DHR probe was added at concentrations of 15 µg/mL and 3 
µM respectively for 30 minutes at 37 °C and five % CO2 to allow phagocytosis and ROS 
production. Five µL of reaction mix was aliquoted into ice-cold PBS with anti-CD16 for 30 
minutes on ice in the dark. Volume was made up to 4 mL with ice-cold PBS and cells were 
analysed on an Attune Nxt™ cytometer.  Neutrophils were identified by CD16 positivity as 
shown, and phagocytosis and ROS were quantified by phagocytic index and MFI 
respectively. The procedure takes less than 60 minutes from blood draw to data analysis 
and involves no RBC lysis or cell fixation steps.   
4. Results 
4.1. Use of Attune Nxt™ to interrogate multiple neutrophil 
functions in whole blood  
The novel whole-blood assay of neutrophil function presented in this chapter makes use of a 
recently developed flow cytometer from Life Technologies, without which the assay is not 
possible in its no-wash, no-lyse form. Figure IV-1 shows the basic workflow of the assay 
which can be completed in under 60 minutes and provide an estimate of two key neutrophil 
functions, phagocytosis and the respiratory burst. Two mL of blood allows quantification of up 
to 13 experimental conditions in triplicate. Example dot plots and histograms in Figure IV-1 
show the distinction of neutrophils from other leukocytes and RBCs by CD16 expression and 
scatter characteristics, as well as the phagocytosis and ROS signals elicited from healthy 



















4.2. Assessment of anticoagulant effects on neutrophil functions 
and selection of argatroban 
The presence of anticoagulant during measurement of neutrophil functions in whole blood 
assays necessitates careful selection of anticoagulants that minimally alter neutrophil 
function. To this end, argatroban, a direct thrombin inhibitor, was selected based on 
previously published studies266,267 and compared to 3 commonly available anticoagulants; 
trisodium citrate, heparin sodium and EDTA. The effect of all 4 anticoagulants on the 
important neutrophil functions of priming, phagocytosis and ROS production were assessed 
using the assay described above. Figure IV-2A shows the PI of pHrodo Bioparticles in the 
presence of argatroban, citrate, heparin and EDTA respectively at both 37 °C and 4 °C, 
indicating that argatroban allows the most phagocytosis of all 4 anticoagulants, and that 
EDTA virtually abolishes it. Cold conditions were included as negative controls, as 
phagocytosis is greatly inhibited at these temperatures.53 Figure IV-2B illustrates two 
functions; priming and ROS production. Argatroban allows the greatest degree of priming in 
response to 30 minutes of TNF-α treatment as well as the greatest absolute ROS production 








Figure IV-2: Effect of anticoagulants on neutrophil phagocytosis and priming 
Whole blood was collected into argatroban (150 µg/mL) citrate (27.34 µg/mL) heparin (16 
IU/mL) and EDTA (1.6 mg/mL). Cells were treated with 20 ng/mL TNF-α or control (PBS) for 
30 minutes, before the combined pHrodo/DHR probe was added for 30 minutes at 37 °C or 
4 °C as indicated. Cells were stained for CD16 to identify the neutrophil population and 
analysed on an Attune Nxt™. Phagocytosis by unprimed cells after 30 minutes at either 37 
°C or 4 °C is shown in A. Priming and ROS production are shown in B. There was no 
statistically significant effect of priming in the citrate-anticoagulated conditions, and EDTA 
virtually abolished ROS production. p < 0.0001 by two-way ANOVA for A and B, ****p < 
0.0001, ***p < 0.001,**p < 0.01 by Sidak’s test of multiple comparisons. 
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4.3. C5a-induces a marked defect in phagocytosis and ROS 
production while other priming agents do not 
Having selected an anticoagulant and developed the basic mechanics of the whole blood 
assay, I set out to apply it to questions of C5a biology. First, I assessed whether C5a 
decreased phagocytosis in this new whole blood assay and to establish the concentration of 
C5a necessary for this effect. Figure IV-4A demonstrates the results of these experiments, 
with a progressive reduction in phagocytosis relative to control, from 10-1000nM. I elected to 
proceed with a concentration of 300 nM for further experiments, as this concentration reliably 
induced a significant defect, was likely to overcome plasma carboxypeptidases203,204,314 and 
lowered costs relative to higher doses.  
Figure IV-3B and C demonstrate that the finding of reduced neutrophil phagocytosis is not 
dependent upon the pH-sensitivity of the probe used to measure phagocytosis, and that 300 
nM C5a treatment is sufficient to induce a phagocytic defect. In B, the conventional pHrodo 
S. aureus Bioparticles were used, whereas in C, a non-pH-sensitive AF488-conjugated S. 
aureus indicator was used with trypan blue to quench extracellular fluorescence. Both assays 
showed a reduction in phagocytosis, which is important given C5a has been shown to alter 
neutrophil cytoplasmic pH261 which could have confounded results acquired using pHrodo 
alone.  
Given that C5a had been shown to markedly reduce phagocytosis in a whole blood model, I 
chose to assess whether this was a characteristic unique to C5a, or whether it occurred in 
response to other conventional neutrophil priming agents. Figure IV-3D and E show that C5a 
pre-treatment markedly reduced phagocytosis and phagosomal ROS production by 
neutrophils in whole blood, whereas other priming agents either had no effect or enhanced 
these neutrophil functions. For pre-treatment durations and priming agent concentrations 
please see the figure legend, these were determined by optimal priming protocols used 
within the Chilvers laboratory. Taken together, these results indicate that C5a, uniquely 
amongst the priming agents investigated, induces a phagocytic and phagosomal ROS 

















Figure IV-3: C5a impairs neutrophil phagocytosis and ROS production in whole blood 
while other priming agents do not 
A: Whole blood was pre-treated with semi-log increasing concentrations of C5a from 1 nM to 
1000 nM for 60 minutes prior to phagocytosis of pHrodo Bioparticles. Data are shown as the 
median and IQR of 4 independent experiments relative to control-treated blood. Friedman p-
value = 0.0024, *p < 0.05 by Dunn’s multiple comparisons. B and C: Whole blood was pre-
treated with 300 nM C5a or control and phagocytosis was measured by pHrodo S. aureus 
Bioparticles (B: p < 0.0001 by Wilcoxon) or AF488 S. aureus Bioparticles (C: p = 0.03 by 
Wilcoxon). Phagocytosis (D) and ROS production (E) after pre-treatment with various 
agonists were assessed. Concentrations and pre-treatment durations were as follows: Ctrl 
(PBS) 60 minutes; C5a 300 nM, 60 minutes; LPS 100 ng/mL, 60 minutes; PAF 1 uM, 5 
minutes; GM-CSF 10 ng/mL, 30 minutes; TNF-α 20 ng/mL, 30 minutes. C5a reduced 
phagocytosis whereas LPS and PAF increased phagocytosis. C5a reduced ROS production 
and LPS increased ROS production. ANOVA p-value < 0.0001 for both D and E, *p < 0.05, 
**p < 0.01 for Dunnett’s multiple comparisons.  
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4.4. C5a induces a prolonged impairment in phagocytosis in 
whole blood 
A novel finding of this thesis is the demonstration of marked C5a-induced phagocytic 
impairment that is long-lasting (Figure III-7). In order to further develop this finding, I 
established whether a similar long-lasting impairment develops in my newly characterised 
whole blood assay. In a slightly different approach from the previous work in purified cells, 
whole blood was exposed to C5a for up to 7 hours, before aliquots were removed for the 
assessment of phagocytosis for 30 minutes as previously described. In this way, 
phagocytosis was measured after each hour of C5a incubation, rather than continually from 
the beginning of the assay as in Figure III-7. Figure IV-4 shows that phagocytosis is markedly 
impaired by C5a, and that this phagocytic defect increases with duration of C5a exposure in 










Figure IV-4: C5a induces a prolonged phagocytic defect in whole blood  
Whole blood was pre-treated with 300 nM C5a or control for the indicated duration before 
phagocytosis was measured as previously indicated. Data are presented as the mean and 
SD of the cumulative phagocytic index for 4 independent experiments. p < 0.0001 by two-
way ANOVA, ****p < 0.0001, ***p < 0.001 by Sidak’s multiple comparisons test. 
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4.5. C5a-induced neutrophil dysfunction is not preventable by 
PI3K inhibition in whole blood 
To further interrogate mechanisms driving the C5a-induced defect in phagocytosis, the role 
of PI3K inhibition in whole blood was determined. In order to establish the concentration of 
PI3K inhibitors to use in whole blood, dose-response curves based on ROS production (also 
known to be PI3K-dependent66) were used to establish functionally active concentrations of 
each inhibitor. The curves shown in Figure IV-5A and B demonstrate the IC50 for both the γ 
and δ isoform-selective inhibitors are 54.6 and 197 nM respectively, indicating a significantly 
higher functional potency than older PI3K inhibitors with which our group is familiar.66 
Concentrations of 50 and 200 nM were used for subsequent studies on phagocytosis. Figure 
IV-5C shows that C5a-induced phagocytic impairment in whole blood is not PI3K-dependent, 
in contrast to data obtained in purified cells with the same inhibitors (Figure III-5). To further 
interrogate this discrepancy, both inhibitors were used at a wide range of concentrations to 
determine if the C5a defect could be prevented. As Figure IV-5 D and E show, no 
concentration of the inhibitors prevented the C5a-induced phagocytic defect in whole blood, 




















Figure IV-5: C5a-induced phagocytic defect is not PI3K-dependent in whole blood 
A: Intracellular ROS production was assessed as detailed in Methods. Whole blood was 
primed with 20 ng/mL TNF-α for 30 minutes and stimulated with 1 µM fMLP for 20 minutes 
and the neutrophil DHR fluorescence was measured by flow cytometry. Data are shown as 
normalised mean values of 5 independent experiments with a non-linear curve fitted. IC50 
(95 % CI) values were 54.7 nM (18.9-156.3) and 197 nM (57.8-651.7) for the ẟ-isoform 
inhibitor CAL-101/idelalisib and γ-isoform inhibitor IPI-549 respectively. B Whole blood was 
pre-treated with 60 nM idelalisib (ẟ isoform inhibitor) or 200 nM IPI-549 (γ isoform inhibitor) 
for 30 minutes prior to C5a treatment (60 minutes) before phagocytosis was quantified as 
previously. P = 0.0033 by two-way repeated measures ANOVA, **p < 0.01, *p < 0.05 by 
Sidak’s test for multiple comparisons. C and D: whole blood was pre-treated for 30 minutes 
with increasing concentrations of ẟ-isoform inhibitor CAL-101/idelalisib (C) or γ-isoform 
inhibitor IPI-549 (D) prior to C5a exposure for 60 minutes. Phagocytosis was quantified as 
previously. No statistical tests were performed on these data as they represent the median 




4.6. C5a does not appear to reduce cell-surface phagocytic 
receptor expression    
To assess whether C5a induced defects in phagocytosis by mechanisms other than 
intracellular signalling involving PI3Ks, the effect of C5a on common phagocytic receptors 
was assessed by flow cytometry. Figure IV-6 shows that over a wide range of concentrations 
known to induce a phagocytic defect, C5a did not decrease surface expression of common 
phagocytic receptors. In fact, C5a exposure led to increased expression of complement 
receptor 3 subunit CD11b. As expected, C5a exposure decreased the expression of C5aR1 
(CD88). Taken together, these data suggest the phagocytic defect induced by C5a is not 









Figure IV-6: C5a does not appear to decrease surface expression of common 
phagocytic receptors 
Whole blood was incubated with semi-log increasing concentrations of C5a for 60 minutes 
as outlined in Chapter II:12. Blood was then stained for the above cell surface receptors and 
expression was quantified using an Attune Nxt™ cytometer. Data area shown as the median 
and range of 2 independent experiments. Statistical tests were not performed owing to the 




4.7. Dual phagocytic challenges reveal subsets of 
phagocytically avid and non-avid cells in healthy human blood 
Throughout the experiments presented to date, both in whole blood and in purified 
neutrophils, I have observed distinct populations of cells; those that phagocytose large 
numbers of particles, and those that phagocytose few or none. In order to interrogate this 
observation in more detail, a double feeding model was used, whereby whole blood was 
sequentially challenged with 2 phagocytic targets detectable in different channels on the 
cytometer as detailed in Chapter II:10.2. Figure IV-7A shows an example of how the 
phagocytic intake of both challenges can be visualised and indicates that pre-treatment with 
C5a decreases the intake during both challenges. Important to note is the presence of cells 
that remain negative for both particles (bottom left quadrant) and cells that become positive 
for both (top right). Interestingly, very few cells that were negative for the first challenge 
become positive on the second challenge (top left quadrant). These effects were quantified 
over a range of concentrations of the first phagocytic stimulus (pHrodo red); results are 
shown in Figure IV-7B. These data indicate cells that do not phagocytose the first challenge 
are also unlikely to phagocytose the second challenge, and that this difference in phagocytic 
avidity becomes more pronounced as the intensity (pHrodo red concentration) of the first 













Figure IV-7: Distinct phagocytic subsets of neutrophils exist in healthy human blood 
Dual phagocytic challenges were administered as detailed in Chapter II::10.2. A (Ctrl) and B 
(C5a) are example flow cytometry dot plots of whole blood neutrophils that have been 
sequentially challenged with pHrodo S. aureus red Bioparticles (15 µg/mL, 30 minutes) then 
pHrodo S. aureus green Bioparticles (15 µg/mL, 30 minutes) before being stained for CD16 
and analysed. Four distinct populations of cells are evident: non-phagocytic, bottom left 
quadrants; 1st challenge-only positive, bottom right; double challenge positive, top right; 2nd 
challenge-only positive, top left. B shows the effect of pre-treatment with 300 nM C5a is to 
decrease phagocytosis of both challenges, shifting cells downward and leftward. The data 
shown in C quantify results shown in A and B, whereby the percentage of cells 
phagocytosing during the second challenge is shown based on whether the cells 
phagocytosed during the first challenge (1st challenge positive, red) or not (1st challenge 
negative, black). Data is presented as the mean and SD of 5 independent experiments. p < 
0.0001 by two-way repeated measures ANOVA, ***p < 0.001, **p < 0.01 by Sidak’s multiple 
comparisons test. Data presented in C kindly generated by Carmelo Zinnato. 
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4.8. Novel whole blood assay can be applied in clinical settings 
Having developed a novel assay of neutrophil function in small, minimally manipulated 
samples of human whole blood, I aimed to demonstrate its utility in an outpatient clinical 
setting. Five individuals with diagnosed immunodeficiency syndromes were recruited from 
the immunodeficiency clinic of a tertiary hospital in the UK. Patient details are listed in Table 
4, and there was no clinical evidence of infection at the time of blood draw. Patient blood 
samples were drawn after standard clinical blood samples during routine outpatient 
appointments. The standard whole-blood assay was performed on patient samples within 
one hour of blood draw, and unmatched controls were drawn from the routine blood donors 
of the Chilvers’/Summers’ group on separate days. Table 4 shows patients were a wide 
variety of ages and were affected by different causes of immune deficiency. Figure IV-8 
shows that all 5 patients recruited had their neutrophil phagocytosis and ROS production in 
response to S. aureus Bioparticles successfully measured by a single operator, and that 
there appears to be a similar reduction in phagocytosis in response to C5a pre-treatment 
amongst immunodeficient patients. Further, the data show that neutrophils from NFKB 
deficient patients may phagocytose less and produce less ROS in response to an S. aureus 
stimulus relative to controls. The 1 APDS patient assessed appeared to have a higher 
baseline level of phagocytosis and ROS production, and their neutrophil phagocytosis was 
not augmented by LPS pre-treatment, in contrast to controls. These results demonstrate 
successful application of this assay in a clinical setting,and raise intriguing questions with 
respect to neutrophil function in patients with immunodeficiency syndromes.   
Table 4: Immunodeficient patient characteristics 
Diagnosis Abbreviation Sex Mutation Phenotype 





(IgG 3) and recurrent 
respiratory infections. 
NFκB deficiency NFKB M As above As above 
NFκB deficiency NFKB M As above As above 
Activated PI3 kinase 
delta syndrome316 






















Figure IV-8: The whole blood assay can be applied in clinical settings 
2 mL blood was drawn from 5 patients with immunodeficiency syndromes during routine 
outpatient appointments, and neutrophil phagocytosis and ROS production in response to S. 
aureus Bioparticles were measured within one hour of blood draw by the standard whole-
blood assay as previously described. Patient characteristics are described in Chapter II:10.4. 
Control samples were drawn on separate occasions. Blood was pre-treated with the 
following agonists and durations: Ctrl (PBS) 60 minutes; LPS 100 ng/mL 60 minutes; PAF 1 
µM 5 minutes; C5a 300 nM 60 minutes. Studies were completed by 1 operator and data was 
available for analysis within 120 minutes of blood draw. No statistical tests were applied as 




A key challenge facing investigators of immunotherapies for critically ill patients is the 
appropriate targeting of therapies.108,167,317 Investigators should consider immunophenotyping 
patients before stratification into intervention arms to ensure the relevant cellular dysfunction 
is actually present before treating it. The adoption of such targeted therapies holds promise; 
a recent retrospective subgroup analysis of the multicentre phase III Sepsis Syndrome 
Study318 of recombinant human IL-1 receptor antagonist in sepsis showed a mortality  benefit 
of the drug in patients who had higher baseline plasma IL-1 receptor antagonist levels.319 
The authors suggest another, targeted trial of the same therapy is indicated. Neutrophil 
dysfunction is known to be a key driver of poor outcomes in critically ill patients,147,149,177,213 
though trials targeting therapies such as GM-CSF to patients with neutrophil dysfunction 
measured by conventional strategies were laborious and unfortunately did not achieve 
statistical significance of the primary outcome.313  
Therefore, there is a need for rapid, scalable assessments of neutrophil dysfunction if 
investigators are to reliably target novel immunotherapies in clinical trials. This chapter 
discusses the initial development of such an assay, its use to interrogate C5a-induced 
neutrophil dysfunction and demonstrates feasibility in a clinical setting. Figure IV-1 shows the 
simple workflow for interrogating neutrophil function without RBC lysis or fixation steps, made 
possible by the novel Attune Nxt™ Acoustic Focusing Cytometer from Life Technologies. 
Couple this cytometer with the pH-sensitive pHrodo Bioparticles used throughout this thesis 
and the well-established indicator of ROS production, DHR,291 and two key neutrophil 
functions can be readily measured in small samples of whole blood.  
In this setting, anticoagulants are not removed by washing steps, and chelated divalent metal 
cations are not replaced as they are in conventional neutrophil preparations (see protocol in 
Appendices). The effect of anticoagulants on cell function therefore become much more 
important when working with whole blood. Previous work by Mollnes and others 
demonstrated brisk complement activation by citrate and heparin,320 whereas the direct 
thrombin inhibitor lepirudin did not interfere with complement activation.266 These data 
informed my choices of anticoagulants for assessment of neutrophil functions. Argatroban is 
an FDA-approved synthetic direct thrombin inhibitor321 analogous to lepirudin, and was used 
as lepirudin is no longer available. The concentration of argatroban was adopted from 
previous ex vivo studies322 and titrated down to the minimal concentration that maintained 
blood in a macroscopically anticoagulated state at 7 hours, which was 150 µg/mL. As Figure 
IV-2 shows, argatroban at a concentration of 150 µg/mL allows the greatest degree of 
neutrophil priming and highest rates of phagocytosis and ROS production relative to EDTA, 
citrate and heparin at respective concentrations recommended by the manufacturer.323 Given 
these data, argatroban was adopted as the anticoagulant used in future studies. 
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Having established this novel assay, I then assessed the effect of C5a and other priming 
agents in this system. The titration of C5a shown in Figure IV-3A shows a dose-response 
effect of C5a on neutrophil phagocytosis in this model, with peak effects reached at 
excessively high concentrations of C5a. A concentration of 300 nM was chosen as it 
balanced the necessity of achieving a robust response with excessive use of costly purified 
human C5a. The higher concentration of C5a used in the whole blood studies may have 
been driven by the presence of plasma carboxypeptidases, known to cleave and inactivate 
C5a which were not present in purified cell systems.204,207 Regardless, concentrations as high 
as 1000 nM have been measured in critical illness,92 and as discussed in Chapter I:, receptor 
saturation rather than concentration of agonist is likely to be a more important determinant of 
functional consequences of C5a.  
Figure IV-3B and C demonstrate the sizeable defect in phagocytosis induced by C5a in this 
model and show that these effects are not simply an artefact of using a pH-sensitive dye. 
Work by Huber-Lang’s group published in 2017 demonstrated that C5a exposure transiently 
increased neutrophil intracellular pH.261 Given the pH-sensitivity of pHrodo fluorescence, it 
therefore became important to demonstrate that the decreased pHrodo fluorescence I had 
observed was genuinely the result of decreased phagocytosis, as opposed simply to a 
reduction in cellular acidification. The use of a non-pH sensitive dye (AF488) conjugated to 
S. aureus Bioparticles confirmed the defect was indeed due to phagocytic failure and justified 
ongoing use of pHrodo Bioparticles.  
Figure IV-3D and E address the question of whether phagocytosis and ROS production were 
uniquely inhibited by C5a, or whether these effects were shared with other typical neutrophil 
priming agents in my hands. A variety of GPCR (PAF) and non-GPCR (LPS, TNF-α, GM-
CSF) ligands were selected to provide a broad cross-section of priming agents acting 
through different pathways324 and pre-treatment durations were chosen based on known 
maximal adhesion molecule upregulation demonstrated by members of our group.325 The 
data presented show C5a reduced phagocytosis and phagosomal ROS production, whereas 
LPS and PAF increased phagocytosis, and LPS alone increased ROS production. GM-CSF 
and TNF-α had no effect in this system. These results are consistent with those of Rosales326 
and Hayashi327 who showed PAF and LPS increased rates of IgG-mediated phagocytosis by 
purified neutrophils respectively, but contrast with data from Mookerjee and colleagues328, 
which showed a reduction in phagocytosis by neutrophils from cirrhotic patients after LPS 
exposure. Previous data from our group showed GM-CSF increased phagocytosis of 
zymosan by adherent, purified neutrophils,177,213 thus the lack of effect of GM-CSF in this 
system was surprising. However, given the exquisitely context-sensitive characteristics of 
neutrophil phagocytosis, it is likely that these discrepant results can be explained by 
differences in phagocytic target and the presence of a multitude of factors in whole blood not 
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assessed in previous assays of phagocytic function. The key finding of a significant 
functional impairment induced by C5a in multiple experimental systems remains and appears 
to be unique to this agent in whole blood. Further experiments are necessary before these 
findings can be generalised and interpreted in the context of conflicting data from other 
experimental systems.   
In keeping with my work in purified cells, C5a induces a marked and prolonged defect in 
neutrophil phagocytosis in whole blood, as shown in Figure IV-4. This defect is persistent for 
up to 7 hours after C5a was added, in keeping with data from purified cells shown in Figure 
III-7. In the whole blood system, phagocytosis was measured after each hour of C5a 
incubation, rather than continually from the beginning of the assay as in Figure III-7. This 
slight difference in methodology ensured that the same phagocytic challenge was applied 
after each hour of C5a exposure and demonstrated that neutrophil phagocytosis was 
decreased by C5a at each successive time point. To my knowledge, this is the first time such 
a prolonged phagocytic defect induced by C5a has been demonstrated in either whole blood 
or purified neutrophils in vitro. This finding has implications for the immunosuppression 
evident in critically ill patients which can persist for days147 and even weeks after an initial 
insult.167,329 Reversal or amelioration of this prolonged deficit are attractive therapeutic 
targets, though total C5a-C5aR blockade, whilst promising in initial animal studies, has not 
yet enjoyed success in human clinical trials and is likely to have a plethora of unwanted off-
target effects.330,331 Therefore, it remains important to identify the signalling events in 
neutrophils precipitated by C5a which mediate this phagocytic defect, so that they may be 
selectively targeted. To this end, the role of PI3K enzymes in the whole blood model was 
assessed. 
Given the role of PI3Ks in mediating C5a-induced phagocytic defects demonstrated earlier in 
this thesis and their previously established role in C5a-mediated impairment of phagocytosis 
of zymosan177,213I set out to assess their role in whole blood, given the important contextual 
difference that this new experimental system represents. The concentration at which to use 
these compounds in whole blood was unclear, as IC50 values drawn from biochemical and 
cellular assays differed markedly depending on function measured and cells used, and wide 
concentrations have been reported in the literature.305,306 Without being able to assess 
directly PI3K activation in whole blood, a surrogate process which is known to PI3K-
dependent was used, namely production of ROS in response to a soluble fMLP stimulus.66 
Data presented in Figure IV-5A shows the resultant dose-response curves and the IC50 
values for CAL-101/idelalisib and IPI-549. Interestingly, in this system the ROS response 
appears to be more sensitive to inhibition of the delta isoform, which may be due to the delta 
isoform selectively being responsible for the prolonged phase of ROS production in human 
cells.66 The IC50 values generated here are significantly higher than published cell-free 
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biochemical IC50’s for the relevant isoform of PI3K, which were 16 nM for IP-549306 and 2.5 
nM for CAL-101.332 However, this observation is not surprising given the requirement of 
these compounds for cell penetration and the complex physiological milieu in which they are 
operating in whole blood. These compounds were then used at their IC50 values to generate 
the data in Figure IV-5B, which demonstrates that PI3K inhibition at these concentrations had 
no effect on C5a-mediated phagocytic impairment induced in whole blood, in stark contrast 
to the finding in Figure III-5. It would also appear from the same data that the gamma-
selective inhibitor IPI-549 has a potent effect on phagocytosis, as even at its IC50 
concentration for ROS production, it induced a significant reduction in baseline phagocytosis. 
To confirm these results were not simply due to inadequate concentrations of each drug in 
this system, or inactivation by components of RBCs or plasma, a wide range of 
concentrations were assessed in Figure IV-5C and D. No concentration of these compounds 
ameliorated C5a-induced phagocytic defects, though as expected at high concentrations 
both drugs inhibited phagocytosis in general. The data presented sound a note of caution 
with respect to the use of systemically administered PI3K inhibitors to treat neutrophil 
dysfunction, in that they may not be as effective as when the drugs are applied directly to 
neutrophils in tissue compartments. This is of particular relevance given idelalisib is already 
licenced for the treatment of relapsed lymphomas333, and that Phase II trials of inhaled PI3K-
ẟ inhibitors are underway in chronic obstructive pulmonary disease334 and APDS.335  
Given the above data on showing PI3K inhibition did not prevent C5a-induced phagocytic 
impairment in whole blood, I assessed whether C5a reduced cell surface expression of 
common phagocytic receptors, as a further attempt to understand the mechanism of our 
previous observations. Over a wide array of concentrations, C5a did not appear to reduce 
cell surface expression of common IgG and complement receptors, and in fact appeared to 
increase the expression of the CR3 component CD11b, consistent with previous data on 
neutrophil priming,325 and as has previously been demonstrated in a whole blood model of 
complement activation.266 C5aR1 expression was downregulated with increasing C5a 
concentrations as expected.336,337 Changes of the C5aR and their relation to phagocytosis 
are the subject of Chapter V: and as such are not discussed in detail here. These data 
indicate simple changes in cell surface phagocytic receptor expression do not explain C5a-
induced phagocytic defects in this system, thus other mechanisms must be sought. We 
chose to adopt an unbiased assessment of the neutrophil phosphoproteome, and these 
experiments are detailed in Chapter VI:.   
The presence of circulating neutrophil subsets in health and disease has long been studied 
and debated within the literature.7,338,339 The novel whole blood assay developed in this 
chapter offers an exciting way to add to this discussion as differences in function are now 
easily measurable in unmanipulated, circulating cells. I used this method to further address 
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an observation long noted by myself and colleagues in the lab; that of apparently 
phagocytically avid and non-avid cells present in most individuals. Figure IV-7A shows the 
stark difference in phagocytosis between cells circulating at the same time in the same 
individual, and that C5a tends to make all cell types phagocytose less (B). Quantification of 
these populations in Figure IV-7C demonstrates that the difference between these cells is 
preserved on the second challenge and becomes more pronounced as the initial stimulus 
intensity is increased. These data are consistent with data from Koenderman’s group who 
have also shown distinct phagocytic functional subsets of purified neutrophils using a cell-
sorting approach.340 Taken together, the data indicate the difference in phagocytic uptake 
between neutrophils observed in experiments to date is not simply due to stochastic 
encounters between cells and target. Rather, there is an intrinsic difference in the phagocytic 
avidity of circulating human neutrophils in healthy individuals, which may be susceptible to 
manipulation, by C5a for instance. 
A key aim of this chapter was to demonstrate the whole blood assay may be suitable for 
eventual clinical use. Having refined an approach made possible by the Attune Nxt™ and 
applied it to questions of C5a biology, I set out to ascertain whether the assay may be usable 
in a clinical setting. To this end we recruited patients with known immunodeficiency 
syndromes covered by existing research ethics committee approvals who were having blood 
drawn for routine clinical tests. Table 4 shows these patients were diagnosed with one of 
three immunodeficiency syndromes, and none of these conditions are associated with 
neutrophil dysfunction based on disease phenotypes identified in the literature.316,341 Figure 
IV-8 illustrates the neutrophil phagocytosis and phagosomal ROS production of five patients 
and four unmatched controls, and demonstrates that data was easily acquired during routine 
clinic appointments from multiple patients by one operator. Further, the data raise the 
possibility of defective phagocytosis by neutrophils from individuals with the NFκB1 mutation, 
a previously undescribed characteristic of these patients.315,341    
The work in this chapter is a further stepwise improvement from a non-physiological system 
with unlikely phagocytic target (adherent neutrophils with zymosan) to a more physiological 
system with relevant pathogens (neutrophils in suspension with S. aureus or E. coli) finally to 
a rapid assay of neutrophil function in whole blood that is applicable in a clinical setting. A 
key finding of this thesis (prolonged impairment of neutrophil phagocytosis by C5a) has been 
replicated in whole blood, and important mechanistic details (PI3K signalling and cell surface 
receptor changes) have been interrogated and found insufficient to wholly explain C5a-
induced dysfunction in this system. Therefore, alternate approaches were used, and are 




Chapter V: Phagocytosis decreases surface 
C5aR1 expression and confers resistance to C5a 
1. Chapter summary 
The work in this chapter arose from the observation that exposing neutrophils to C5a at the 
same time as bacteria (as opposed to pre-treatment models used elsewhere in this thesis) 
did not lead to impairment of phagocytosis. Further, I had often noted a decrease in C5aR1 
expression measured on the surface of neutrophils after phagocytosis (without C5a present) 
and wondered whether this receptor was directly involved in phagocytosis, and if this 
reduced receptor expression mediated the subsequent resistance to C5a-induced phagocytic 
impairment. To my knowledge, a report by Doroshenko and colleagues211 is the only 
published study to make note of C5aR1 downregulation during phagocytosis, though it was 
not the focus of the report and the data were not shown or discussed. An intriguing possibility 
was also raised by Bamberg and colleagues231 who demonstrated co-localisation of C5aR1, 
2 and β-arrestin in endosomes, and posited an ongoing signalling function of this complex. I 
therefore wanted to establish whether pre-incubation with bacteria prevents C5a-induced 
phagocytic defects, and then to interrogate the fate of C5aR1 in the context of phagocytosis.     
2. Hypotheses and aims 
C5aR1 is internalised during phagocytosis, localises to phagosomes and plays a 
role in subsequent signalling and phagosomal maturation. 
• To demonstrate that cells allowed to phagocytose pathogens prior to C5a exposure 
are protected from C5a-induced phagocytic defects. 
• To assess whether C5aR1 surface expression is reduced by phagocytosis of 
pathogens. 
• To assess whether the reduction in surface C5aR1 expression is due to protease-
dependent receptor shedding. 






3. Notes on methods 
Methods used within this chapter are not dissimilar to assays discussed extensively in 
previous chapters and in the Methods section. Two protease inhibitors were used to 
generate data presented in Figure V-3: recombinant human secretory leukocyte protease 
inhibitor (SLPI,  R&D Systems) a broad-spectrum endogenous protease inhibitor with high 
potency against common neutrophil proteases including neutrophil elastase and cathepsin 
G342 and marimastat (Sigma) a broad spectrum metalloprotease inhibitor.51 These inhibitors 
were chosen as they were found to have no inhibitory effect on phagocytosis, unlike other 
protease inhibitors such as (1,10)phenanthroline (data not shown). Protease inhibitors were 
chosen and the data in Figure V-3 were produced by Carmelo Zinnato, who was introduced 






4.1. C5a-induced impairment of phagocytosis is prevented by 
exposure to phagocytic target 
The data presented here arose from experiments initially designed in parallel with those 
shown in Figure 4.6, with the aim of understanding the duration of C5a exposure required to 
impair phagocytosis. As these were purified cells (as opposed to whole blood) neutrophils 
were exposed to 100 nM C5a at various time points (either 60 minutes before, at the same 
time, or 60 minutes after addition of S. aureus). C5a was not removed by washing, and the 
cells were allowed to phagocytose for the time points indicated. Figure V-1A shows that 
exposure of cells to C5a at the same time or after pathogen exposure fails to induce the 
customary phagocytic defect, and that this phenomenon persists over the 7 hours of 
assessment. Data from an experiment testing the same hypothesis in whole blood is shown 
in Figure V-1B, which indicate 60 of C5a pre-treatment induces a phagocytic defect as 















Figure V-1: C5a-induced impairment of phagocytosis is prevented by pre-exposure to 
S. aureus 
A: S. aureus Bioparticles (3 µg/mL) were incubated with isolated PMNs in the presence of 
100 nM C5a or PBS, which was added at the indicated time points, with time 0 representing 
the time at which S. aureus Bioparticles were added. Cells were allowed to phagocytose for 
the indicated time points and phagocytic index was quantified by flow cytometry as previous. 
Data are presented as the mean and SD of the phagocytic index of C5a-treated cells relative 
to their paired PBS control for 5 independent experiments. p < 0.0001 for time and p = 
0.0186 for treatment by two-way ANOVA. ****p < 0.0001 by Dunnett’s multiple comparisons 
test. B: Whole blood was incubated with 300 nM C5a, added 60 minutes prior to (pre-
treatment) or at the same time (co-treatment) as addition of S. aureus Bioparticles. Cells 
were allowed to phagocytose for 30 minutes and phagocytic index was quantified by flow 
cytometry as previous. p = 0.0173 for pre-treatment vs co-treatment by two-way ANOVA.  
** p = 0.0035 by Sidak’s test of multiple comparisons. 
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4.2. C5aR1 expression is reduced by multiple stimuli but only 
prior phagocytosis protects from C5a-induced dysfunction 
To interrogate the role of C5aR1 in mediating the protective effects of phagocytosis, C5aR1 
expression was assessed on neutrophils in whole blood incubated with a variety of neutrophil 
priming agents and inflammatory stimuli. Data shown in Figure V-2A indicate that multiple, 
different stimuli appear to reduce surface expression of C5aR1, though only C5a reached a 
statistically significant reduction on post-hoc testing for multiple comparisons. In light of these 
findings, experiments assessing the ability of these other agents to protect against C5a-
induced phagocytic impairment were performed. The data shown in Figure V-2B 
demonstrate that these stimuli, despite their ability to downregulate C5aR1 surface 
expression, had no ability to protect from C5a-induced phagocytic dysfunction, with the 
exception of S. aureus as already demonstrated. Shown in Figure V-2C are C5aR1 
expression measurements from the dual phagocytic challenge experiments originally shown 
in Figure IV-7. These data illustrate that the downregulation of C5aR1 after phagocytosis is 
dose-responsive to the amount of phagocytosis that has occurred, with cells positive for both 
phagocytic challenges having lower levels of C5aR1 surface expression relative to single 



















Figure V-2: C5aR1 surface expression is reduced by multiple inflammatory stimuli, 
only phagocytosis confers protection from C5a 
A: Whole blood was incubated with the following inflammatory stimuli for 60 minutes prior to 
measurement of neutrophil C5aR1 expression by flow cytometry: 300 nM C5a; 100 ng/mL 
LPS; 10 µg/mL LTA; 20 ng/L TNF-α; 10 ng/mL GM-CSF; S. aureus green 10 µg/mL. 
Individual data points and their median values from n = 5 independent experiments are 
shown. Friedman’s test with p-value = 0.0003, ***p < 0.001 by Dunn’s multiple comparisons 
test. B: whole blood was pre-incubated with control or inflammatory stimuli as in (A) and then 
with 300 nM C5a for 60 minutes. Cells were then allowed to phagocytose 10 µg/mL S. 
aureus red Bioparticles for 60 minutes before phagocytosis was assessed by flow cytometry 
as previously described. Individual data points and their median values from n = 6 
independent experiments are shown. Friedman’s test with p-value = 0.0038, *p < 0.05 by 
Dunn’s multiple comparisons test. C: whole blood was subjected to dual phagocytic 
challenges (15 µg/mL S. aureus red, 30 minutes then 15 µg/mL S. aureus green, 30 
minutes) as previously described and C5aR1 expression was measured by flow cytometry. 
Individual data points and their median values from n = 5 independent experiments are 
shown. Friedman’s test p-value 0.0008 **p < 0.01 by Dunn’s multiple comparison’s test.  
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4.3. Decreased C5aR1 expression is not due to protease action 
A potential explanation for the data above is that plasma or liberated cellular proteases 
cleave C5aR1 from the neutrophil surface. We therefore assessed expression of the cell 
surface receptors C5aR1, TNFR1 and CD16 (FcγRIII) after stimulation with S. aureus or 
fMLP in the context of protease inhibition. The protease inhibitors were SLPI and marimastat 
which inhibit serine/threonine proteases and metalloproteases respectively, as previously 
discussed. Figure V-3 demonstrates that the reduction in surface C5aR1 mediated by S. 
aureus phagocytosis or fMLP is not dependent on either subset of protease. This contrasts 
with TNFR1 shedding, which could be prevented by metalloprotease inhibition but not 
serine/threonine protease inhibition, as shown in B. Finally, the data presented in Figure 
V-3C show that surface expression of CD16 does not appear to be significantly altered in this 
setting, indicating that the downregulation of TNFR1 and C5aR1 during S. aureus exposure 
are not simply due to internalisation of large portions of cell membrane during phagocytosis.      
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Figure V-3: C5aR1 is not shed by proteases as opposed to TNFR1. Reduction of 
C5aR1 is not simply due to gross membrane internalisation with phagocytosis 
Whole blood was treated with vehicle control, 10 µg/mL SLPI, 100 nM marimastat or both for 
30 minutes. Blood was then stimulated with vehicle control, 10 µg/mL S. aureus or 1 µM 
fMLP for 60 minutes. Cells were stained for C5aR1 (A), TNFR1 (B) and CD16 (C) on ice in 
the dark before being analysed by flow cytometry as previously described. Individual data 
points with respective mean values are shown for n = 7 independent experiments. A: Two-
way ANOVA p = 0.154 for drug and p = 0.0021 for stimuli, p = ****p < 0.0001 by Dunnett’s 
test of multiple comparisons. B: Two-way ANOVA p = 0.0063 for drug and p < 0.0001 for 
stimuli *p < 0.05 **p < 0.01 ***p < 0.001 by Dunnett’s test of multiple comparisons. C: Mixed-
effects model (due to missing data for marimastat treatment for one experiment) p = 0.62 for 
drug and p = 0.058 for stimuli, not significant so no post-hoc testing performed. 
78 
 
4.4. Investigating the fate of C5aR1 after phagocytosis  
Given the data presented above, I hypothesised that C5aR1 is internalised (rather than shed 
into the extracellular milieu) during phagocytosis and exposure to other pro-inflammatory 
stimuli. I attempted to identify and localise C5aR1 in unstimulated cells as it should be mostly 
present on the cell surface. Using the protocol outlined in Methods, I was able to visualise f-
actin and cell nuclei but failed to achieve convincing staining of C5aR1. Figure V-4 
demonstrates that the isotype control antibody stains similar structures within the cell to a 
similar degree (if not brighter) than the anti-C5aR1 antibody.        
 
  
Figure V-4: Confocal staining of purified neutrophil cell-surface C5aR1 was 
unsuccessful 
Purified human neutrophils were adhered to AS-coated 24-well glass imaging plates for 30 
minutes in the presence of Hoescht 22342. Neutrophils were fixed, washed and 
permeabilised and blocked as in Methods. Primary antibody (A: mouse monoclonal anti-
human C5aR1 clone S5/1, 1:200) or isotype control (B: mouse monoclonal IgG2a κ clone 
MG2A-53, 1:200) were added and cells stained for 60 minutes. Cells were washed and 
secondary antibody (AF568-goat polyclonal anti-mouse IgG heavy and light chain, 1:500) 
and AF488-phalloidin (1:200) were added and cells stained for 60 minutes protected from 
light. Neutrophils were washed, left in PBS and visualised by confocal microscopy at 630 X 
magnification. White arrows indicate areas of non-specific staining observed with antibody 




The work presented in this chapter details my attempts to understand changes that occur 
with C5aR1 during phagocytosis, and if these changes mediate resistance to the effects of 
C5a observed in Figure V-1 and Figure V-2B. There are numerous reports of C5aR1 
expression in a variety of contexts by our group147,213 and others.225 However, to my 
knowledge, only one study mentions any association between decreased C5aR1 expression 
and phagocytosis specifically,211 though others have identified the ability of S. aureus 
supernatants to downregulate C5aR1 expression.343 Given that a known mechanism 
modulating responsiveness to inflammatory molecules is homologous or heterologous 
downregulation of surface receptors,344–346 I wondered whether phagocytosis-induced 
downregulation of cell surface C5aR1 was a mechanism by which cells controlled 
responsiveness to subsequent C5a exposure, perhaps allowing them to remain in-situ and 
destroy internalised bacteria. Another explanation advanced by Veldkamp and colleagues343 
is that C5aR1 downregulation is in response to an S. aureus virulence factor which impairs 
neutrophil function, though this is a less likely explanation for my data as the bacteria used in 
the pHrodo Bioparticles are heat-killed and inert.  
The data shown in Figure V-2A demonstrate that multiple inflammatory molecules cause a 
reduction in cell surface C5aR1 expression, though none to the same degree as C5a itself. 
However, the data in part B demonstrate that despite all of the same molecules causing a 
decrease in C5aR1 surface expression, only exposure to and phagocytosis of an initial S. 
aureus stimulus demonstrated any ability to protect phagocytosis from subsequent C5a 
exposure. The data shown in Figure V-2C provide further evidence that the reduction in 
C5aR1 with phagocytosis is indeed related to the process of phagocytosis itself (as opposed 
to unidentified paracrine factors in the experimental milieu) as there is a dose-response 
relationship between C5aR1 downregulation and the number of particles ingested. Dandekar 
and colleagues have suggested that actin dynamics modulate subsequent signal responses 
to chemoattractants such as fMLP and C5a,347 though they did not report on phagocytic 
stimuli specifically. Further, the necessity of using an inhibitor cocktail (previously 
characterised by that group348) to arrest actin dynamics limits extrapolation of these results to 
the situation in vivo. In context of these reports and the data presented in this chapter, there 
is a suggestion that significant actin dynamics (rather than simply receptor downregulation) 
modulates responsiveness to subsequent C5a exposure.  
The final two figures presented in this chapter attempt to address the fate of C5aR1 after it 
has disappeared from the cell surface. Figure V-3A shows that C5aR1 does not appear to be 
shed in a serine/threonine protease or metalloprotease-dependent manner during 
phagocytosis or treatment with fMLP, in contrast to TNFR1 (B), which is protected from 
shedding by inhibition of metalloproteases. These data are consistent with those from van 
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den Berg212 who also showed a reduction in C5aR1 expression after fMLP treatment. There 
was a slight increase in TNFR1 surface expression when control cells were exposed to 
marimastat, which likely reflects background metalloprotease activity being slightly enhanced 
in blood anticoagulated with a direct thrombin inhibitor such as the argatroban used in these 
assays.349 
Given the indirect evidence above for C5aR1 being internalised rather than shed in the 
context of phagocytosis or soluble inflammatory mediator exposure, I elected to attempt to 
directly visualise the fate of C5aR1 using confocal microscopy. In 2010 Bamberg and 
colleagues231 published a seminal report on the localisation of both C5aR1 and C5aR2 in 
primary human neutrophils after stimulation with C5a. I attempted to replicate these methods 
in my studies given their previous success. Unfortunately, I was not able to source the 
specific clone (3C5) used for immunofluorescence by those authors, and thus used a well-
established clone (S5/1) with which most of my other studies had been conducted without 
issue. After initial failures to demonstrate appropriate specific signal with this antibody 
combination, I suspected the issue was related to the permeabilisation technique stripping 
epitope off the cell surface, and tried different solutions Triton X-100, methanol and no 
permeabilisation step without improvement. I also used a variety of blocking solutions (none, 
human and mouse serum), overnight antibody staining and staining of non-adherent cells 
prior to spinning onto glass microscopy slides without success (results not shown). Further 
potential steps to troubleshoot these experimental issues are detailed in Chapter VII:. At this 
stage, results from my phosphoproteomics screen became available and the focus shifted to 






Chapter VI:  unbiased phosphoproteomic profiling 
reveals novel biology of C5a-induced neutrophil 
dysfunction  
1. Chapter summary 
A priority for this thesis has been the identification of signalling pathways within neutrophils 
that mediate C5a-induced phagocytic dysfunction. If pathway(s) relevant to this dysfunction 
can be identified, consideration can be given to pharmacological manipulation to rescue this 
functional defect. Should such efforts meet with success, they would present an attractive 
option for further drug development in a treatment space currently devoid of effective 
immunotherapies.  
Significant progress has been made toward understanding C5a-induced signalling changes 
in purified neutrophils by our group and others, including reduced phosphorylation of NOX-2 
subunits,179 activation of NHE1,261 and a class I PI3K-mediated reduction in RhoA activity213 
and phagocytosis (see Figure III-5). This work has revealed important signalling ‘nodes’ 
affected by C5a, however a challenge has been to integrate these isolated changes into 
wider signalling networks and different cellular contexts, as discussed in Chapters III and IV. 
To address this challenge, I have adopted an unbiased phosphoproteomic approach to 
assess global changes in neutrophil signalling networks after C5a exposure and 
phagocytosis. Given the rapidity of C5a-induced phagocytic impairment demonstrated in 
Chapter III: 4.6, and the signalling kinetics of PI3Ks66,303 and GPCRs350 an examination of 
post-translational modification by phosphorylation (i.e. a phosphoproteomic approach) was 
considered most likely to reveal signalling mechanisms of interest.  
Proteomic and phosphoproteomic studies have been attempted previously in this cell type, 
though they are traditionally hampered by the low expression of kinase proteins, low 
stoichiometry and short time-courses of phosphorylation, in addition to the highly destructive 
nature of neutrophil lysates, rich in phosphatases and proteases.351 Recent proteomic 
studies of whole, human neutrophil lysates have yielded a depth of < 2200 proteins352 and < 
960 phosphoproteins,353 which provide a benchmark by which contemporaneous proteomic 
studies can be measured. This chapter discusses the workup involved in developing an 
appropriate neutrophil lysis buffer, technical validation of our results and finally, key novel 




2. Hypotheses and aims 
The phosphoproteome of whole neutrophil lysates after C5a exposure and 
phagocytosis of S. aureus Bioparticles will reveal novel pathways driving 
complement-induced neutrophil dysfunction. 
• To optimise a cell lysis buffer that balances competing requirements of protease and 
phosphatase inhibition with downstream proteomics workflows. 
• To demonstrate that C5a-induced phagocytic impairment has occurred in the 
samples analysed (functional positive control).  
• To assess the technical validity of the resultant neutrophil proteome and 
phosphoproteome. 
• To compare phosphoprotein changes between conditions of interest: control vs C5a; 
control + S. aureus vs C5a + S. aureus) and map them to known signalling pathways.   
• To interrogate the functional significance of these pathways through pharmacological 
manipulation in a relevant in vitro system such as whole blood.  
3. Notes on methods 
The techniques discussed in this chapter have been detailed in the Methods Chapter II:13-
17, summarised in Figure II-1 and chiefly relate to the extraction of minimally degraded 
protein from human neutrophils. First, an appropriate lysis buffer was developed which 
preserved protein integrity despite the abundant proteases and phosphatases in neutrophil 
lysates. This aim had to be balanced with downstream phosphoproteomics workflow 
requirements; namely trypsin activity for protein digestion and low levels of detergents and 
metal chelators for phosphopeptide enrichment.354,355 The suitability of lysis buffers was 
determined by silver staining of SDS-PAGE gels and Western blotting for the phosphoprotein 
p-Akt (protein kinase B: PKB) to indicate protein and phosphoprotein integrity in the lysates, 
using GM-CSF stimulation previously described by our group.356 Once the lysis buffer was 
optimised, the proteomics workflow could commence, the results of these key elements are 







4.1. Optimisation of proteomics lysis buffer 
Protein abundance and integrity was assessed in neutrophil lysates prepared with a variety 
of buffers by silver staining of SDS-PAGE gels. The initial lysis buffer suggested by the 
CRUK-CI proteomics core was SDS 0.1 % and TEAB 0.1 %. As demonstrated in Figure 
VI-1A, SDS concentrations of 0.1 % were insufficient to prevent almost total protein 
degradation in neutrophil lysates. The addition of protease inhibitors markedly reduced 
degradation (2nd lane from left) however the absolute protein abundance was still lower than 
the control 4 % SDS buffer previously used in our laboratory. Titration of SDS concentrations 
down to 0.5 % preserved proteins almost as well as the 4 % SDS buffer. Assessment of 
phosphoprotein integrity was performed using Western blotting for p-Akt, shown in B. All 
samples (except control second from right) were treated with GM-CSF to stimulate p-Akt 
production and lysed in different buffers as indicated. Again, the inability of 0.1 % SDS to 
prevent protein degradation in neutrophil lysates was demonstrated, with virtually no staining 
in those lanes, even when the concentration of protease/phosphatase inhibitor was trebled. 
The samples lysed in 0.5 % SDS had good preservation of p-Akt staining, and the addition of 
extra HALT protease/phosphatase inhibitor did not appear to improve this. Therefore, the 0.5 
% SDS/0.1 M TEAB + HALT buffer was chosen as an appropriate compromise between 














Figure VI-1: Optimisation of proteomics lysis buffer 
A: Neutrophils were purified, left untreated and then lysed in different lysis buffers as 
indicated. Lysates were run in 12 % SDS-PAGE gels and then stained using the silver stain 
protocol detailed in Chapter II:14. B: Neutrophils were purified and treated with 10 ng/mL 
GM-CSF for 10 minutes (to stimulate Akt phosphorylation) in all lanes except control second 
from right. Cells were lysed in different lysis buffers as indicated and run in 12 % SDS-PAGE 
gels. Proteins were transferred to PVDF membranes using a wet transfer method, 
membranes were blocked (5 % BSA) and stained for p-Akt (1:5000, rabbit anti-human) and 
Akt (1:5000, rabbit anti-human) overnight at 4 °C. Secondary HRP-conjugated goat anti-
rabbit antibodies (1:10 000) were added for 60 minutes at room temperature, before 




4.2. Technical validation of phosphoproteomics experiment 
To ensure the validity of the phosphoproteomics results, it is important to demonstrate the 
phenotype of interest (C5a-induced neutrophil phagocytic dysfunction) was present in the 
samples sent for phosphoproteomic analysis. For this reason, phagocytosis was assessed in 
aliquots of the same neutrophils sent for phosphoproteomics analysis using a variation of the 
assay described in Chapter II:0. Figure VI-2 shows a significant reduction in phagocytosis 
occurred with 60 minutes of C5a pre-treatment in the samples that were sent for 









Figure VI-2: Phagocytosis analysis confirms defect in C5a-treated samples sent for 
phosphoproteomics 
Neutrophils were purified and treated with 100 nM C5a for 60 minutes or 1 µM PAF for 5 
minutes prior to phagocytosis of 15 µg/mL of S. aureus Bioparticles for 15 minutes. C5a pre-
treatment led to a reduction in median phagocytosis of 33.2 % relative to control. Data points 




Further evidence of technical validity can be gained from interpretation of the proteomics 
data. Table 5 demonstrates the unprecedented depth of sequencing from this study; 4859 
proteins and 2712 phosphoproteins were quantified by peptide intensity. Of note, each 
protein and phosphoprotein was independently identified and quantified in all four donors; 
species identified in fewer than four donors were not included in subsequent analyses. This 
table also shows the number and percentage of proteins and phosphoproteins that were 
significantly altered between the conditions indicated. These data indicate protein expression 
was relatively stable across conditions, indicated by the low percentage of total protein 
changes, as expected for the time points and stimuli involved. Phosphoprotein expression, 
however, varied markedly between conditions as expected. Figure VI-3 demonstrates that 
the measured phosphoprotein intensities are highly consistent between conditions on each 
plex, indicating technically reproducible phosphoprotein measurements prior to normalisation 
of data. Finally, Figure VI-4 shows a selection of two key phosphoproteins (C5aR1 and PI3K 
subunit alpha) which, based on the literature discussed in Sections 3.3, demonstrated 
increased phosphorylation after C5a treatment as expected.336,337,357  
Table 5: Marked phosphoproteome changes with treatment 
This table shows statistically significant numbers of protein/phosphoprotein alterations in the 
total proteome and total phosphoproteome between the conditions indicated. These 
alterations are shown as both the absolute number and as a percentage of the respective 
proteome/phosphoproteome.  
 
 Total proteome (4859 
proteins quantified) 















Percentage of total 
phosphoproteome 
significantly altered 
Ctrl-untreated 0 0.0% 16 0.6% 
C5a-ctrl 7 0.1% 111 4.1% 












Figure VI-3: Peptide intensities are highly consistent between conditions 
Median, IQR and outliers of the measured peptide intensity for the 2712 quantified 
phosphoproteins are shown for each experimental condition on each plex. Intensities are 




Figure VI-4: Phosphorylation of key proteins expected in C5a condition 
Log2-transformed normalised phosphoprotein intensities are shown for C5aR1 and 
phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2α), 
both of which have undergone the phosphorylation expected after C5a treatment. p-values 
were computed by limma-based linear models with Bonferroni’s correction for multiple 
testing.   
 
4.3. Global assessment of proteome and phosphoproteome 
Following validation of technical success of the experiment, attention can be turned to 
analysis of phosphoproteomic data. Given the small changes evident in the total proteome 
over the time points of this experiment, the majority of analysis is focussed on the 
phosphoproteome. Raw data used to generate the figures and tables in this section has yet 
to be published but can viewed using the following Dropbox link for the purposes of this 
thesis: https://www.dropbox.com/sh/lsveytwgscznd9o/AABe5RB5XHNdtftXX5kbaQe8a?dl=0  
Figure VI-5 is a heatmap diagram of the entire 2712 quantified phosphoproteins and their 
fold change over each experimental condition or time point relative to the untreated control 
condition (not shown). Hierarchical clustering shows the S. aureus conditions cluster closely 
together, followed by PAF-treated cells, whereas control and C5a tend to cluster separately. 
There are clear differences in relative expression between subsets of phosphoproteins 
across conditions; notably there are subsets which are phosphorylated in the Control + S. 
aureus condition which are less phosphorylated in the C5a + S. aureus condition. These 




Figure VI-5: Global phosphoprotein expression changes  
Phosphoprotein expression intensity was quantified by mass spectrometry and normalised 
using median scaling as in discussed in Methods. Log2FC was calculated for each 
phosphoprotein relative to untreated baseline condition (not shown) for each experimental 
condition. Increased phosphoprotein expression is indicated in red, decreased in green. 
White boxes draw attention to phosphoproteins with grossly different expression between 
the S. aureus-treated conditions pre-treated with either control or C5a.  
90 
 
4.4. Effect of C5a on the human neutrophil phosphoproteome 
C5a treatment for 60 minutes induced a marked change in phosphoprotein expression of 
human neutrophils, with 119 phosphoproteins expressed differentially relative to control-
treated cells. Of these 119 hits, 87 were phosphorylated and 32 were de-phosphorylated 
relative to control, as the volcano plot in Figure VI-6 shows. Subsequent pathway analysis of 
the phosphorylated and de-phosphorylated proteins using the Reactome Pathway 
Knowledgebase358 identified 60 pathways significantly phosphorylated and 31 
dephosphorylated by C5a exposure. The pathways with the 10 lowest Benjamini-Hochberg 
corrected p-values from each analysis are shown in Table 6. Multiple pathways related to 
downstream signal transduction are phosphorylated in the C5a pre-treated condition 
including MAP-kinases and small GTPases as expected. There also appears to be 
involvement of endosomal sorting pathways such as SUMOylation and membrane trafficking 
in both groups of proteins, indicating a role for these pathways in C5a-mediated effects, as 






Figure VI-6: Volcano plot of C5a-induced protein phosphorylation 
2712 proteins are shown, with increasing phosphorylation shown on the right and 
decreased on the left. Proteins with adjusted p-values < 0.05 are shown in blue, and the 25 
proteins with the highest absolute log2FC are labelled. p-values were computed by limma-
based linear models with Bonferroni’s correction for multiple testing.   
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Table 6: Top 10 signalling pathways significantly enriched by C5a exposure 
Significantly (adjusted p < 0.05 in the C5a vs control comparison) phosphorylated or de-
phosphorylated proteins were identified from the phosphoproteomic screen and input into the 
Reactome database, which maps the input proteins to known signalling pathways and 
determines whether pathways are enriched in the data submitted. Key pathways of 
mechanistic interest are shown in bold. Entities found: the number of curated molecules that 
are common between the submitted data set and the pathway named in column; Entities 
total: known proteins involved in the signalling pathway; p-values: Benjamini-Hochberg 
corrected p-values for significant pathway enrichment. 
 






Processing and activation of SUMO 3 10 8.66E-05 
Activation of RAC1 3 13 1.87E-04 
Smooth Muscle Contraction 4 35 2.22E-04 
Gastrin-CREB signalling pathway via PKC and 
MAPK 
3 18 4.82E-04 
SUMO is proteolytically processed 2 6 1.19E-03 
RSK activation 2 6 1.19E-03 
CREB phosphorylation 2 7 1.61E-03 
MAPK1 (ERK2) activation 2 10 3.22E-03 
Innate Immune System 19 1180 3.45E-03 
SLBP Dependent Processing of Replication-
Dependent Histone Pre-mRNAs 
2 11 3.88E-03 
DE-PHOSPHORYLATED 
Glycogen storage disease type II (GAA) 1 2 6.29E-03 
Glycogen storage disease type XV (GYG1) 1 2 6.29E-03 
Glycogen storage disease type 0 (muscle GYS1) 1 2 6.29E-03 
Ovarian tumor domain proteases 2 38 6.48E-03 
TRAF3 deficiency - HSE 1 3 9.42E-03 
Membrane Trafficking 6 631 1.32E-02 
E3 ubiquitin ligases ubiquitinate target proteins 2 60 1.55E-02 
Neutrophil degranulation 5 480 1.67E-02 
HuR (ELAVL1) binds and stabilizes mRNA 1 8 2.49E-02 
Role of ABL in ROBO-SLIT signalling 1 8 2.49E-02 
4.5. C5a pre-treatment reduces phosphorylation of signalling 
pathways involved in transcription and nuclear structural 
change  
A key goal of this experiment was to assess the C5a-induced changes in signalling in the 
context of phagocytosis of S. aureus to allow identification of phosphorylation changes of 
relevance to this complex biological process. Figure VI-7 shows the phosphoproteins 
differentially expressed in neutrophils after pre-treatment with control or C5a followed by 15 
minutes of phagocytosis. Of note, only 20 proteins are differentially phosphorylated between 
the two conditions when the effect of S. aureus phagocytosis is controlled experimentally. All 
20 of these differentially phosphorylated proteins are more phosphorylated in cells pre-
treated with control relative to C5a, an observation that is further explored in Section 4.6 
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below. When the 20 differentially expressed phosphoproteins are entered into the Reactome 
pathway database, a preponderance of pathways involving changes in nuclear morphology, 
apoptosis and transcriptional regulation are enriched, as shown in Table 7.      
  
Figure VI-7: Volcano plot of phagocytosing cells pre-treated with control relative to 
C5a 
2712 phosphoproteins are shown, with increased phosphorylation in the Ctrl + S. aureus vs 
C5a + S. aureus shown on the right. Proteins with adjusted p-values < 0.05 are shown in 
blue and labelled. p-values were computed by limma-based linear models with Bonferroni’s 
correction for multiple testing.   
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Table 7: Signalling pathways differentially phosphorylated between phagocytosing 
cells pre-treated with control relative to C5a 
Significantly (adjusted p < 0.05 in the Ctrl + S. aureus vs C5a + S. aureus comparison) 
phosphorylated proteins were identified from the phosphoproteomic screen and input into the 
Reactome database, which maps the input proteins to known signalling pathways and 
determines whether pathways are enriched in the data submitted. Key pathways of 
mechanistic interest are shown in bold. Entities found: the number of curated molecules that 
are common between the submitted data set and the pathway named in column; Entities 
total: known proteins involved in the signalling pathway; p-values: Benjamini-Hochberg 
corrected p-values for significant pathway enrichment. 
 






Mitotic Prophase 3 133 1.00E-03 
Apoptotic cleavage of cellular proteins 2 38 2.00E-03 
Apoptotic execution phase 2 54 4.00E-03 
Nuclear Envelope Breakdown 2 63 5.00E-03 
Breakdown of the nuclear lamina 1 3 5.00E-03 
Gene and protein expression by JAK-STAT 
signalling after Interleukin-12 stimulation 
2 74 7.00E-03 
Transcriptional regulation by small RNAs 2 79 7.00E-03 
Transport of Mature mRNA derived from an Intron-
Containing Transcript 
2 81 8.00E-03 
Interleukin-12 signalling 2 85 9.00E-03 
Transport of Mature Transcript to Cytoplasm 2 90 1.00E-02 
4.6. C5a induces a profound ‘phosphorylation failure’ during 
phagocytosis 
One of the most striking features of the phosphoproteome screen is the marked difference in 
the magnitude of the phosphorylation response to S. aureus depending on whether cells 
were pre-treated with C5a or control. This is most evident in Figure VI-8; S. aureus after 
control pre-treatment significantly changed the phosphorylation status of 31 % of the 
phosphoproteome, which illustrates the enormous stimulation encountering this pathogen 
represents for the cell. In contrast, cells that were pre-treated with C5a and then allowed to 
phagocytose S. aureus demonstrated a statistically significant change in phosphorylation 
status of 0.63 % of the phosphoproteome. When proteins significantly phosphorylated by 
phagocytosis of S. aureus in cells pre-treated with control are mapped to known pathways 
using the Reactome database and compared to their counterparts in C5a pre-treated cells, a 
pattern of defective or absent phosphorylation emerges, as shown in Table 8. Pathways 
involved in PIK3C2α, Rho-GTPase and phosphoinositide signalling are prominently 
phosphorylated in control but not C5a pre-treatment. Further, the previously unappreciated 
pathways related to endosomal sorting, membrane trafficking and nuclear morphology 










Table 8: Key C5a-driven phosphorylation failures 
Significantly (adjusted p < 0.05 in the control + S. aureus condition vs control alone 
condition) phosphorylated proteins were identified from the phosphoproteomic screen and 
input into the Reactome database, which maps the input proteins to known signalling 
pathways and determines whether pathways are enriched in the data submitted. Key 
pathways of mechanistic interest are shown in bold. Blue columns indicate phosphoproteins 
and enrichment p-values from the control + S. aureus vs control alone comparison; red 
columns from the C5a + S. aureus vs C5a alone comparison. Entities found: the number of 
curated molecules that are common between the submitted data set and the pathway named 
in column; Entities total: known proteins involved in the signalling pathway; p-values: 
Benjamini-Hochberg corrected p-values for significant pathway enrichment. 
 
Pathway name Entities 
Ctrl + S. 
aureus 
Entities 





Ctrl + S. 
aureus 
p-value  
C5a + S. 
aureus 
Cytokine Signalling in 
Immune system 
60 0 1055 8.51E-06 N/A 
Innate Immune System 65 3 1302 1.73E-04 1.82E-01 
Membrane Trafficking 45 4 661 1.60E-06 5.75E-03 
Neutrophil degranulation 35 3 480 5.84E-06 1.62E-02 
Nuclear Envelope 
Breakdown 
11 0 63 7.34E-06 N/A 
Nuclear Pore Complex 
(NPC) Disassembly 
9 0 40 6.91E-06 N/A 
PtdIns(3,4,5)P3 activates 
AKT signalling 
18 0 312 1.17E-02 N/A 
PTEN Regulation 12 1 171 9.26E-03 1.79E-01 
Signalling by Receptor 
Tyrosine Kinases 
29 1 518 2.50E-03 4.53E-01 
Signalling by Rho 
GTPases 
32 0 447 2.10E-05 N/A 
SUMOylation 17 0 187 1.29E-04 N/A 
Toll Like Receptor 2 
(TLR2) Cascade 
10 0 113 3.65E-03 N/A 
Vesicle-mediated 
transport 
46 4 820 1.42E-04 1.22E-02 
Figure VI-8: C5a-induced phosphorylation failure in response to S. aureus 
2712 phosphoproteins are shown, with increased phosphorylation after S. aureus shown on 
the right of each plot. A: Protein phosphorylation in the control + S. aureus condition relative 
to control alone condition. S. aureus treatment after control increased phosphorylation of 
391 proteins and decreased phosphorylation of 472 proteins, the sum of which (863) 
corresponds to 31 % of the phosphoproteome.  B: Protein phosphorylation in the C5a + S. 
aureus condition relative to C5a alone condition. S. aureus treatment after C5a increased 
phosphorylation of 15 proteins and decreased phosphorylation of 2 proteins, the sum of 
which (17) corresponds to 0.63 % of the phosphoproteome. Proteins with adjusted p-values 
< 0.05 are shown in blue and the 25 (A) or 17 (B) proteins with the highest absolute log2FC 
are labelled. p-values were computed by limma-based linear models with Bonferroni’s 
correction for multiple testing.  
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4.7. Phosphorylation failure of PI3K and membrane trafficking 
pathways impairs phagosomal maturation 
As noted in Table 8, key signalling pathways which fail to be phosphorylated after S. aureus 
in the context of C5a pre-treatment are related to endosomal transport or trafficking, PI3K 
function and notably, the V-type ATPase subunit G1 which is critical to phagosomal 
acidification.  I therefore went on to examine whether C5a induced a specific defect in 
phagosomal acidification, distinct from its inhibition of phagocytosis.  Using the maturation 
probe discussed in Chapter II: Section 10.3 (which allows simultaneous assessment of ROS, 
phagosomal pH and particle ingestion in the existing whole blood assay) I have shown that 
C5a does indeed impair phagosomal acidification in addition to phagocytosis itself (Figure 
VI-9).  As discussed in Section 1.5 of Chapter I:, these endosomal maturation processes are 
key for the effective maturation of a nascent phagosome into a bactericidal phagolysosome, 
and rely heavily on PI3P which is predominantly produced by the class III PI3K, Vps34.62,254 
The phosphoproteomic screen identified several proteins likely to be involved in these 
processes:  Zinc finger FYVE domain-containing protein 16 (ZFYVE16), target of Myb protein 
1 (TOM1) and Ras-related protein 7a (RAB7A). All were significantly phosphorylated in the 
control + S. aureus condition (log2FCs 1.19, 0.77, 1.81 respectively) with ZFYVE16 and 
TOM1 not significantly phosphorylated in the C5a + S. aureus condition. These proteins are 
known to be dependent on PI3P for effective recruitment to the phagolysosome.359 Thus, 
pharmacological inhibition of Vps34 may reproduce C5a-induced defects in phagocytosis, 
and particularly, phagosomal maturation. I then made use of a recently-developed selective 
inhibitor of Vps34 (VPS34-IN1) and showed that inhibition of Vps34 recapitulates the 
phagosomal acidification defect, with no statistically significant effect on phagocytosis or 
ROS production measured in the same assay (Figure VI-10). These data functionally validate 
the phosphoproteomic studies conducted and shed new light on the mechanisms by which 























Figure VI-9: C5a induces a failure in phagosomal maturation  
Whole blood was pre-treated with 300 nM C5a for 60 minutes prior to addition of 5 µg/mL 
phagosomal maturation probe. A: Contour flow plots after 60 minutes 300 nM C5a or control 
and then 120 minutes phagocytosis showing how both phagocytosis (x-axis) and 
phagosomal pH (y-axis) can be measured simultaneously in the same population of cells. 
pHrodo fluorescence increases with decreasing pH, indicating phagosomal maturity as 
shown. B: Cells were allowed to phagocytose for the time points indicated and the 
percentage of particle positive (AF488 positive) cells with low pH (mature) and high pH 
(immature) phagolysosomes is shown for control and C5a-treated conditions. Data are 
shown as mean and SD of n = 5 independent experiments. ***p < 0.0001 by repeated-
measures two-way ANOVA with Tukey’s multiple comparisons test. NB: these experiments 
were carried out using my whole blood assay by Dr Andrew Conway Morris and have been 




Figure VI-10: VPS34-IN1 impairs neutrophil phagosomal maturation but not 
phagocytosis or ROS production in whole blood 
Whole blood was pre-treated with 1 µM VPS34-IN1 nM for 60 minutes prior to addition of the 
phagosomal maturation probe. Cells were allowed to phagocytose for the time points 
indicated. As previously described, phagocytosis (A) ROS production (B) and phagosomal 
pH (C) were quantified by flow cytometry. There were no significant differences according to 
drug treatment in phagocytosis or ROS. There was a reduction in phagosomal acidification 
as shown. Data are shown as mean and SD of n = 5 independent experiments. **p = 0.0058 
for drug by repeated measures two-way ANOVA with Bonferroni’s multiple comparisons test. 
NB: these experiments were carried out using my whole blood assay by Dr Andrew Conway 




The data presented in this chapter constitute, to my knowledge, the deepest sequencing of 
the human neutrophil proteome and phosphoproteome published, and certainly the first such 
assessment of the neutrophil response to C5a.353,360,361 Further, these data provide the first 
phosphoproteomic assessment of the host neutrophil response to S. aureus (as opposed to 
changes in the proteome of the pathogen) once again in the context of C5a, a key driver of 
innate immune dysfunction.362 Unlike previous studies using transcriptomic or microarray 
data363–365 proteomics provides a direct assessment of mediators and may be more likely to 
have functional implications, especially in short-lived cells such as neutrophils.351,366 
Therefore, these data provide an opportunity to uncover mechanisms driving important 
bactericidal processes and their impairment in primary human neutrophils. This discussion 
begins by contextualising and validating the phosphoproteomic screen. It then divides into 
two parts: the first deals with hits from the phosphoproteome which may indicate a role for 
nuclear morphological change in allowing efficient phagocytosis. The second discusses the 
expanded role (identified and validated during this work) of membrane trafficking signals in 
driving phagosomal maturation.  
My first aim was to isolate protein of a high quality from primary human neutrophils which 
would be suitable for downstream phosphoproteomic analysis. The CRUK-CI proteomics 
core makes use of an SDS/TEAB-based buffer system for trypsin digestion and downstream 
LC-MS/MS which requires an SDS concentration of ≤ 0.1 % and at least 100 µg of protein 
per sample.  To assess protein integrity in neutrophil lysates, I used a combination of silver 
staining and Western blotting of SDS-PAGE gels. As shown in Figure VI-1, an SDS 
concentration of 0.1 % was inadequate to prevent significant protein degradation, even when 
high concentrations of protease and phosphatase inhibitors were used, in keeping with the 
high concentrations of proteases in neutrophil lysates.361 I therefore elected to use large 
numbers of cells (12 x 106/condition) and an SDS concentration of 0.5 % which would allow 
dilution of the resultant lysate down to 0.1 % SDS whilst maintaining amounts of protein 
sufficient for phosphoproteomic analysis. This buffer was designed to represent a 
compromise between the maintenance of protein integrity and providing an appropriate 
lysate for downstream analysis. Of note, protein degradation was not completely abolished 
(note lower MW bands in the p-Akt Western Figure VI-1) which may represent an area for 
improvement in subsequent experiments.   
Once the phosphoproteome screen was conducted, the first task was technical validation of 
the results. I approached this issue in three ways: first I ensured that only samples with a 
demonstrable C5a-induced phagocytic defect were sent for phosphoproteomic analysis 
(Figure VI-2) to avoid sequencing samples without the phenotype of interest. At this short 
time-point with a high inoculum of S. aureus Bioparticles (15 minutes and 15 µg/mL 
100 
 
respectively)  there was no augmentation of phagocytosis with PAF as previously observed 
in whole blood (Chapter IV:5) though these differences are most probably due to differences 
in experimental setup. Second, the raw phosphopeptide intensities were inspected for 
uniformity between conditions (Figure VI-3) which confirmed there were no sizeable 
differences between experimental conditions which could confound interpretation of results. 
Finally, the depth of sequencing was found to be much higher than previous reports of 
proteins obtained from primary human neutrophils,352,353 with a total of 4859 proteins and 
2712 phosphoproteins of which expression was not only detected but quantified. Whilst this 
depth of sequencing is substantially less than the 20 397 curated human proteins listed in the 
Uniprot367 database and less than recent proteomics of human fetal fibroblast cells,368 it 
compares extremely favourably to other primary human neutrophil datasets as previously 
discussed.352,353 These observations are most probably due to the multitude of proteases and 
phosphatases in neutrophil lysates as well as substantial variations in genome translation 
between tissues. The reasons for the success of this experiment relative to comparable cell 
types include: careful testing of lysis buffers in this specific context, fractionation of lysates 
prior to phosphopeptide enrichment and recent advances in LC-MS/MS technology 
employed at CRUK-CI (personal communication: Dr Clive D’Santos, Proteomics Core, 
CRUK-CI). Receptor phosphorylation has been shown to mediate signalling driven by C5a-
C5aR92 along with other GPCRs350 and PI3K signalling.177,213,331  In this dataset, such 
proteins were indeed phosphorylated after C5a exposure, providing more evidence which 
validates this screen as shown in Figure VI-4.  
An overall impression of the phosphoproteomic dataset is given in Figure VI-5. This figure 
shows Log2FC values relative to the untreated control condition (not shown), as well as 
hierarchical clustering of phosphoproteins (left dendrogram) and experimental conditions (top 
dendrogram). These data show, as expected, the enormous stimulus pathogen exposure 
constitutes for the cell, as these conditions cluster together irrespective of pre-treatment. 
There are at least three groups of proteins that are differentially phosphorylated between 
phagocytosing cells pre-treated with C5a or control; these are highlighted by white boxes and 
discussed below. These proteins are generally more phosphorylated in the control + S. 
aureus condition relative to the C5a + S. aureus condition, an observation further delineated 
in subsequent pathway analyses. 
Figure VI-6 shows phosphorylation changes induced by 60 minutes of C5a exposure, which 
map to pathways identified in Table 6. It is interesting to note the persistence of a 
phosphorylation signal in multiple proteins 60 minutes after chemoattractant exposure, a 
process traditionally thought to induce responses over seconds to minutes and indicates that 
prolonged signalling may be responsible for the prolonged defects noted in Chapter 
III:4.6.324,350,369 Rather unsurprisingly, pathways involving promiscuous neutrophil signalling 
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molecules are phosphorylated, including MAPK/ERK signalling and membrane trafficking 
proteins. Interestingly, proteins related to neutrophil degranulation and other membrane 
trafficking functions are de-phosphorylated, which may reflect time-dependent changes in the 
metabolism of these proteins, or indicate the development of an ‘exhaustion phenotype’ 
occurring after stimulation by an agonist known to induce degranulation.261  
We now turn to the novel and unanticipated results shown in Figure VI-7, which indicate pre-
treatment with C5a of cells phagocytosing S. aureus significantly reduced phosphorylation of 
just 20 proteins relative to phagocytosing cells pre-treated with control. Pathway analysis 
shown in Table 7 demonstrates enrichment of several pathways related to modulation of 
nuclear morphology, transcription and apoptosis. The concept of phagocytosis-induced cell 
death (PICD) as a transcriptionally-regulated host response to phagocytosis of pathogenic 
bacteria was advanced by Kobayashi and colleagues in 2002,365 and extended in 2003.370 
These authors assessed apoptosis of neutrophils in response to live bacteria at late time 
points (the earliest was 90 minutes) after phagocytosis.365,370 Whilst the enrichment of 
pathways involved in apoptosis and nuclear envelope breakdown observed in our dataset 
may simply represent an earlier, phosphoproteomic response driving PICD or indeed 
NETosis,371 this explanation would not account for the demonstrated phagocytic defect noted 
in the C5a-treated cells. Further, previous work has demonstrated minimal apoptosis in 
response to heat-killed bacteria,372 as used in this thesis. It is tempting to speculate that the 
nucleus is an active player in phagocytosis, as it is in other processes involving significant 
changes to the cytoskeleton such as transmigration,36,38 and that C5a impairs nuclear 
morphological change, thus leading to rapid defects in phagocytic function.  
Key players within these pathways include Lamin B1 (LMNB1), which has known dose-
responsive associations with nuclear morphology,373,374 and NUP153, a component of the 
nuclear pore complex,375 both of which were less phosphorylated in phagocytosing cells pre-
treated with C5a. The combination of mechanistic plausability (significantly altered proteins in 
our screen correspond to known modulators of nuclear morphology) and the precedent set 
by evidence of nuclear deformation occurring during transmigration36,38,376 make this an 
attractive target for further research, as discussed in Chapter VII:. 
The second key set of findings from this phosphoproteomic screen relate to the profound 
phosphorylation failure induced by C5a pre-treatment in response to phagocytosis of S. 
aureus, illustrated in Figure VI-8. These data indicate that cells pre-treated with C5a are 
unable to respond to a pathogen challenge in the same way that control-treated cells are. 
These data also provide a potential explanation for the inability of C5a to inhibit phagocytosis 
if phagocytosis has already commenced (Figure V-1) whereby the overwhelming 
phosphoproteomic response of cells to S. aureus has already been initiated and is thus 
resistant to fatigue by C5a. There are, however, some important points to consider here. 
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Firstly, it should be noted that the amount of phagocytosis occurring in the C5a pre-treated 
cells was less than in their control pre-treated counterparts (Figure VI-2) and indeed this was 
a key component of experimental design. I would suggest that whilst the amount of 
phagocytosis may have been less in the C5a pre-treated cells, the total stimulus (amount of 
S. aureus) administered to the cells was the same between the conditions. Therefore whilst a 
component of the reduced signal in the C5a pre-treated cells may have been due to les 
phagocytosis, the cells can indeed be considered significantly less responsive to the same 
pathogenic stimulus. Further, the relative reduction in phagocytosis shown is modest (33.2 
%) relative to the profound alteration in the phosphoproteome.  
There is a possibility that the lack of phosphoproteomic signal we see after C5a pre-
treatment simply represents cellular exhaustion377 or reduced signalling secondary to 
heterologous receptor desensitisation.378 I would argue that this is not the case for several 
reasons: firstly, heterologous desensitisation has only been demonstrated with 
chemoattractant receptors and only shown to persist for a few minutes,378 whereas we 
observe persistent C5a-induced dysfunction hours after exposure. Secondly, other 
chemoattractants and priming agents do not induce a phagocytic defect like C5a, as shown 
in Figure IV-3, which argues against receptor desensitisation or exhaustion being the cause. 
Finally, the selective nature of the diminished response (affecting signalling pathways with a 
common theme) and its functional effects argue against a whole-cell exhaustion phenotype. 
On a related note, whether this phosphorylation failure is a cause of the diminished 
phagocytic response or a consequence of it can only be answered by subsequent 
experiments examining specific pathways and by a more granular temporal profile of the 
phosphoproteome. This is often case with many findings from ‘omics’ datasets and these 
data should therefore be interpreted in light of these considerations.  
When the proteins phosphorylated by S. aureus phagocytosis in control cells are subjected 
to pathway analysis, several pathways of interest are highly enriched, and are markedly less 
so in the C5a pre-treated condition (Table 8). Of interest, pathways related to 
phosphoinositide signalling, Rho GTPase function and membrane trafficking feature 
prominently. These data provide further evidence for the role of PI3Ks and Rho GTPases in 
C5a-mediated phagocytic dysfunction previously described by our group, and importantly 
demonstrate that these are not restricted to the context in which they were originally 
identified.177,213 In addition, the preponderance of membrane trafficking and endosomal 
sorting signals raised an intriguing possibility that C5a not only influences the action of class I 
PI3Ks involved in phagocytosis, but also the class III PI3K driving maturation of the 
phagosome, and that impairment of both pathways combined drives the killing defect 
demonstrated in Figure III-6. 
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Using a maturation probe prepared in-house by Dr Conway Morris, I show in Figure VI-9 that 
cells pre-treated with C5a demonstrated not only a defect in baseline phagocytosis but a 
defect in phagosomal acidification, designated maturation in the figure for simplicity. I then 
sought to functionally validate hits from our phosphoproteomic screen using a recently 
characterised, highly selective inhibitor of the class III PI3K, Vps34, appropriately designated 
VPS34-IN1.379,380 The selected concentration of 1 µM for 60 minutes was based on data 
established in osteosarcoma cell lines showing inhibition of PI(3)P co-localisation with 
endosomes,379 as well as this being the concentration used in the laboratory of our 
collaborator and PI3K biologist, Professor Klaus Okkenhaug. Using the same maturation 
probe and DHR in duplicate conditions (as DHR and AF488 cannot be analysed in the same 
cells due to overlapping emission spectra) I demonstrated that VPS34-IN1 selectively 
impaired phagosomal maturation, without impairing phagocytosis, with a trend to reduction in 
phagosomal ROS Figure VI-10. These data are broadly consistent with those of Anderson 
and colleagues, who showed Vps34 did not play an appreciable role in phagocytosis.381 Our 
data showed a trend to decreased ROS production with Vps34 inhibition, though this was not 
as marked as that shown by the authors above381 and others.62,382 The reasons for this 
difference are likely due to different cellular contexts, measures of phagosomal ROS, and the 
use of a highly selective VPS34 inhibitor in this current work. 
To summarise, the data presented in this chapter provide an unprecedented insight into the 
phosphoproteomic response of primary human neutrophils to a common pathogenic 
stimulus, and the perturbation of this response by C5a. These data indicate that C5a exerts 
pleiotropic effects on neutrophils and induces a profound phosphorylation failure in response 
to subsequent pathogen encounter. This failure is characterised by defects in multiple 
signalling pathways, including phosphoinositide signalling. In follow-up experiments, the 
phosphoproteomic data has been validated in a physiologically-relevant in vitro system, 
where we have shown that Vps34 inhibition selectively recapitulates the phagosomal 
maturation defect induced by C5a. The screen has also raised the intriguing and exciting 
prospect of direct nuclear involvement in phagocytosis, and the impairment of nuclear 
membrane disassembly by C5a as another mechanism by which C5a may drive neutrophil 
dysfunction. As usual, such experiments generate a host of new avenues for investigation, 
some of which are discussed in the next, and final, chapter.   
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Chapter VII: Future directions and conclusion 
1. Summary of key findings 
Throughout the course of this body of work, several novel findings were made, which 
together have implications for our understanding of innate immune dysfunction in critical 
illness. This section summarises these findings and relates them both to each other and to 
our understanding of critical illness-induced immune dysfunction.  
First, and of critical importance to the remainder of work presented here, is the 
demonstration and extension of the C5a-induced defect in neutrophil phagocytosis. Whilst 
C5a-induced defects in phagocytosis have been noted for some time by our group177,213 and 
others179,269,270 these studies were performed in isolated cells with a large phagocytic target, 
zymosan. Here, I have extended these findings in several ways. The first was demonstration 
of C5a-induced phagocytic defects of the physically smaller, physiologically relevant 
pathogens E. coli and S. aureus by purified cells in suspension (Figure III-5), and then in 
whole blood, showing an accompanying reduction in phagosomal ROS production (Figure 
IV-3). Further, the relevance of these findings to bacterial killing of S. aureus has now been 
demonstrated (Figure III-6). Importantly, in both experimental systems the rapid onset and 
persistence of the effects of C5a have been shown (Figure III-7 and Figure IV-4), findings of 
particular interest given the prolonged and often fatal immunosuppression observed in 
diverse groups of critically ill patients.97,158,167 
I made use of my time in Cambridge to work with new technologies; the Attune Nxt™ flow 
cytometer made possible the whole blood assay I refined, without RBC lysis or wash steps. 
This cytometer, when combined with fluorescent probes and an appropriate anticoagulant 
(argatroban), allows rapid assessment of neutrophil functions in small samples of blood 
(Figure IV-1). This technique is readily applicable in clinical settings (Figure IV-8). Further, 
the assay has been used by my supervisor, Dr Andrew Conway Morris, to interrogate 
neutrophil function in murine blood samples with success (not shown). The ready availability 
of this assay facilitated further work on the biology of C5a: this work demonstrated important 
differences in the involvement of PI3K signalling between whole blood and purified cells 
(Figure III-5 and Figure IV-5). The reasons for this difference are not clear at present, though 
likely candidates include other cell types such as monocytes, which have previously been 
shown to modulate neutrophil responses to LPS.383 Further, the plethora of complement and 
coagulation factors present in whole blood, once stimulated by the addition of C5a,190,200 may 
generate a response so intense it is not preventable by inhibition of any one signalling 
pathway, necessitating multi-pronged pathway blockade similar to that recently employed by 
Skjeflo and colleagues in a porcine model of sepsis.384  
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An unanticipated finding of my work was the resistance to C5a-induced phagocytic 
impairment by previous S. aureus phagocytosis (Figure V-1). Initially I believed this was due 
to phagocytosis reducing C5aR1 expression, thereby rendering the cell unresponsive to 
subsequent C5a exposure. However, other priming agents and stimuli (including the soluble, 
S. aureus-derived TLR2 agonist LTA) also reduce C5aR1 expression but do not protect from 
subsequent C5a-induced impairment (Figure V-2), refuting that hypothesis. Given the known 
interplay between actin remodelling, endocytosis and signalling,347,359 a more likely 
explanation may be that large-scale actin changes induced by phagocytosis49 affect the 
signalling functions of C5aR1. Further, given what we now know about the massive 
phosphoproteomic response to S. aureus, a simple ‘drowning out’ of any subsequent C5a 
signal should also be considered a potential explanation for the above observations. 
A key consideration arising from the data presented throughout this thesis is the possibility 
that the inhibitory effect of C5a pre-treatment on phagocytosis is due to homologous 
desensitisation of C5aR1. This line of reasoning posits that C5aR1 allows efficient 
phagocytosis of pathogens under homeostatic conditions as demonstrated in both mice385 
and humans266 and discussed in Chapter I: Section 3. Therefore, pre-exposure to C5a results 
in homologous desensitisation, reducing cell-surface C5aR1 and hence the efficiency of 
subsequent phagocytosis. I do not believe that this homologous desensitisation hypothesis 
wholly explains the C5a-induced phagocytic defect observed throughout my thesis for a 
number of reasons outlined below. 
Firstly, data from the two studies cited above indeed demonstrate that intact C5a-C5aR1 
signaling is required for efficient phagocytosis when neutrophils encounter E. coli266 or 
Cryptococcus neoformans.385 However, a key difference between the above studies and my 
own work is the rapidity of C5a exposure. In the above publications, C5a was generated 
endogenously in whole blood or serum after bacteria were added, as occurs in localised 
tissue infection or low-volume bacteraemia.92 In my system, C5a was spiked into the 
experimental milieu in high concentrations, as observed in critical illness,92 which resulted in 
an immediate, pre-phagocytic flood of C5a rather than a gradual increase of C5a 
concentrations alongside phagocytosis. The mechanism by which C5a-C5aR1 signaling was 
shown to enhance phagocytosis was upregulation of CD11b on the cell surface.266,385 
Importantly, I have also shown that CD11b is upregulated by pre-treatment with high-
concentrations of C5a (Figure IV-6) yet under the same conditions, these cells exhibit 
defective phagocytosis (Figure IV-3). In short, the two experimental systems differ in their 
physiology and C5a exerts different effects in different contexts. I therefore believe it is more 
likely that my data indicate a specific effect of C5a pre-treatment on phagocytosis, rather 
than dampening of an effect shown in a significantly different system. 
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Further, data presented in Figure IV-7 from the ‘double phagocytic challenge’ experiment 
show that the overwhelming majority of cells positive for the second phagocytic challenge 
were positive on the first challenge, and Figure V-2C shows that C5aR1 expression 
decreases with phagocytosis of each challenge. Therefore, my data indicate that cells which 
have phagocytosed on the first challenge (and hence have lower C5aR1) are actually more 
likely to phagocytose when challenged again, relative to their non-phagocytic, C5aR1 high 
counterparts. I have also shown in Figure V-2 that GM-CSF, LPS and LTA induce a trend 
toward reduced C5aR1 expression whilst driving an increase in phagocytosis. Figure III-7 
demonstrates that phagocytic defects increase with time after C5a exposure (minimal at 10 
minutes but marked at 60 minutes) despite the receptor being near-maximally internalised by 
5-10 minutes.386,387 Taken together, these data indicate that homologous desensitisation of 
C5aR1 by C5a pre-treatment is unlikely to fully explain the phagocytic defect induced by 
C5a. 
This question could be addressed experimentally through pre-treatment of neutrophils with 
the small molecule C5aR1 inhibitor PMX-53388 or monoclonal antibodies against C5aR1 
signaling such as MEDI7814284 and IFX-1 prior to C5a exposure.389 Indeed, Conway Morris 
and colleagues have shown that pre-treatment with a monoclonal antibody against C5aR1 
had a negligible effect on phagocytosis in control cells, and partially prevented C5a-induced 
phagocytic defects.177 However, from the above experiment (and any that employ the 
strategy of C5aR1 blockade) it is impossible to dissect whether the observed results are due 
to a prevention of homologous desensitisation or inhibition of direct C5a-induced signaling 
which impairs phagocytosis. Another option would be to selectively inhibit receptor 
endocytosis as reviewed by Dutta and Donaldson,390 though it is likely that inhibition of 
endocytosis would have off-target effects on the closely related phenomenon of 
phagocytosis. Given these considerations, I believed a global assessment of C5a-induced 
signalling followed by experimental interrogation of key pathways was more likely to yield 
insights into the mechanism of C5a-induced phagocytic defects, as discussed below. 
The carefully planned phosphoproteomic screen has provided a wealth of data and 
constitutes the deepest profile of the human neutrophil phosphoproteome to date. It is the 
first phosphoproteomic assessment of this cell type in response to S. aureus, and certainly 
the first to interrogate the effect of C5a in this context. Despite the importance of this 
particular host-pathogen interaction for human disease,391 there is a paucity of systematic 
proteomic data interrogating this relationship: a search of the comprehensive 
ProteomeXchange database392,393 using the keyword ‘neutrophil’ yields four studies on 
human neutrophils, two of which have yet to be published and hence data are unavailable, 
one with which I have compared my own dataset already,352 and the last relates to proteomic 
profiling of granule subsets of limited relevance for global cell signalling networks.364 None of 
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these datasets relate to neutrophils in the context of phagocytosis or S. aureus infection. 
Further, the above search, coupled with interrogation of the PubMed database using the 
subject headings ‘neutrophil’ ‘S. aureus’ and ‘proteome’ revealed no publications addressing 
the host neutrophil phosphoproteomic (or indeed proteomic) response to S. aureus infection. 
Given the lack of other datasets addressing S. aureus-host interactions, comparisons must 
be made with other cell types encountering this pathogen.  
Richter and colleagues infected human bronchial epithelial (16HBE14o) cells with live S. 
aureus (strain HG001) and measured the ‘host’ cell phosphoproteome at 15, 120 and 240 
minutes, with concomitant assessments of phagocytosis and bacterial replication.394 Peak 
phosphoproteomic responses were observed at 120 and 240 minutes in this cell type,394 
likely owing to the much slower rate of phagocytosis of non-professional phagocytes relative 
to neutrophils.49,53,63 Given these caveats, it is reassuring to note enrichment of pathways 
similar to those found in my dataset associated with phagocytosis, including cytoskeletal 
reorganisation, Rho-family GTPase signalling, and vesicle trafficking.394 There is a notable 
lack of protein phosphorylation related to nuclear membrane dissolution,394 which currently 
appears to be unique to my dataset. Of note, there is a significant literature on viral infection 
of other cell-types,368,395,396 and on S. aureus proteomes in the context of infection, as 
recently reviewed by Hecker and colleagues.362 However, the absence of active 
phagocytosis and assessment of the host response in the above studies, respectively, limits 
meaningful comparisons with my dataset.        
Analysis of the differential expression of the 2712 phosphoproteins quantified in Chapter VI: 
demonstrated three key findings. First, C5a pre-treatment induced a profound 
phosphorylation failure in response to S. aureus (Figure VI-8). This paralysis of subsequent 
responses is evident in the phosphoprotein signature for at least one hour after C5a 
stimulation, and indeed our phagocytosis data suggests that it persists for several hours. 
This finding led to the second and third important insights: pathway analysis revealed 
signalling failures disproportionately affecting nuclear envelope breakdown and class III 
PI3K-mediated phagosomal maturation.  
The finding of class III PI3K involvement in phagosomal maturation and appropriate targeting 
of endosomes is not new,62,381,397 which provides further validation of the phosphoproteomic 
screen. However, C5a-induced impairment of PtdIns3P signals in response to S. aureus 
have not been shown before and constitutes yet another way in which C5a impairs neutrophil 
microbicidal function. Further, the data presented in Figure VI-9 and Figure VI-10 provide 
initial functional validation of observed phosphoproteomic signals in the whole blood model, 
the importance of which cannot be understated if these signalling findings are to be 
translated to therapies for patients.  
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Finally, the phosphorylation of proteins involved in nuclear membrane disassembly, to my 
knowledge, had not been demonstrated in the context of phagocytosis. The concept of 
nuclear envelope breakdown and reorganisation has precedent in the transmigration 
literature, where nuclei are inserted into the leading edges of cells36 and undergo rupture and 
repair cycles.38 Further, nuclear deformations during transmigration have recently been 
shown to involve lamins,398 components of the fibrous nuclear lamina, which also modulate 
nuclear hypersegmentation.35,374 A prominent ‘hit’ from the phosphoproteomic screen was 
lamin B1 (LMNB1, Figure VI-7) which further strengthens my suspicion that nuclear envelope 
changes may well be involved in phagocytosis, and impaired by C5a pre-treatment. The 
relevance of these findings, if functionally validated, could extend from neutrophils in the 
context of C5a exposure to phagocytes and phagocytosis in general. However, 
demonstrating nuclear involvement in functional assays of phagocytosis will be challenging, 
and is discussed in the next section. 
2. Avenues for further investigation 
2.1. Reconcile contrasting data on the effect of C5a and other 
agonists in different circumstances 
The question of why C5a, the prototypical anaphylatoxin, which induces inflammation and 
tissue infiltration of immune cells, simultaneously seems to impair other functions of the very 
cells it recruits, remains unanswered. Many groups have demonstrated C5a-induced defects 
in phagocytosis177,179,213,270 (and we can now extend this to ROS production and phagosomal 
acidification in whole blood) whilst others have shown that signalling through C5a is, at the 
same time, important for efficient phagocytosis.266 The idea that these differential effects are 
simply concentration-dependent, as advanced by Ward and colleagues,92,210 whilst likely a 
contributor, does not withstand the weight of published evidence and is not supported by 
data I have collected. Could the subset of immune cell involved, timing of exposure, 
presence of a concentration gradient or differential receptor ligation explain these apparent 
paradoxes? Whilst many reported differences may be due to context, I think an important 
component of future work will be to address these conflicting findings in contexts relevant to 
the situation in vivo. We now have workable, scalable assays with which to address these 
questions.  
Investigation could commence with a paired comparison of whole blood, purified neutrophils 
in plasma or serum and ultrapure neutrophils treated with a range of concentrations of C5a 
with subsequent measurement of phagocytosis, phagosomal ROS and maturation. C5a 
exposure before and after transmigration (either through transwells, or endothelial cells) 
could also be assessed for differential effects. There is some precedent for susceptibility to 
C5a being driven by cellular maturation or transmigration: Seow and colleagues have shown 
C5a is known to exert different effects on monocytes compared to macrophages,275 and it 
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would be interesting to explore this hypothesis in terminally differentiated neutrophils. Finally, 
the concept of biased agonism of GPCRs (different cellular effects from ligation of the same 
receptor, recently reviewed by Lefkowitz and others399,400) may drive the contrasting effects of 
C5a observed in different experiments, and this problem could be interrogated by a 
proteomic approach as we have previously employed.      
2.2. Interrogate C5aR1 localisation after phagocytosis 
In Chapter V:4.4 I attempted to localise C5aR1 by confocal microscopy, but these attempts 
were unsuccessful, most likely due to non-specific staining of the antibody. I believe this is an 
important component of work, as the direct involvement of C5aR1 in phagocytosis has not 
previously been explored. To troubleshoot the issues I had during these experiments I would 
first change the primary antibody and test a variety of concentrations. If that failed, I’d 
consider permeabilising cells with saponin (as employed by Bamberg and colleagues231 to 
localise the receptor) rather than Triton X-100 or methanol, as these harsher agents may 
degrade antibody-binding epitopes of the receptor.401 Once reliable antibody staining has 
been achieved, time courses of phagocytosis of S. aureus could be carried out and C5aR1/2 
localisation assessed.  
2.3. Follow-up on class III PI3K impairment after C5a 
Preliminary data acquired in whole blood validates significant hits from the 
phosphoproteomic dataset with respect to the importance of PtdIns3P in phagosomal 
maturation, and its impairment by C5a. In order to follow-up on these findings, further 
experiments should assess the effect of VPS34-IN1 treatment on whole blood staphylococcal 
killing. For completeness, an increase in PtdIns3P levels in the context of S. aureus 
phagocytosis and their reduction by C5a and VPS34-IN1 treatment should also be 
demonstrated. Assays similar to the one I used to quantify PtdIns(3,4,5)P3 (Chapter II::8) are 
now employed by our collaborators at the Babraham Institute, Professors Phillip Hawkins 
and Len Stephens, to measure other phosphoinositide species and are thus readily 
available.402  
2.4. Validate whole blood assay as a scalable, clinically useful 
tool 
I demonstrated the whole blood assay is feasible in a clinical setting, though it has not yet 
been validated or correlated with known measures of neutrophil function or patient-important 
outcomes. Before these aims can be achieved, I believe the assay would benefit from a 
concerted effort to minimise experimental variation, and assessment of whether this variation 
represents true biological variation or ‘noise’ within the system. I suspect a significant source 
of variation is pipetting error or incomplete homogenisation of the pHrodo S. aureus 
Bioparticles, despite aliquots being taken from the same batch and stored at -20°C. These 
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issues could be addressed initially by measuring neutrophil function in samples of blood 
drawn from the same donors on the same day and on subsequent days to determine 
whether function remains stable over time. Should reproducibility be shown, the next step 
would be to apply the assay to clinical populations. This process could begin to correlate 
neutrophil function with established measures of immunosuppression, such as monocyte 
HLA-DR and C5aR1 expression and Treg numbers.110,147 Eventually patient-important 
outcomes such as nosocomial infection and mortality could be interrogated, and receiver 
operator characteristic (ROC) curves, predictive values, sensitivity and specificity could be 
generated.403 The use of whole blood samples in this assay easily lends itself to the 
assessment of multiple cell types identified by cell surface markers, allowing a global 
snapshot of immune function to be generated. Whilst these processes are certain to require 
new ethical approvals as well as significant time and financial investment, a sensitive, 
scalable test which will allow clinicians and researchers to accurately immunophenotype 
patients is of pivotal importance for the development of novel therapies in the critical illness 
space.111,317,404        
2.5. Map neutrophil phosphoproteomic response to S. aureus in 
critical illness 
My work has identified discrete C5a-induced phosphorylation failures in purified neutrophils 
from healthy donors. For this work to have translational relevance, I believe it is important to 
establish whether similar phosphorylation failures are evident in patient neutrophils exposed 
to the same stimulus. Therefore, experiments are underway to assess the phosphoproteomic 
signature of critically ill patient neutrophils. Importantly, I am interested in a specific, 
immunophenotypically defined group of patients with impaired phagocytosis; therefore, only 
those with phagocytic impairment and evidence of C5a exposure will be assayed. These 
parameters will be assessed in whole blood and purified cells prior to sending samples for 
phosphoproteomic analysis.  
Another key aspect of this experiment is the application of a known stimulus (S. aureus) and 
measurement of a phosphoproteomic response, rather than simply assessing the ‘baseline’ 
phosphoproteome of critically ill patient neutrophils. This is important as the heterogeneity of 
this population will undoubtedly lead to substantial baseline variation in signalling networks, 
which is less relevant to this question, and indeed has already been assessed in much larger 
studies using a transcriptomic approach.312,405,406 Clinical variables will be collected but in this 
sample size (n = 5 patients) these are unlikely to be informative. Should similar patterns of 
phosphorylation failure in response to S. aureus challenge be demonstrated in patient 
neutrophils, the translational relevance of my findings will be significantly increased.  
111 
 
2.6. Interrogate the role of nuclear reformation in phagocytosis  
Further exploration of the role of nuclear membrane dissociation in phagocytosis poses a 
significant challenge and will most likely necessitate a shift in methodology. Initial work 
should start with simply observing the nucleus during phagocytosis, which should be 
achievable using live cell confocal microscopy in combination with non-toxic nuclear stains 
such as Hoescht 22342. Such techniques are currently employed in our laboratory. However, 
it is likely that more advanced, higher-resolution microscopy techniques (such as stimulated 
emission depletion; STED microscopy) combined with selective nuclear membrane staining 
will be required to progress this project further. Such work has been performed 
transmigrating murine dendritic cells expressing green-fluorescent protein-tagged nuclei38 
and I anticipate a similar approach will be possible with the promyelocytic HL-60 cell line.407  
Once techniques above have been established and validated, pathways of interest can be 
perturbed in primary human neutrophils using commercially-available small molecule 
inhibitors of cyclin-dependent kinases, aurora kinase B and MAPK3, which have been 
identified as kinases mediating observed phosphoprotein signals in our dataset. Further, in 
HL-60 cells, siRNA-induced gene silencing or clustered regularly interspaced short 
palindromic repeats (CRISPR) editing can be attempted to mitigate issues of drug selectivity 
and off-target effects likely to be encountered in primary human cells. It is anticipated that 
this work will again involve significant time and financial investments. 
3. Conclusion 
Neutrophils are key components of the innate immune response. They are produced in 
enormous numbers and migrate rapidly through complex environments to phagocytose and 
destroy pathogens. Defects in these processes drive disease and comprise a significant 
component of the morbidity associated with critical illness. Factors driving neutrophil 
dysfunction are only partially understood, though we know somewhat paradoxically, a key 
role is played by the anaphylatoxin C5a, released in saturating concentrations during critical 
illness.  
This project sought to understand the mechanisms of C5a-induced neutrophil dysfunction. 
Key findings from this research include the unanticipated persistence of C5a-induced 
neutrophil dysfunction, mirroring the immunosuppressive phase we observe in patients. I 
have taken steps towards developing an assay that may one day facilitate rapid, reliable and 
functional immunophenotyping of patient blood samples. I have shown that C5a is unique 
amongst other priming agents in inducing phagocytic dysfunction and performed the first 
ever phosphoproteomic study of the neutrophil response to S. aureus in the context of C5a. 
These data have demonstrated a profound phosphorylation failure evident in cells pre-
treated with C5a, with downstream effects on phosphoinositide metabolism and nuclear 
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reorganisation. Over the course of this work, some questions were answered, though many 
more possibilities and uncertainties have arisen. I am reassured, however, that collaborative 
efforts and translation of detailed biological understanding to clinical practice will ultimately 
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Chapter IX: Appendices 
1. Neutrophil isolation from venous blood 
Chilvers laboratory protocol 
1.1. Materials 
• Place following into warmer bath at 37°C  
o 6% dextran 
o 0.9% saline - also keep one Falcon tube of saline at 4°C for diluting Percoll 
o PBS +/+ (with Ca2+/Mg2+) 
o PBS -/- (without Ca2+/Mg2+) 
• Prepare anticoagulated Falcon tubes 
• Set up 50 mL BD Falcon polypropylene tubes- 40 mL blood per Falcon tube 
• Put 3.8% sodium citrate (vials in fridge) into Falcon tubes 
o Use 1 mL citrate/10mL blood = 4 mL citrate/40 mL blood 
• Prepare bleach solution 
o 2 bleach tablets + water 
1.2. Procedure 
• Collect blood with 19G butterfly and 50 mL syringes (40 mL per syringe) 
• Add 40mL blood down the side of each Falcon tube; invert gently to mix 
• Remember to spray each item before placing in hood 
• 1st spin programme 1 (20 min, 300 x g)- separates into: 
• Supernatant (S/N) = platelet rich plasma (PRP), pellet = white and red cells 
• Remove (pipette/Pasteur) S/N (PRP) into fresh 50 mL Falcon tubes 
• Use to make platelet poor plasma (PPP) and autologous serum 
• Sediment remaining cells 
• Add 6% dextran down sides of tubes- add 2.5 mL dextran /10 mL cell pellet 
• Then add warm saline to make up volume to 50 mL 
• Mix by gently rolling tubes several times to re-suspend cells 
o Leave with caps loosely on (to let air in) for 25-40 min at room temp 
• Upper layer - white cells, bottom layer = red cells 
• Prepare Percoll gradients whilst waiting for sedimentation 
• Once Percoll prepared, place in fridge whilst remainder of sedimentation occurring. 
• Add 10 mL PRP into sterile glass vial 
• Then add 220 μL of 10 mM CaCl2 (do not add CaCl2 first) => vortex 
• Place in CO2 incubator, leave for 30-60 min with lid of vial loose 
o Then store at 4°C or freeze 
• Use remaining PRP- 2nd spin programme 2 (20 min, 1400 x g) - separates into: 
a. S/N = PPP,  pellet = platelets 
• Remove (pipette/Pasteur) S/N (PPP) into fresh 50 mL Falcon tubes; discard pellet 
(platelets) 
• Sedimented cells: upper layer - white cells, bottom layer = red cells 
• Remove (pipette/Pasteur) upper layer (white cells) into fresh Falcon tubes 
• Discard bottom layer (red cells) 





•  (Discard S/N, use cell pellet for below) 
• Make one set of gradients for each individual 
tube 
• Make 90% Percoll 
• mL Percoll + 0.5 mL Cold 0.9% saline => 
Vortex to mix 
• Make gradients - add Percoll and PPP => 
Vortex 
• Get white cells after 3rd spin 
o Discard (pour carefully) S/N into 
waste container with bleach 
o Resuspend remaining pellet by tapping tube gently 
o Pool maximum of 2 tubes of cell pellets together into 15 mL Falcon tube (use 
glass or plastic Pasteur not Gilson) 
o Add PPP to make up volume to 2 mL per tube of cells ("wash" old tube with 
required PPP then pipette into small tube) 
• Underlay Percoll gradients: 42% first, then 51% 
o Use glass Pasteur with Pipette boy 
o Take all of Percoll up glass Pasteur- avoid air bubbles 
o Slide Pasteur down side of cell tube to the bottom of tube, then slowly release 
Percoll- avoid air bubbles 
• Transfer tube carefully to centrifuge 
• 4th spin programme 4 (14 min, 150 x g, 1/ \0) - layers: 
o Top (PPP/42%) interface: mononuclear cells (PBMCs) 
o Next (42%/51%) interface: polymorphonuclear cells (PMNs) 
• Collect PMNs 
o Remove PPP, mononuclear cells and 42% with P1000 Gilson/Pasteur - 
discard 
o Collect PMNs with fresh Pasteur- put into fresh 50 mL Falcon tube 
o Discard 51% and red cell pellet 
• Add remaining PPP to PMN, mix 
a. Discard S/N 
o Resuspend cells then make up volume to 50 mL with PBS -/- 
o Use these cells in PBS -/- for cytospin and haemocytometer 
• From this point onwards use Cell Saver (wide bore) pipette tips 
• Breathe onto haemocytometer to moisten 
• Slide cover slip over until Newton's refraction (rainbow-
like) rings appear 
• Fill each of the two chambers with 10 μL of cells suspend 
in PBS -/- 
• Calculate total number of cells 
• Counting area of 5 x 5 large squares with total area = 1mm2 
• Depth of chamber = 0.1 mm 
• Number of cells per mL = Haemocytometer count x 10000 
• Total number of cells in 50 mL - Haemocytometer count x 
10000 x 50 
• Calculate volume of PBS +/+ required to make concentration 
of 5 million cells 
• Label slides with pencil 
• Set up into clip (bottom to top): slide, filter paper smooth side facing down towards 
slide, funnel 
• Add 100 μL of cells suspended in PBS -/- into funnel (use Cell Saver tips) 
• Spin in Cytospin3 machine: programme 1 (300 x rpm, 3 min, high acceleration) 
• Remove slides and air dry for 10-15 min 
• Stain slides 
42%: [0.8 mL + 40 μL] of 90% 
Percoll 
[1.0 mL + 160 μL] of PPP 
51%: [1.0 mL + 20 Μl] of 90% 
Percoll 
[0.9 mL + 80 μL] of PPP 
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• 4 min in methanol => 1 min in orange stain => 3 min in blue stain 
• Rinse with water then air dry 
• When dry, mount with 1 drop of DPX then add cover slip 
• Count cells under microscope for differential count 
• Count 200 cells- count neutrophils, eosinophils, PBMCs, RBCs 
• Cells in PBS -/-: 5th spin programme 5 (5 min, 256 x g) 
o Discard S/N 
• Resuspend cells then make up volume to 50 mL with PBS +/+ 
• Cells now in PBS +/+:  5th spin programme 5 (5 min, 256 x g) 
o Discard S/N 
• Resuspend cells 
• Add volume of PBS +/+ required to make up a concentration of 5 million cells / mL  












2. PMN phagocytosis assay 
Author: Alex Wood. Last revised October 2016. 
2.1. Materials 
• pHrodo Bioparticles (Life Technologies) 
o Red E. coli : P35361 (2 mg) 
o Green E. coli: P35366 (2mg) 
o Green zymosan: P35365 (1mg) 
o Ensure to protect Bioparticles from light at all times – work with lights off in 
hood + foil covering if exposed to ambient light 
o NOTE BATCH NUMBER USED IN EACH EXPERIMENT  
• RPMI 1640 + 10 mM HEPES 
• 2mL round-bottom Eppendorfs 
• Effectors e.g.: 
o Cytochalasin D (Sigma C2618-200UL) made up to  
o C5a (R&D Systems 2037-C5) 
• FACS tubes 
• CellFix mix (1 :40) = 1 mL CellFix  + 9 mL dH2O + 30 mL PBS -/- 
o Keep on ice until used 
• Freshly prepared neutrophils and autologous serum  
o 5x106/mL in RPMI 1640 with 10 % autologous serum by volume 
2.2. Procedure 
• Setup and label Eppendorfs with relevant conditions. Examples below. Always 
include 1 and 2. 
o Neutrophils + pHrodo cold (negative) 
o Opsonised pHrodo + neutrophils (positive control) 
o pHrodo alone in HCl solution (pH = 4 as positive control) 
• Opsonisation 
o Resuspend pHrodo in 2 mL phenol red-free IMDM (0.5 mg/mL zymosan, 1 
mg/mL E.coli/S.aureus). Aliquot 50 uL into Eppys and store at -20 protected 
from light. 
o Vortex for 1 minute. Pipette required volume for experiment into separate 
Eppendorf. Store stock and protect from light.  
o Sonicate in Eppendorf for 10 minutes 
o Opsonise with 50 % autologous serum for 30 minutes at 37 °C in 
shaker/incubator 
• Preparing neutrophils 
o Whilst opsonisation occurring, can incubate neutrophils with effector 
compounds 
o Resuspend 106 purified neutrophils (200 µL) in 2 mL Eppendorfs 
o Add effector compounds at relevant concentrations (e.g. 20 µL will give 1:10 
dilution) 
o Place in thermomixer at 37 °C for 30 minutes  
• Phagocytosis 
o Final concentration of pHrodo S. aureus needs to be 3 µg/mL 
o Add 0.6 µL unopsonised (neat) or 2.8 uL opsonised (diluted 1:2 in serum) 
pHrodo bioparticles to neutrophils as appropriate 
o Place tubes back in thermomixer at 37 °C for 30 minutes 
• Quenching and transfer to FACS tubes 
o Add 400 µL cold CellFix mix to quench reaction and fix cells 
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o Transfer solutions to labelled FACS tubes and place on ice to prevent further 
phagocytosis. Take care to resuspend cells and pipette 3 times to ensure cells 
not lost 
o Take FACS tubes for flow cytometry on ice 
• Flow cytometry 




3. Whole blood assay of neutrophil function 
Author: Alex Wood. Last revised June 2017. 
3.1. Materials 
• Whole blood collected in Argatroban anticoagulant 150 µg/mL. Stock tubes at -70 ˚C, 
200 uL of 1500 µg/mL diluted to 2 mL with fresh blood 
o 10 mg Argatroban powder dissolved in 200 uL DMSO (vortex vigorously until 
dissolved) 
o Dilute the 200 uL volume to 6600 uL (add 6400 uL PBS -/-)  
o Gives concentration of 1500 µg/mL. Aliquot 200 uL aliquots into 2 mL 
Eppendorfs and store at -70. I then add 1.8 mL blood to 200 uL argatroban 
aliquot to give final concentration of 150 µg/mL. 
• RPMI 1640 (phenol free) with 10 mM HEPES 
• PBS -/- vehicle control 
• 2 mL sterile Eppendorfs  
• Combined ROS/phagocytosis indicator 
o pHrodo red Bioparticles @ 1 mg/mL for S. aureus/E. coli or 0.5 mg/mL for 
zymosan in PBS -/- (stock).  
o DHR ROS probe (stored in DMSO in -70). Dilute 1:100 in PBS -/- on day. 
▪ Final concentration in-assay 15 µg/mL pHrodo and 3 µM DHR 
▪ Prepare working solution of 150 µg/mL pHrodo and 30 µM DHR (10 X 
and will be diluted by 10 in-assay) and vortex. 
▪ These concentrations should be calculated by titrating pHrodo required 
for given experimental system/time point. These are appropriate for 30 
minutes phagocytosis. 
• Antibodies/fluorophores 
o CD16-PacBlue Clone 3G8 302021 Biolegend (0.5 uL per 100 uL stain) 
o C5aR1 PerCP/Cy5.5 S5/1 Biolegend (1 uL per 100 uL stain)  
3.2. Procedure 
• Whole blood (WB) collected into argatroban via butterfly.  
• Prepare 96-well plate wells in triplicate – final volume 100 uL. Include 
cold/compensation controls as appropriate 
o 50 uL anticoagulated blood pre-treated as appropriate 
• Add 10 uL of 10 X phagocytosis/ROS indicator so final concentrations are 15 µg/mL 
and 3 µM respectively. 
• Make volume up to 100 uL with RPMI 1640 with 10 mM HEPES (i.e. add 40 µL) using 
multichannel pipette and pipette up and down x 5 to homogenise. 
• Allow 30 minutes phagocytosis time in 5 % CO2 and 37 ˚C in incubator. 
• At end of phagocytosis time point place plate onto ice. 
• Homogenise by pipetting up and down x 5, take 5 uL from each well and add to 
FACS tube with 100 uL stain mix. Can pool triplicates at this stage if required. 
• Stain on ice in dark for 30 minutes 
• Dilute final volume in each tube to 4 mL (add 3.9 mL) 





4. Western blotting of purified human neutrophil proteins 
Original by Katharine Lodge 2016, last revised August 2018 by Alex Wood. 
4.1. Materials 
• 1 x 2 L conical flasks, 1 x 2 L Duran bottle, 2 x 200 mL Duran bottles, 1 x 1 L 
measuring cylinder 
• If making own gels: 
o Protogel, resolving buffer (4X) and stacking buffer  
o dH2O  
o 10 % ammonium persulfate (APS) 
o TEMED 
o 10 or 12 well combs, 1.5 mm thickness 
o Glass plates, gel setting stands + holders 
o Ethanol 
• If using pre-cast gels 
o Pre-cast gel at appropriate SDS percentage 
o Appropriate gel running buffer 
• Running gels 
o Running buffer (diluted from 10 X with dH2O) 
o Running tank + lid (rounded Bio-Rad tanks) + power pack 
o Gel casette and blank gel if only running 1 sample gel (need 2 in total for 
current to travel through casette)  
• Sample preparation (for reduced proteins) 
o 5 X Laemmli’s buffer, stored in 2nd drawer Mark Ormiston’s -20 in main lab, 
made up by Paul Upton. 
o Beta mercaptoethanol (BME, reducing agent) stored in Cat 1 lab, door of 
Dong’s 4 degree fridge 
o Lysis buffer used to make neutrophil lysates (see protocol AW3). Currently 
this is simply 0.5 % SDS and 0.1 % TEAB (with 1 X HALT protease inhibitor 
cocktail for lysate, not required here).   
o 1.5 mL or 0.6 mL eppendorfs and pre-heat thermomixer to 95 C 
o Long-tipped gel loading pipettes 
• Gel transfer to PVDF membrane 
o PVDF membrane x 1 for each blot, cut to 8 cm x 6.5 cm 
o Blotting paper x 4 for each blot, cut to 8.5 cm x 7.0 cm 
o Sandwich x 1 and sponges x 2 for each blot 
o Clean flat tub for preparing sandwiches 
o Methanol (in solvents cupboard) 
o Transfer buffer: prepare first thing and put in -20 to cool down in morning; will 
freeze if left in -20 for long periods. If prepared in bulk, store at 4C.  
▪ 3.03 g Trizma base 
▪ 14.4 g glycine 
▪ 200 mL methanol 
▪ 800 mL dH2O 
o Running tank + lid (square lid) + power pack 
o Ice box full of wet ice and -20 ice pack from -20 freezer top shelf outside Cat 1 
lab 
• Washes, blocking and antibody staining 
o 1 L 10 X Tris buffered saline (TBS)  
▪ 24.2 g Trizma base 
▪ 80 g NaCl 
▪ Adjust pH to 7.6 with HCl 
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o TBS with 0.1 % Tween (TBS-T) 
▪ Make 1 L X TBS by diluting 100 mL 10 X TBS with 900 mL dH2O 
▪ Add 1 mL Tween 20 to 1 L. Will need to cut pipette tip as viscous 
o Small plastic tubs (cleaned with ethanol)  
o 5 % milk in TBS-T for blocking and antibody dilutions/staining: use 5 % milk as 
default unless specified by antibody manufacturer. Some use 5 % BSA 
instead. 
▪ 5 g non-fat milk diluted in 100 mL TBS-T 
▪ Beware that this can take time to dissolve fully, store at 4C when not in 
use 
o Antibodies 
▪ Often raised in mouse or rabbit. Try to choose validated Abs, 
preferably in primary human neutrophils, though this is rare!  
• Usually diluted 1:1000 with blocking buffer 
• Ideally purchase a protein standard known to work with 
antibody from same manufacturer to test 
▪ Ensure we have relevant secondary (HRP-conjugated) 
• Usually diluted 1:5000 with blocking buffer 
• Goat anti-rabbit-HRP conjugate in blue secondary antibody box 
in small lab fridge 
• Developing 
o ECL kit (stored in 4 degree lab fridge where antibodies kept 
o Xray film and cassette 
o Bin liner 
o Access to dark room and film developer (down corridor opposite Dougan lab) 
4.2. Methods 
• Preparing and reducing samples for loading 
o Perform Bradford protein assay (Protocol AW.4) and calculate volume of 
sample required to add 25 ug of protein to each well.  
o Dilute sample with lysis buffer to achieve 1 ug/uL concentration 
o Take 5 X Laemmli’s buffer, add 50 uL BME (do this in fume hood in Cat 1 lab) 
and vortex 
o Add 20 uL sample to 5 uL Laemmli/BME. 
o Make spare/blank well mixture (for 8 wells) by adding 160 uL lysis buffer to 40 
uL Laemmli/BME 
o Boil samples for 10 minutes at 95 C rotating at 300 rpm; be careful after 
boiling as lids can pop off 
o Spin down briefly to minimise sample loss  
o Setup gels and/or spacer in cassette, load into tank, pour running buffer into 
cassette and ensure no leaks, then fill tank up to relevant mark for number of 
gels 
o Load 10 uL PageRuler Plus ladder into first well (5 uL for pre-cast gels). Load 
from right to left, as this will lead to the ladder being on the left of the PVDF 
membrane. 
o Load 25 uL sample into each well. Space wells/ladders with a blank well in-
between if numbers permit. Load all wells from right to left with sample or 
blank well mixture (otherwise gel will deform) 
o MAKE A NOTE OF THE CONTENTS OF EACH WELL 
o Close lid, connecting red electrode to red electrode, connect to powerpack 
(red to red) and run at 100 V for 10-15 minutes (stacking). 
o Transition to resolving once ladder starts to separate: 150 V for approximately 
60 minutes, check at 30 and 45 minutes to ensure still running and 
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appropriate pace. Voltage can be adjusted depending on time available and 
protein of interest.  
o If not already prepared and doing Western, prepare transfer buffer now and 
keep in -20 
o Submerge PVDF membrane in methanol 
o Stop running when protein ladder has reached close to bottom of gel. 
o This gel can be stained using a Coomassie stain or silver stain, or transferred 
to PVDF/nitrocellulose membrane for Western blotting 
• Transfer to PVDF membrane for western blotting 
o Prepare items specified in materials on bench (transfer buffer should be cold 
by now)  
o Transfer tank in ice box surrounded by ice (needs to stay cold during transfer)  
o Pour transfer buffer into tub, enough to submerge sandwich 
o Setup sandwich as follows:  
o Black side on right, sponge, 2 pieces of blotting paper 
o White on left, sponge, 2 pieces of blotting paper 
o Remove gel cassette from electrophoresis tub  
o Break seal with green gel tool, remove stacking gel and discard 
o Carefully manipulate gel onto right side (black) so that it sits on top of blotting 
paper 
o Using forceps, place PVDF membrane (soaked in methanol) on top of gel, 
ensuring all edges are covered and that there are no bubbles between PVDF 
and gel 
o Place left-sided blotting papers and sponge on top, close sandwich carefully 
making sure not to dislodge gel/membrane 
o Place sandwich in tank WITH BLACK SIDE OF SANDWICH FACING BLACK 
PART OF TANK  
o Place -20 ice pack in gap on other side of tank 
o Fill tank with remaining transfer buffer right to the brim 
o Place lid, connect to powerpack and run 75 V for 2 hours 
• Blocking and primary antibody staining 
o Prepare TBS-T and 5 % milk/BSA solutions as in materials 
o Take sandwich out of transfer tank, carefully peel membrane off gel without 
dislodging and check if ladder has transferred. If not can replace and re-run 
o Place PVDF protein side up in small plastic tub. Discard gel and blotting paper 
o Add 15 mL TBS-T to tub, wash gel briefly on bench. 
o Discard TBS-T and add 5 % milk to block non-specific binding. Incubate for 
one hour on rocker, at room temperature  
o Prepare antibodies whilst this is occurring 
o Need 10 mL antibody solution minimal per tub/membrane  
o Remove blocking solution, add 10 mL antibody solution to each tub 
o Incubate rocking gently at 4C overnight 
• Method 5: washes and secondary antibody staining 
o Remove primary antibody mixture, can keep this for future staining if 
necessary. Store as directed by antibody manufacturer 
o Add 15 mL TBS-T, wash on rocker at room temp for 5 minutes. Repeat twice 
(3 washes in total) 
o Prepare 10 mL secondary antibody 
o Dilute 1:5000 in 5 % milk or BSA as appropriate (add 2 uL to 10 mL) 
o Add 10 mL secondary antibody and incubate for one hour at RT on rocker 
o Wash x 3 as previously 
o Can prepare ECL solution during this time 
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o Add 500 uL solution A to 500 uL solution B in 2 mL Eppendorf, vortex and 
protect from light 
• ECL Chemiluminescence and developing blot 
o Prepare the necessary materials as above. Cut bin liner to appropriate size 
o Prepare clean flat surface on bench (gladwrap or same tub used for transfer) 
o After final wash, hold membrane with forceps, wick excess TBS-T off onto 
paper towel, place PVDF protein side up and add 1 mL ECL mix on top of it 
o Flip PVDF over and ensure fully coated with ECL mix. Incubate for 5 minutes 
protected from light 
o Wick excess ECL off, place inside bin liner close and tape in place ensuring 
no bubbles, close cassette 
o Take cassette and x-ray film to dark room, ensure door closed and only 
infrared lights on 
o Remove film, bend one corner to allow orientation and place over membrane 
in cassette, ensuring reproducible placement 
o Expose for 1 minute initially as test 
o Develop by feeding film into developer  
o Adjust exposure time based on band intensity from (8) 
o Can store membranes in PBS -/- in fridge for later analysis (2-3 days max) 
o Can do densitometry in Image-J for quantification 
• Stripping and re-probing (optional) 
o After development of blot, can strip and re-probe using different 
primar/secondary antibody 
o Wash PVDF briefly in PBS -/- 
o Add 15 mL stripping buffer (from bottle above Ben’s bench) in small tub and 
incubate rocking gently at RT for 10 minutes MAX (longer incubations risk 
stripping more protein from PVDF) 
o You can ensure all antibody has been stripped by re-ECLing the PVDF at this 
stage 
o Then block and re-probe as previous 
4.3. Notes 
• This protocol has been adapted as stated and modified according to protocol from 
Cell Signalling Technologies (worth reading anyway): 
https://media.cellsignal.com/www/pdfs/resources/white-papers/guide-to-
successful-wb.pdf  
• This is a long and complex protocol but will become easier with practice. A lot of 
steps have been listed for the benefit of the absolute beginner 
• Be very careful not to tear the gels or membranes. Gels are considerably more 
fragile, and the 12 % pre-cast gels are more fragile again. 
• Try to look ahead and prepare buffers/samples/equipment as this will greatly 
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